

REFINITIV

DELTA REPORT

10-K

ZYXI - ZYNEX INC

10-K - DECEMBER 31, 2023 COMPARED TO 10-K - DECEMBER 31, 2022

The following comparison report has been automatically generated

TOTAL DELTAS 3275

█ CHANGES 253

█ DELETIONS 747

█ ADDITIONS 2275

[Table of Contents](#)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-K

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the year ended December 31 ~~2022~~, 2023

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number 001-38804

ZYNEX, INC.

(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction of
incorporation or organization)

90-0275169
(IRS Employer
Identification No.)

9655 Maroon Circle, Englewood, CO
(Address of principal executive offices)

80112
(Zip Code)

Registrant's telephone number, including area code: (303) 703-4906

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Ticker symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	ZYXI	The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act:

Title of each class
Common Stock, \$0.001 par value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large, accelerated filer	<input type="checkbox"/>	Accelerated filer	<input checked="" type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

The aggregate market value of the registrant's common stock held by non-affiliates of the registrant as of **June 30, 2022** **June 30, 2023**, the last business day of the Registrant's last completed second quarter, based upon the closing price of the common stock as reported by the Nasdaq Stock Market on such date was approximately **\$175.2** **\$205.2** million.

As of **March 13, 2023** **February 28, 2024**, **1,531,169** **42,042,617** shares of common stock are issued and **36,634,459** **32,170,182** shares are outstanding.

Documents incorporated by reference:

Portions of the Registrant's definitive proxy statement relating to its **2023** **2024** annual meeting of stockholders (the "Proxy Statement") are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.

[Table of Contents](#)

TABLE OF CONTENTS

ZYNEX, INC.
ANNUAL REPORT ON FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, **2022 **2023****

	Page
PART I	2
Item 1. Business	2
Item 1A. Risk Factors	11
Item 1B. Unresolved Staff Comments	27
Item 1C. Cybersecurity	28
Item 2. Properties	28
Item 3. Legal Proceedings	29
Item 4. Mine Safety Disclosures	28
Item 4A. Executive Officers of the Registrant	29
PART II	30
Item 5. Market For Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	30
Item 6. [Reserved]	31
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations	31
Item 7A. Quantitative and Qualitative Disclosures About Market Risk	40
Item 8. Financial Statements and Supplementary Data	40
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosures	40
Item 9A. Controls and Procedures	41
Item 9B. Other Information	42

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	42
PART III	43
Item 10. Directors, Executive Officers and Corporate Governance	43
Item 11. Executive Compensation	43
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	43
Item 13. Certain Relationships and Related Transactions, and Director Independence	44
Item 14. Principal Accounting Accountant Fees and Services	44
PART IV	45
Item 15. Exhibits and Financial Statement Schedules	45
Item 16. Form 10-K Summary	47
Signatures	48

[Table of Contents](#)

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This report includes statements of our expectations, intentions, plans, and beliefs that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Nonetheless, it is important for an investor to understand that these statements involve risks and uncertainties. These statements relate to the discussion of our business strategies and our expectations concerning future operations, margins, profitability, liquidity, and capital resources and to as well as analyses and other information that are based on forecasts of future results and estimates of amounts not yet determinable. We have used words such as "may," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "think," "estimate," "seek," "expect," "predict," "could," "project," "potential," "may" "will" "should" "expect" "intend" "plan" "anticipate" "believe" "think" "estimate" "seek" "expect" "predict" "could" "project" "potential" and other similar terms and phrases, including references to assumptions, in this report to identify forward-looking statements. These forward-looking statements are made based on expectations and beliefs concerning future events affecting us and are subject to uncertainties, risks, and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that could cause our actual results to differ materially from those matters expressed or implied by these forward-looking statements.

Such risks and other factors also include those listed in Item 1A. "Risk Factors" and elsewhere in this report and our other filings with the Securities and Exchange Commission. When considering these forward-looking statements, you should keep in mind the cautionary statements in this report and the documents incorporated by reference. New risks and uncertainties arise from time to time, and we cannot predict those events or how they may affect us. We assume no obligation to update any forward-looking statements after the date of this report as a result of new information, future events or developments, except as required by applicable laws and regulations.

When used in this annual report, the terms the "Company," "Zynex", "we," "us," "ours," and similar terms refer to Zynex, Inc., a Nevada corporation, and its our wholly-owned active subsidiaries, Zynex Medical, Inc., Zynex NeuroDiagnostics, Inc., Zynex Monitoring Solutions Inc., Kestrel Labs, Inc., Zynex Europe ApS, and Pharmazy, Inc. As of the date of this annual report, our only operating subsidiary is Zynex Medical, Inc. ("ZMI") and Zynex Monitoring Solutions, Inc. ("ZMS") has developed its fluid monitoring system product as described below.

[Table of Contents](#)

PART I

ITEM 1. BUSINESS

History

Zynex, Inc. was founded by Thomas Sandgaard in 1996, when he founded two privately held companies that eventually were folded into Zynex, Inc. Zynex, Inc., a Nevada corporation, is the parent company of six active and inactive subsidiaries. As of December 31, 2022, the Company's only active subsidiaries are Zynex Medical, Inc. ("ZMI," a wholly-owned Colorado corporation) and Zynex Monitoring Solutions, Inc. ("ZMS," a wholly-owned Colorado corporation). The Company's inactive subsidiaries include Kestrel Labs, Inc. ("Kestrel," a wholly-owned Colorado corporation), Zynex Europe ("ZEU," a wholly-owned Colorado corporation), Zynex NeuroDiagnostics, Inc. ("ZND," a wholly-owned Colorado corporation), and Pharmazy, Inc. ("Pharmazy," a wholly-owned Colorado Corporation), which was incorporated in June 2015. The Company's compounding pharmacy operated as a division of ZMI dba as Pharmazy through January 2016.

In December 2021, the Company acquired 100% of Kestrel Labs, Inc. ("Kestrel"), a laser-based, noninvasive patient monitoring technology company. Kestrel's laser-based products include the NiCO™ CO-Oximeter, a noninvasive multi-parameter pulse oximeter, and HemeOx™, a noninvasive total hemoglobin oximeter that enables continuous arterial blood monitoring. Both NiCO and HemeOx are yet to be presented to the FDA for market clearance. All activities related to Kestrel flow through our ZMS subsidiary. ZMS has developed the CM-1500 monitoring system ("CM-1500") which was granted 510(k) clearance in February 2020 by the FDA in the United States of America. ZMS filed a 510(k) application for the CM-1600 in December 2021, its next generation wireless monitoring system ("CM-1600") and is continuing to work with the FDA on obtaining clearance. ZMS has achieved no revenues to date.

Substantially all of the Company's consolidated revenue in 2022 and 2021 is attributable to ZMI. Our headquarters are located in Englewood, Colorado.

Active Subsidiaries Overview

Zynex Medical, Inc. (ZMI):

ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The Company's devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current ("IFC"), neuromuscular electrical stimulation ("NMES"), and transcutaneous electrical nerve stimulation ("TENS"). All of our medical devices are designed to be patient friendly and designed for home use. Our devices are small, portable, battery operated, and include an electrical pulse generator which is connected to the body via electrodes. All of our medical devices are marketed in the U.S. and are subject to FDA regulation and clearance. Our products require a physician's prescription before they can be dispensed in the U.S. Our primary product is the NexWave device. The NexWave is marketed to physicians and therapists by our field sales representatives. The NexWave requires consumable supplies, such as electrodes and batteries, which are shipped to patients, **on a recurring monthly basis**, as needed.

ZMI distributes complementary **rehabilitation** products such as **back, knee and wrist braces, cervical and lumbar support, cervical traction, knee bracing**, and **hot/cold therapy** ("Distributed Rehabilitation Products"). These complement our pain management products and are critical for physicians and therapists. These products require a prescription and are covered by most insurance plans and Medicare.

ZMI designs, manufactures, and markets the NeuroMove product. The NeuroMove contains electromyography and electric stimulation technology that is primarily used for stroke, spinal cord and traumatic brain injury rehabilitation ("SCI"), by reaching parts of the brain to re-connect with muscles, also known as neuroplasticity. The NeuroMove product is primarily marketed to medical clinics. Zynex did not have material sales of this product in **2022** **2023** or **2021** **2022**.

ZMI also designs, manufactures, and markets the InWave product, an in-home electrical stimulation device used to treat female urinary incontinence. The device requires a prescription and is covered by most insurance plans and Medicare. Zynex did not have material sales of this product in **2022** **2023** or **2021** **2022**.

2

Table ZMI designs, manufactures and markets the E-Wave product. The E-Wave is a user-friendly NMES device designed for muscle stimulation and re-education. E-Wave is a fully programmable, compact, battery-powered device with adjustable treatment timer, compliance meter, biphasic or monophasic waveforms, and exceptional safety features. The E-Wave is marketed to physicians and therapists and requires consumable supplies, electrodes and batteries, for use. On October 25, 2023, Zynex submitted FDA application for M-Wave, the next generation E-Wave device. The M-Wave will offer a more modern design and enhanced ease of use with the same versatility as the E-Wave. As of March 12, 2024, the Company does not anticipate a material financial impact of the M-Wave on the Company's consolidated financial statements.

Zynex Monitoring Solutions (ZMS):

ZMS was formed in 2011 to develop and market medical devices for non-invasive patient monitoring beginning with our Zynex Fluid Monitoring System. The monitor is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery. The CM-1500 received 510(k) clearance from the FDA in February 2020 and the wireless CM-1600 received clearance in June 2023.

The Zynex Fluid Monitoring System has been tested in several Institutional Review Board ("IRB") approved clinical studies, both in well-controlled healthy volunteer settings as well as in clinical use environments. In 2022 and 2023, the clinical trials were expanded to include the next generation CM-1600. Enrollment was completed in apheresis blood donation study with Vitalant Research Institute (the research arm of Vitalant, the nation's largest independent, nonprofit blood services provider) to track changes in the device's patented Relative Index ("RI") during platelet apheresis blood donation procedures. Multiple studies were A healthy volunteer study was also completed at Yale University Medical School where volunteer study subjects underwent simulated hemorrhage using a lower body negative pressure, chamber a well-validated protocol for simulated hemorrhage while wearing the device. Finally, enrollment was initiated in a large-scale multi-site study to measure the sensitivity and specificity of the

2

[Table of Contents](#)

CM-1600 at detecting minor blood loss, which is anticipated to finish recruitment and data collection in April 2023. Finally, a non-cardiac surgery perioperative observational study to determine the first half impact of complex perioperative events on the parameters and RI measured by the CM-1600 was completed in May 2023.

We have built a number of commercial devices in pilot-production and continue to refine the algorithms for the patented Relative Index. We have received two U.S. utility patents for this unique application, the first in the fourth quarter of 2018 and the second in the first quarter of 2021, and we believe this product could serve a currently unmet need in the market for safer surgeries and safer monitoring of patients during recovery.

In addition to FDA clearance, we are pursuing plan to pursue European Union ("EU") Certificate European ("CE") Marking. CE Marking is a certification that a product meets the standards established by the 27 nations of the EU and qualifies for sale in the EU and 4-nation European Free Trade Association.

In early 2022, the integration of Kestrel and their pulse oximetry products into the ZMS organization was completed. Pulse oximetry is a commonly used noninvasive monitoring method for estimation of oxygen saturation in arterial blood. The inaccuracies of traditional Light Emitting Diode ("LED")-based pulse oximeters have recently been highlighted specific to skin pigmentation bias and the inability to accurately measure blood oxygen levels in the presence of other conditions such as in cases of carbon monoxide poisoning or methemoglobinemia. ZMS's investigational laser-based products are designed to address these inaccuracies and include the novel NiCO™ CO-Oximeter, and HemeOx™, a total hemoglobin oximeter that is designed to enable continuous noninvasive arterial blood monitoring. NiCO is anticipated to be submitted to the FDA for clearance in the third quarter first half of 2023. NiCO is currently undergoing Institutional Review Board ("IRB") approved clinical studies on human subjects to measure hypoxemia. Enrollments at the University of California San Francisco were completed in May 2023 and enrollments at Duke University are ongoing.

As ZMS' products are still in development, ZMS did not produce any revenue for the years ending December 31, 2022 December 31, 2023 and 2021.

In addition to the fluid volume monitor, ZMS filed for a provisional patent for a non-invasive sepsis monitor in December 2020 and an updated utility patent, which was filed in December 2021.

[History](#)

Zynex, Inc. was founded by Thomas Sandgaard in 1996, when he founded two privately held companies that were eventually folded into Zynex, Inc., a Nevada corporation. Zynex, Inc. is the parent company of two active subsidiaries; Zynex Medical, Inc. ("ZMI," a wholly-owned Colorado corporation) and Zynex Monitoring Solutions, Inc. ("ZMS," a wholly-owned Colorado corporation).

Substantially all of the Company's consolidated revenue in 2023 and 2022 is attributable to ZMI. Our headquarters are located in Englewood, Colorado.

[SALES AND GROWTH STRATEGIES](#)

To date, ZMI accounts for substantially all of our revenue and profit. We are focused on expanding our sales force to address what we believe is an untapped market for electrotherapy products for pain management which has become more attractive due to large competitors exiting the market. As of **December 31, 2022** **December 31, 2023**, we had approximately **450** **500** field sales representatives on staff or in the hiring process. We continue to hire field sales representatives at a rapid rate, focusing on the quality of each candidate with the goal of having approximately **500-600** **600** sales representatives in the U.S. by the end of **2023** **2024**. We will be focused on increasing performance management standards for our sales force.

In an effort to increase revenue and diversification, **in order to** **we** provide our prescribers and patients with diverse solutions for their pain management **needs**, **we** **needs**. **We** are continually adding new complementary products to our ZMI sales channel, **such as** **in addition to** **our** **hot/cold therapy, cervical traction, knee braces and LSO back braces**. **In addition, in March 2020 we introduced a full catalog of over 3,300 physical therapy products to promote in the clinics which we serve.** **current Distributed Products**. We believe adding these complementary products will increase our market share **in the marketplace** and, in the future, grow our core business by providing our electrotherapy patients additional non-pharmacological pain relief and complementary products to our manufactured devices.

[Table of Contents](#)

Distribution and Revenue Streams:

Currently, substantially **Substantially** all of our revenue is generated through our ZMI subsidiary from our electrotherapy products.

We sell through a direct sales force in **the** United States. Our field sales representatives are engaged to sell in predefined geographic markets and are compensated with a base salary **and incentives** **plus incentive compensation aligned to corporate objectives** based on the type of product sold and insurance. Our efforts to date have been focused on the United States market.

Our revenue is derived from several sources including patients with insurance plans held by commercial health insurance carriers or government payers who pay on behalf of their insureds. The remaining portion of revenue is primarily received from workers' compensation claims, **and** **auto claims**, attorneys representing injured patients, hospitals, clinics, and private-pay individuals.

A large part of our revenue is recurring. Recurring revenue results primarily from the sale of surface electrodes and batteries sent to existing patients with our **units**, **devices**. Electrodes and batteries are consumable items that are considered an integral part of our products.

Private Labeled Distributed Rehabilitation Products

In addition to our own products, we **distribute**, **offer** our suite of **Distributed Rehabilitation Products**, through our sales force, a number of private labeled supplies and complementary products from other **domestic** manufacturers. **These products generally include patient consumables, such as electrodes and batteries plus cervical traction, lumbar support, knee braces and hot/cold therapy**. Customarily, there are no formal contracts between vendors in the durable medical equipment industry. Replacement products and components are easily found, either from our own products or other manufacturers, and purchases are made by purchase order.

Products

We currently market and sell Zynex-manufactured products and distribute complementary products and private labeled supplies for Zynex products, as indicated below:

Products

We currently market and sell Zynex-manufactured products and distribute rehabilitation products and private labeled supplies for Zynex products, as indicated below:

Product Name	Description
Zynex Medical Products	
NexWave	Dual channel, multi-modality IFC, TENS, NMES device

NeuroMove	Electromyography (EMG) — triggered electrical stimulation device
InWave	Electrical stimulation for treatment of female urinary incontinence
E-Wave	NMES device
M-Wave	NMES device - cleared by FDA in February 2024

Private Labeled Supplies

Electrodes	Supplies, re-usable for delivery of electrical current to the body
Batteries	Supplies, for use in electrotherapy products

Distributed Complementary Rehabilitation Products

Comfortrac/Saunders	Cervical traction
JetStream/Pain Management Technologies	Hot/cold therapy
LSO Back Braces	Lumbar support

4

Table of Contents

Knee Braces/Bracing	Knee Rehabilitation brace support
Zynex Monitoring Solutions Products (Products in Development, Not Yet Available for Sale)	
CM-1500	Zynex Fluid Monitoring System – cleared by FDA in February 2020
CM-1600	Zynex Wireless Fluid Monitoring System – Submitted to the cleared by FDA December 2021, not yet FDA cleared, in June 2023
NiCO CO-Oximeter	Laser-based Noninvasive CO-Oximeter (Not yet FDA cleared)
HemeOx tHb Oximeter	Laser-based Total Hemoglobin Pulse Oximeter (Not yet FDA cleared)

Product Uses

Pain Management and Control

Standard electrotherapy is a clinically proven and medically accepted alternative to manage acute and chronic pain. Electrical stimulation has been shown to reduce most types of local pain, such as tennis elbow, neck or lower back pain, arthritis, and others. The devices used to accomplish this are commonly described as the TENS family of devices. Electrotherapy is not known to have any negative side effects, a significant advantage over most pain relief medications. The benefits of electrotherapy can include: pain relief, increased blood flow, reduced edema, prevention of venous thrombosis, increased range-of-motion, prevention of muscle disuse atrophy, and reduced urinary incontinence.

Electrotherapy introduces an electrical current applied through surface electrodes. The electrical current "distorts" a pain signal on its way to the central nervous system and the brain, thus reducing the pain. Additionally, by applying higher levels of electricity, muscles contract and such contraction is believed to assist in the benefits mentioned above.

Numerous clinical studies have been published over several decades showing the effectiveness of IFC and TENS for pain relief. Our primary electrotherapy device, the NexWave, has received FDA 510(k) clearance. The NexWave is a digital IFC, TENS and NMES device that delivers pain-alleviating electrotherapy.

Stroke and Spinal Cord Injury ("SCI") Rehabilitation

Our proprietary NeuroMove product is a Class II medical device that has been cleared by the FDA for stroke rehabilitation. Stroke and SCI usually affect a survivor's mobility, functionality, speech, and memory, and the NeuroMove is designed to help the survivor regain movement and functionality.

Sales of NeuroMove did not generate material revenue for the years ended December 31, 2022 December 31, 2023 and 2021, 2022.

Hemodynamic Fluid Monitoring

Hemodynamic Fluid monitoring is the process of involves measuring the blood flow and pressure exerted in the heart, veins, and arteries. It provides an assessment of a patient's circulatory status fluid balance, especially regarding fluid inputs and their ability outputs contributing to assure cardiac output total intravascular volume. Adequate fluid balance is vital for patient stability and oxygen delivery to recovery, as both low and high volumes outside of the body desired range are associated with complications. Maintaining effective circulating blood volume and pressure are key to assuring adequate oxygen saturation and perfusion.

Hemodynamic Monitoring methods used for hemodynamic and intravascular volume monitoring devices have been historically classified as (a) invasive, using a central or pulmonary artery catheter, (b) minimally invasive, with the placement of an arterial line, and (c) noninvasive, where no device is inserted into the body for clinical assessment.

5

Table of Contents

The Zynex Fluid Monitoring System CM-1500 and the Zynex Wireless Fluid Monitoring System CM-1600 are noninvasive monitoring devices designed to measure relative changes in fluid volume in adult patients. Fluid status is determined using Zynex's proprietary algorithm and expressed as the patented Relative Index™, a simple value designed to accurately trend patient vital signs and alert clinicians for early intervention.

The CM-1500 was cleared by the FDA in 2020. The 2020, and the wireless CM-1600 has been submitted to was cleared in June 2023 by the FDA and is pending clearance, FDA.

Pulse Oximetry Monitoring

Pulse oximetry is a noninvasive method of measuring the oxygen saturation level ("SpO2") of arterial blood. As one of the most common medical devices used in and out of hospitals around the world, pulse oximeters have gained widespread clinical acceptance as the standard of care for monitoring oxygen saturation. SpO2 has become the "fifth vital sign", which, together with heart rate, blood pressure, respiratory rate, and temperature, provides crucial clinical information about a person's health status.

The NiCO™ Noninvasive CO-Oximeter, the first laser-based photoplethysmographic patient monitoring technology, is designed to noninvasively measure and monitor four crucial species of hemoglobin with unprecedented accuracy.

The HemeOx™ Total Hemoglobin Pulse Oximeter is designed to noninvasively measure total hemoglobin and oxygen saturation, two critical parameters that typically require invasive arterial blood sampling for measurement. Total hemoglobin is a very commonly ordered blood test in healthcare, and HemeOx™ measures it with the continuous and noninvasive ease of a pulse oximeter at the patient bedside.

The NiCO™ Noninvasive CO-Oximeter and the HemeOx™ Total Hemoglobin Pulse Oximeter have not yet been cleared by the FDA.

MARKETS

Zynex Medical, Inc. (ZMI):

To date, the majority of our revenue has been generated by our ZMI electrotherapy products, and private labeled supplies. supplies, and distributed complementary rehabilitation products. Thus, we primarily compete in the home electrotherapy market for pain management with products based on IFC, TENS and NMES devices and consumable supplies. rehabilitation. We estimate the annual domestic market for home electrotherapy and rehabilitation products at approximately \$500 million to \$1 billion. During 2022 2023 and 2021, 2022, we maintained our sales force of approximately 450 400-500 direct sales representatives to address what we believe is an underserved electrotherapy market. The current opioid epidemic has been declared a health emergency, and we are uniquely positioned to help reduce the amount number of opioids prescribed for treatment of chronic and acute pain symptoms. We are committed to providing health care healthcare professionals with alternatives to traditional opioid based treatment programs with our prescription-strength products which have no side effects. This has never been more necessary than it is today considering the staggering statistics.

- Pain impacts the lives of more Americans than diabetes, heart disease, and cancer combined.
- Pain is the leading cause of disability, and seeking treatment for chronic or acute pain is the most common reason American's seek health care. Approximately 50 million Americans suffer from chronic pain.
- Nearly 20 million Americans experienced high-impact chronic pain, defined as "limiting life or work activities on most days or every day", day in the past 3 months. months".
- If pharmaceuticals such as opioids continue to be used as the first line of defense, America will continue to see a rise in opioid misuse, addiction, and drug-related deaths.

We also distribute complementary products such as JetStream Hot/Cold Therapy, Knee bracing, LSO Back bracing and Comfortrac and Saunders cervical and lumbar traction units, all products targeted at treating acute as well as chronic pain with minimal side-effects.

6

[Table of Contents](#)

Key characteristics of our electrotherapy and rehabilitation market are:

- Collection cycles of initial payment from insurance carriers can range from less than 30 days to many months and considerably longer for many attorney, personal injury, and workers' compensation cases. Such delayed payment negatively

6

[Table of Contents](#)

impacts our cash flow and can slow our growth or strain our liquidity. Collections are also impacted by whether effective billing submissions are made by our billing and collections department to the third-party payers.

- Prior to payment, third-party payers often make or take significant payment adjustments or discounts. This can also lead to denials and billing disputes with third-party payers.
- The majority of our revenue is generated by the sale of medical devices and from recurring patient supplies specifically from our electrotherapy products sold through ZMI. We are reliant on third-party payer reimbursement.

Zynex Monitoring Solutions (ZMS):

ZMS is focused on developing products within the non-invasive multi-parameter patient-monitoring marketplace. ZMS is currently focusing on its fluid monitoring system, the sepsis monitor, and the pulse oximetry products acquired in its acquisition of Kestrel. Kestrel Labs. We believe our products, once released into the marketplace (of which there can be no guarantee), will compete against multiple competitors, ranging from large manufacturers with multiple business lines to small manufacturers that offer a limited range of products. ZMS has not generated any revenue. revenue to date.

Competition

Since we are in the market for medical electrotherapy products, we face a mixture of competitors ranging from large manufacturers with multiple business lines to small manufacturers that offer a limited selection of products. Our principal competitors include International Rehabilitative Sciences, Inc. d/b/a RS Medical, EMSI, and H-Wave. In addition, we face competition from providers of alternative medical therapies, such as pharmaceutical and medical device companies.

RESOURCES

Manufacturing and Product Assembly

Our manufacturing and product assembly strategy consists of the following elements:

- Compliance with relevant legal and regulatory requirements.
- Use of contract manufacturers as needed, thereby allowing us to quickly respond to changes in volume and avoid large capital investments for assembly and manufacturing equipment of certain product components. We believe there is a large pool of highly qualified contract manufacturers, domestically and internationally, for the type of manufacturing assistance needed for our manufactured devices.
- Utilization of in-house final assembly and test capabilities.
- Development of proprietary software and hardware for all products **in house, in-house**.
- Testing all units in a real-life, in-house environment to help ensure the highest possible quality and patient safety while reducing the cost of warranty repairs.

Table of Contents

We utilize contract manufacturers located in the U.S. to manufacture components for our NexWave and NeuroMove units and for some of our other products and assemble in-house for our NexWave and NeuroMove units. We do not have long-term supply agreements with our contract manufacturers, but we utilize purchase orders with agreed upon terms for our ongoing needs. We believe there are numerous suppliers that can manufacture our products and provide our required raw materials. Generally, we have been able to obtain adequate supplies of our required raw materials and components. We are always evaluating our suppliers for price, quality, delivery time, and service. The reduction or interruption in supply, and an inability to develop alternative sources for such supply, could adversely affect our operations.

Intellectual Property

Zynex is committed to aggressively protecting the intellectual property rights the Company has worked so hard to obtain and to expand our intellectual property portfolio for advances to our existing products and for new products as they are developed.

Zynex has received two U.S. utility patents, as well as a utility patent in Europe, for our fluid monitoring system. The acquisition of Kestrel Labs, Inc. **by Zynex Inc.** included an intellectual property portfolio surrounding the acquired laser-based photoplethysmographic technology. This expands both the size and scope of Zynex's intellectual property portfolio to include key aspects of the exciting pulse oximetry market. **Additional patents for photoplethysmographic technology were filed in 2022 and 2023. Zynex also received issued trademarks for NiCO™ and HemeOx™ by the US Patent Trade Office ("USPTO") in 2023.**

Zynex is trademarked in the U.S.

We utilize non-disclosure and trade secret agreements with employees and third parties to protect our proprietary information.

GOVERNMENT REGULATION

US Food and Drug Administration (FDA)

All of our ZMI products are classified as Class II (Medium Risk) devices by the FDA, and clinical studies with our products are considered to be **NSR (Non-Significant Non-Significant Risk Studies) Studies ("NSR")**. Our business is regulated by the FDA, and all products typically require 510(k) market clearance before they can be put into commercial distribution. Section 510(k) of the Federal Food, Drug and Cosmetic Act, is available in certain instances for Class II devices. It requires that, before introducing most Class II devices into interstate commerce, the sponsor must first submit information to the FDA demonstrating that the device is substantially equivalent in terms of safety and effectiveness to a device legally marketed prior to March 1976 or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act that do not require approval of a premarket approval application.

When the FDA determines that the device is substantially equivalent, the agency issues a "clearance" letter that authorizes marketing of the product. We are also regulated by the FDA's Quality System Regulation (QSR) ("QSR"), which sets forth current Good Manufacturing Practice (GMP) ("GMP") requirements for devices. We believe that our products have obtained or are good candidates for the requisite FDA clearance or are exempt from the FDA clearance process. In November 2001, Zynex received FDA 510(k) clearance to market NeuroMove. In September 2011, Zynex received FDA 510(k) clearance to market the NexWave, our current generation IFC, TENS and NMES device. In August 2012, Zynex received FDA 510(k) clearance to market the InWave, our next generation muscle stimulator for treatment of female incontinence. Failure to comply with FDA requirements could adversely affect us.

International

Zynex continues to explore opportunities to gain regulatory clearance for its devices in markets outside of the U.S.

CE marking is the medical device manufacturer's claim that a product meets the essential requirements of all relevant European Medical Device Directives. The CE mark is a legal requirement to place a device on the market in the EU. Zynex is currently in the process of applying for pursuing CE marking on several of its electrotherapy devices and its CM-1500 CM-1600 Zynex Fluid Monitoring System.

We comply with applicable regulatory requirements within the markets in which we currently sell. If and when we decide to enter additional geographic areas, we intend to comply with applicable regulatory requirements within those markets.

Table of Contents

In 2019, Zynex has received ISO13485: 2016 certification for its compliance with international standards in quality management systems for design, development, manufacturing, and distribution of medical devices. This certification is not only important as assurance that we have the appropriate quality systems in place but is also crucial to our international expansion efforts as many countries require this certification as part of their regulatory approval.

Government Regulation

The delivery of health care services and products has become one of the most highly regulated professional and business endeavors in the United States. Both the federal government and individual state governments are responsible for overseeing the activities of individuals and businesses engaged in the delivery of health care services and products. Federal law and regulations are based primarily upon the Medicare and Medicaid programs. Each program is financed, at least in part, with federal funds. State jurisdiction is based upon the state's interest in regulating the quality of health care in the state, regardless of the source of payment. Many state and local jurisdictions impose additional legal and regulatory requirements on our business including various states and local licenses, taxes, limitations regarding insurance claim submission and limitations on relationships with referral parties. Failure to comply with this myriad of regulations in a particular jurisdiction may subject us to fines or other penalties, including the inability to sell our products in certain jurisdictions.

Federal health care healthcare laws apply to us when we submit a claim to any other federally funded health care healthcare program, in addition to requirements to meet government standards. The principal federal laws that we must abide by in these situations include:

- Those that prohibit the filing of false or improper claims for federal payment.
- Those that prohibit unlawful inducements for the referral of business reimbursable under federally funded health care healthcare programs.

The federal government may impose criminal, civil, and administrative penalties on anyone who files a false claim for reimbursement from federally funded programs.

A federal law commonly known as the "anti-kickback law" prohibits the knowing or willful solicitation, receipt, offer, or payment of any remuneration made in return for:

- The referral of patients covered under federally-funded health care federally funded healthcare programs; or
- The purchasing, leasing, ordering, or arranging for any goods, facility, items, or service reimbursable under those programs.

Healthcare Regulation

Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, also apply to our business. If we fail to comply with those laws, we could face substantial penalties and our business, results of operations, financial condition, and prospects could be adversely affected. The laws that may affect our ability to operate include but are not limited to: the federal Anti-Kickback Statute, which prohibits prohibits, among other things,

soliciting, receiving, offering, or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; and federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent. Additionally, we are subject to state law equivalents of each of the above federal laws, which may be broader in scope and apply regardless of whether the payer is a federal healthcare program, and many of which differ from each other in significant ways and may not have the same effect, further complicate compliance efforts.

Numerous federal and state laws, including state security breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, and disclosure of personal information. In addition, most healthcare providers who are expected to prescribe our products and from whom we obtain patient health information are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology and Clinical Health Act or HIPAA. ("HIPAA"). We could be subject to criminal penalties if we knowingly obtain individually

Table of Contents

identifiable health information from a HIPAA-covered entity, including healthcare providers, in a manner that is not authorized or permitted by HIPAA. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states requiring security breach notification. These laws could create liability for us or increase our cost of doing business.

In addition, the Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act of 2010 or the ACA, ("ACA"), created a federal requirement under the federal Open Payments program that requires certain manufacturers to track and report to the Centers for Medicare and Medicaid Services or CMS, ("CMS"), annually certain payments and other transfers of value provided to physicians and certain advanced non-physician health care healthcare practitioners and teaching hospitals made in the previous calendar year, as well as ownership and investment interests held by physicians and their immediate family members. In addition, there are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities.

Research and Development

Research and Development costs are expensed when incurred. During 2022 2023 and 2021 2022, we incurred approximately \$9.2 million and \$7.1 million and \$2.6 million in operating expenses, respectively, related to our ZMS operations. During 2023 and 2022, approximately \$1.0 million \$7.7 million and \$6.0 million of the operating expenses, qualified for respectively, required capitalization under Section 174 - "Amortization of Research and Experimental Expenditures" tax treatment. We expect our research and development expenses to increase in 2023 2024 as our ZMS business expands.

HUMAN CAPITAL

As of December 31, 2022 December 31, 2023, we employed approximately 900 1,100 full time employees.

Our employees are our most important assets and set the foundation for our ability to achieve our strategic objectives. All of our employees contribute to our success and, in particular, our sales representatives are instrumental in our ability to reach more patients in pain.

The success and growth of our business depends in large part on our ability to attract, retain and develop a diverse population of talented and high-performing employees at all levels of our organization. To succeed in a competitive labor market, we have developed recruitment and retention strategies, objectives, and measures that we focus on as part of the overall management of our business. These strategies, objectives, and measures form our human capital management framework and are advanced through the following programs, policies, and initiatives:

- Competitive pay and benefits. Our compensation programs are designed to align the compensation of our employees with our performance and to provide the proper incentives to attract, retain, and motivate employees to achieve superior results.
- Training and development. We invest in learning opportunities that foster a growth mindset. Our formal offerings include a tuition reimbursement program, an e-learning program that all corporate employees have access to, and in-house learning opportunities through the Company's Zynex Growth and Development program.

- Health and Wellness. We invest in the health and wellness of our employees by offering monthly benefits and offer programs and support to assist our employees.

[Table of Contents](#)

ITEM 1A. RISK FACTORS

RISKS RELATED TO OUR

BUSINESS AND THE INDUSTRY IN WHICH WE OPERATE

Unfavorable global economic conditions could adversely affect our business, financial condition, or results of operations.

Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including conditions that are outside of our control, such as the impact of health and safety concerns, including SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) ("COVID-19") pandemic and various variants, as well as military conflicts or wars (such as the recent inflation in ongoing conflicts between Russia and Ukraine and Israel and Palestine) that can cause exacerbated volatility and disruptions to various aspects of the United States, foreign and domestic government sanctions imposed on Russia as a result of its recent invasion of Ukraine, global economy, and other disruptions to global supply chains. Each of these events has caused or may continue to result in extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, whether due to inflationary pressures or otherwise, could result in a variety of risks to our business, including weakened demand for our products and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could strain our suppliers, possibly resulting in supply disruption, or cause delays in payments for our services by third-party payors or our collaborators. Any of the foregoing could harm our business, and we cannot anticipate all the ways in which the current economic climate and financial market conditions could adversely impact our business.

A pandemic, epidemic, or outbreak of an infectious disease, such as of COVID-19 and subsequent variants, may materially and adversely affect our business and results of operations.

Public health crises such as pandemics or similar outbreaks could adversely impact our business. In 2019, COVID-19 surfaced in Wuhan, China and has since spread worldwide. The COVID-19 pandemic is evolving and to date has led to the implementation of various responses including government-imposed quarantines, travel restrictions, and other public health safety measures. The effects of this outbreak on our business have included and could continue to include temporary closures of our providers and clinics and suspensions of elective surgical procedures. This has and could continue to impact our interactions and relationships with our customers.

[Table of Contents](#)

In addition to temporary closures of the providers and clinics that we serve, we could also experience temporary closures of the facilities of our suppliers, contract manufacturers, or other vendors in our supply chain, which could impact our business, interactions and relationships with our third-party suppliers and contractors, and results of operations. The extent to which COVID-19 will impact our future business and the economy will also depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the pandemic, adverse impacts of the Omicron COVID-19 variant or other COVID-19 variants, new information that will emerge concerning the severity of COVID-19, and the actions to contain COVID-19 or treat its impact, among others. Accordingly, we cannot predict the extent to which our financial condition, results of operations, and value of our common stock will be affected. The uncertainty surrounding the COVID-19 outbreak has caused the Company to increase its inventory in anticipation of possible supply chain shortages related to the COVID-19 virus. While we did not incur significant disruptions to our operations during 2021 and 2022, we are unable at this time to predict with confidence the impact that COVID-19 will have on our business, financial position, and operating results in future periods due to numerous uncertainties.

Rapid technological change could cause our products to become obsolete and if we do not enhance our product offerings through our research and development efforts, we may be unable to effectively compete.

The technologies underlying our products are subject to rapid and profound technological change. Competition intensifies as technical advances in each field are made and become more widely known. We can give no assurance that others will not develop services, products, or processes with significant advantages over the products, services, and processes that we offer or are seeking to develop. Any such occurrence could have a material and adverse effect on our business, results of operations, and financial condition.

We plan to enhance and broaden our product offerings in response to changing customer demands and competitive pressure and technologies, but we may not be successful. The success of any new product offering or enhancement to an existing product will depend on numerous factors, including our ability to:

- properly identify and anticipate physician and patient needs;

11

[Table of Contents](#)

- develop and introduce new products or product enhancements in a timely manner;
- adequately protect our intellectual property and avoid infringing upon the intellectual property rights of third parties;
- demonstrate the safety and efficacy of new products, including through the conduct of additional clinical trials;
- obtain the necessary regulatory clearances or approvals for new products or product enhancements; and
- achieve adequate coverage and reimbursement for our products.

If we do not develop and, when necessary, obtain regulatory clearance or approval for new products or product enhancements in time to meet market demand, or if there is insufficient demand for these products or enhancements, our results of operations will suffer. Our research and development efforts may require a substantial investment of time and resources before we are adequately able to determine the commercial viability of a new product, technology, material, or other innovation. In addition, even if we are able to successfully develop enhancements or new generations of our products, these enhancements or new generations of products may not be covered or reimbursed by government healthcare programs such as Medicare or private health plans, may not produce sales in excess of the costs of development, and/or may be quickly rendered obsolete by changing customer preferences or the introduction by our competitors of products embodying new technologies or features.

12

[Table of Contents](#)

We are dependent on reimbursement from third-party payers, most of whom are larger than we are and have substantially more employees and financial resources; changes in insurance reimbursement policies or application of them have resulted in decreased or delayed revenues.

A large percentage of our revenues come from third-party payer reimbursement. Most of the third-party payers are large insurance companies with substantially more resources than we have. Upon delivery of our products to our patients, we directly bill the patients' private insurance companies or government payers for reimbursement. If the third-party payers do not remit payment on a timely basis or if they change their policies to exclude or reduce coverage for our products, we would experience a decline in our revenue as well as cash flow. In addition, we may deliver products to patients and invoice based on past practices and billing experiences only to have third-party payers later deny coverage for such products.

In some cases, our delivered product may not be covered pursuant to a policy statement of a third-party payer, despite a payment history with the third-party payer and benefits to the patients. A third-party payer may seek repayment of amounts previously paid for covered products. We maintain an allowance for provider discounts and amounts intended to cover legitimate requests for repayment. Failure to adequately identify and provide for amounts for resolution of repayment demands in our allowance for provider discounts could have a material adverse effect on our results of operations and cash flows. For government

health care healthcare programs, if we identify a deficiency in prior claims or practices, we may be required to repay amounts previously reimbursed to us by government health care healthcare programs.

We frequently receive, and expect to continue to receive, refund requests from insurance providers relating to specific patients and dates of service. Billing and reimbursement disputes are very common in our industry. These requests are sometimes related to a few patients and other times include a significant number of refund claims in a single request which can accumulate to a significant amount. We review and evaluate these requests and determine if any refund is appropriate. During the adjudication process, we review claims where we are rebilling or pursuing additional reimbursement from that insurance provider. We frequently have significant offsets against such refund requests which may result in amounts that are due to us in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of such refund requests, we are generally unable to determine if a refund request is valid. Although we cannot predict whether or when a request for repayment or our subsequent request for reimbursement will be resolved, it is not unusual for such matters to be unresolved for a long an extended period of time. No assurances can be given with respect to our estimates for our allowance for provider discounts refund claim reimbursements and offsets or the ultimate outcome of the refund requests.

We are dependent on our Medicare Supplier Number.

We are required to have a Medicare Supplier Number in order to have the ability to bill Medicare for services provided to Medicare patients. Furthermore, all third-party and Medicaid contracts require us to have a Medicare Supplier Number. We are required to

12

[Table of Contents](#)

comply with Medicare DMEPOS Durable Medical Equipment, Prosthetics, Orthotics, and Supplies ("DMEPOS") Supplier Standards in order to maintain such number. If we are unable to comply with the relevant standards, we could lose our Medicare Supplier Number. Without such number, we would be unable to continue our various third-party and Medicaid contracts. A significant portion of our revenues are dependent upon our Medicare Supplier Number, the loss of which would materially and adversely affect our business, financial condition, results of operations, and cash flows.

The Center for Medicare and Medicaid Services ("CMS") requires that all Durable Medical Equipment providers must be accredited by a CMS-approved accreditation organization. On February 1, 2013, we initially received accreditation from the Accreditation Commission for Health Care ("ACHC"), and we have remained accredited to date. If we lost our accredited status, our business, financial condition, revenues, and results of operations would be materially and adversely affected.

13

[Table of Contents](#)

We face periodic reviews and billing audits from governmental and private payers, and these audits could have adverse results that may negatively impact our business.

As a result of our participation in the Medicaid program and our registration in the Medicare program, we are subject to various governmental reviews and audits to verify our compliance with these programs and applicable laws and regulations. We also are subject to audits under various government programs in which third-party firms engaged by CMS conduct extensive reviews of claims data and medical and other records to identify potential improper payments under the Medicare program. Private pay sources also reserve the right to conduct audits. If billing errors are identified in the sample of reviewed claims, the billing error can be extrapolated to all claims filed which could result in a larger overpayment than originally identified in the sample of reviewed claims. Our costs to respond to and defend reviews and audits may be significant and could have a material adverse effect on our business, financial condition, results of operations, and cash flows. Moreover, an adverse review or audit could result in:

- required refunding or retroactive adjustment of amounts we have been paid by governmental or private payers;
- state or Federal agencies imposing fines, penalties, and other sanctions on us;

- loss of our right to participate in the Medicare program, state programs, or one or more private payer networks; or
- damage to our business and reputation in various markets.

Any one of these results could have a material adverse effect on our business, financial condition, results of operations, and cash flows.

Failure to secure and maintain adequate coverage and reimbursement from third-party payers could adversely affect acceptance of our products and reduce our revenues.

The majority of our revenues come from third-party payers, primarily insurance companies.

In the U.S., private payers cover the largest segment of the population, with the remainder either uninsured or covered by governmental payers. The majority of the third-party payers outside the U.S. are government agencies, government sponsored entities, or other payers operating under significant regulatory requirements from national or regional governments.

Third-party payers may decline to cover and reimburse certain procedures, supplies, or services. Additionally, some third-party payers may decline to cover and reimburse our products for a particular patient even if the payer has a favorable coverage policy addressing our products or previously approved reimbursement for our products. **Additionally, Furthermore,** private and government payers may consider the cost of a treatment in approving coverage or in setting reimbursement for the treatment.

Private and government payers are increasingly challenging the prices charged for medical products and services. Additionally, the containment of healthcare costs has become a priority of governments. Adoption of additional price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures could further limit our revenues and operating results. If third-party payers do not consider our products or the combination of our products with additional

13

[Table of Contents](#)

treatments to be cost-justified under a required cost-testing model, they may not cover our products for their populations or, if they do, the level of reimbursement may not be sufficient to allow us to sell our products on a profitable basis.

Reimbursement for the treatment of patients with medical devices is governed by complex mechanisms. These mechanisms vary widely among countries, can be informal, somewhat unpredictable, and evolve constantly, reflecting the efforts of these countries to reduce public spending on healthcare. As a result, obtaining and maintaining reimbursement for the treatment of patients with medical devices has become more challenging. We cannot guarantee that the use of our products will receive reimbursement approvals and cannot guarantee that our existing reimbursement approvals will be maintained in any country.

Our failure to secure or maintain adequate coverage or reimbursement for our products by third-party payers in the U.S. or in the other jurisdictions in which we market our products could have a material adverse effect on our business, revenues, and results of operations and cause our stock price to decline.

14

[Table of Contents](#)

We may not be successful in maintaining the reimbursement codes necessary to facilitate accurate and timely billing for our products or physician services attendant to our products.

Third-party payers, healthcare systems, government agencies, or other groups often issue reimbursement codes to facilitate billing for products and physician services used in the delivery of healthcare. If we are unable to maintain the Healthcare Common Procedure Coding System codes ("HCPCS codes") for physician services related to our products, our revenues and results may be affected by the absence of such HCPCS codes, as physicians may be less likely to prescribe the therapy when there is no certainty that adequate reimbursement will be available for the time, effort, skill, practice expense, and malpractice costs required to provide the therapy to patients.

Outside the U.S., United States, we have not secured codes to describe our products or to document physician services related to the delivery of therapy using our products. The failure to obtain and maintain these codes could affect the growth of our business.

We at times have concentrations of credit risk with third-party payers; failure to collect these and other billed receivables could adversely affect our cash flows and results of operations.

The At December 31, 2023 the Company had did not have gross receivables from one any third-party payer at December 31, 2022 which made up approximately 14% over 10% of the accounts receivable balance. The Company had gross receivables from one third-party payer at December 31, 2021 December 31, 2022, which made up approximately 22% 14% of the accounts receivable balance.

Future changes in coverage and reimbursement policies for our products or reductions in reimbursement rates for our products by third party payers could adversely affect our business and results of operations.

In the United States, our products are prescribed by physicians for their patients. Based on the prescription, which we consider an order, we submit a claim for payment directly to third-party payers such as private commercial insurance carriers, government payers, and others as appropriate, and the third-party payer reimburses us directly. Federal and state statutes, rules, or other regulatory measures that restrict coverage of our products or reimbursement rates could have an adverse effect on our ability to sell or rent our products or cause physical therapists and physicians to dispense and prescribe alternative, lower-cost products.

There are significant estimating risks associated with the amount of revenue, related refund liabilities, accounts receivable, and provider discounts that we recognize, and if we are unable to accurately estimate these amounts, it could impact the timing of our revenue recognition and cash collections, which have a significant impact on our operating results, or lead to a restatement of our financial results.

There are significant risks associated with the estimation of the amount of revenues, related refund liabilities, accounts receivable, and provider discounts that we recognize in a reporting period. The billing and collection process is complex due to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of coverage, differing provider discount rates, and other third-party payer issues. Determining applicable primary and secondary coverage for our customers at any point in time, together with the changes in patient coverage that occur each month, require complex, resource-intensive processes. Errors in determining the correct coordination of benefits may result in refunds to payers. Revenues associated with government programs are also subject to estimating risk related to the amounts not paid by the primary government payer that will ultimately be collectable from other

14

[Table of Contents](#)

government programs paying secondary coverage, the patient's commercial health plan secondary coverage or the patient. Collections, refunds, and pay or retractions typically continue to occur for up to three years and longer after our products are provided. While we typically look to our past experience in collections with a payer in estimating amounts expected to be collected on current billings, recent trends and current changes in reimbursement practice, the overall healthcare environment, and other factors nonetheless could ultimately impact the amount of revenues recorded and the receivables ultimately collected. If our estimates of revenues, related refund liabilities, accounts receivable, or provider discounts are materially inaccurate, it could impact the timing of our revenue recognition and have a significant impact on our operating results. It could also lead to a restatement of our financial results.

15

[Table of Contents](#)

Tax laws and regulations require compliance efforts that can increase our cost of doing business and changes business. Changes to these laws and regulations could impact financial results.

We are subject to a variety of tax laws and regulations in the jurisdictions in which we do business. Maintaining compliance with these laws can increase our cost of doing business and failure to comply could result in audits or the imposition of fines or penalties. Further, our future effective tax rates in any of these jurisdictions could be affected, positively or negatively, by changing tax priorities, changes in statutory rates, or changes in tax laws or the interpretation thereof.

The most significant recent example of this is the impact of the U.S Tax Cuts and Jobs Act of 2017 (the "Tax Act") which was enacted on December 22, 2017. These changes significantly revised the ongoing U.S. corporate income tax law by lowering the U.S. federal corporate income tax rate from 35% to 21%, implementing a territorial tax system, imposing a one-time tax on foreign unremitted earnings, and setting limitations on deductibility of certain costs, among other things. The Company has implemented the Tax Act and does not expect any significant changes related to the Tax Act at this time.

The impact of healthcare reform legislation and other changes in the healthcare industry and in healthcare spending on us is currently unknown but may harm our business.

Our revenue is dependent on the healthcare industry and could be affected by changes in healthcare spending and policy. The healthcare industry is subject to changing political, regulatory, and other influences. The Patient Protection and Affordable Care Act or PPACA, ("PPACA") made major changes in how **healthcare** is **both** delivered and reimbursed, and increased access to health insurance benefits to the uninsured and underinsured population of the United States.

The PPACA, among other things, increased the number of individuals with Medicaid and private insurance coverage, implemented reimbursement policies that tie payment to quality, facilitated the creation of accountable care organizations that may use capitation and other alternative payment methodologies, strengthened enforcement of fraud and abuse laws, and encouraged the use of information technology. Such changes in the regulatory environment may also result in changes to our payer mix that may affect our operations and net revenue.

In addition, certain Certain provisions of the PPACA authorize voluntary demonstration projects, which include the development of bundling payments for acute, inpatient hospital services, physician services, and post-acute services for episodes of hospital care. Further, the PPACA may negatively impact payers by increasing medical costs generally, which could have an effect on the industry and potentially impact our business and revenue as payers seek to offset these increases by reducing costs in other areas. The full impact of these changes on us cannot be determined at this time.

We are also impacted by the Medicare Access and CHIP Reauthorization Act, under which physicians must choose to participate in one of two payment formulas, Merit-Based Incentive Payment System or MIPS, ("MIPS") or Alternative Payment Models or APMs, ("APMs"). Beginning in 2019, MIPS allows eligible physicians to receive upward or downward adjustments to their Medicare Part B payments based on certain quality and cost metrics, among other measures. As an alternative, physicians can choose to participate in an Advanced APM. Advanced APMs are exempt from the MIPS requirements, and physicians who are meaningful participants in APMs will receive bonus payments from Medicare pursuant to the law.

In addition, current and prior healthcare reform proposals have included the concept of creating a single payer or public option for health insurance. If enacted, these proposals could have an extensive impact on the healthcare industry, including us. We are unable predict whether such reforms may be enacted or their impact on our operations.

15

[Table of Contents](#)

We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments and other third-party payers will pay for healthcare services, which could harm our business, financial condition, and results of operations.]

16

[Table of Contents](#)

The Patient Protection and Affordable Care Act of 2010 has had an impact on our business which may be in part beneficial and in part detrimental.

In March 2010, broad federal **health care** **healthcare** reform legislation was enacted in the United States. This legislation did not become effective immediately in total and may be modified prior to the effective date of some provisions. This legislation has had an impact on our business in a variety of ways including increased number of Medicaid recipients, increased number of individuals with commercial insurance, additional audits conducted by public health insurance plans such as Medicaid and Medicare, changes to the rules that govern employer group health insurance, and other factors that influence the acquisition and use of health insurance from private and public payers. This legislation has resulted in a change in reimbursement for certain durable medical equipment. We

believe the new healthcare legislation and these changes to reimbursement have caused uncertainty with prescribers, which we believe contributed to our drop in orders and revenue during 2013 and 2014 and the lack of any significant increase in 2015. Orders and revenue increased in 2016 through 2022; 2023; however, we are currently unable to determine whether such trend will continue in future periods or whether the **health care** **healthcare** reform legislation will have other adverse consequences to our business and results of operations. To the extent prescribers write fewer prescriptions for our products or there is an adverse change to insurance reimbursement for our products, due to the new law or otherwise, our revenue and profitability will be materially adversely affected.

The uncertainty of continuing healthcare changes and regulations may negatively affect our business.

There is some doubt on the continuation of the Affordable Care Act and the legislation that the current Congress will enact to replace it, if any. Because we cannot be certain about the continuation of the Affordable Care Act or any changes or replacements thereto, even if the Affordable Care Act remains the law of the land, there is also some doubt whether the President will support it or take regulatory action to negatively impact its benefits. The amount of uncertainty creates concern on our **customer's** **customers'** willingness to buy products which may or may not be covered by future **health care** **healthcare** benefits even if they are covered currently.

We are subject, directly or indirectly, to United States federal and state healthcare fraud and abuse and false claims laws and regulations. Prosecutions under such laws have increased in recent years, and we may become subject to such litigation. If we are unable to or have not fully complied with such laws, we could face substantial penalties.

Our operations are subject to various state and federal fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal Stark Law, and the federal False Claims Act. These laws may impact, among other things, our sales, marketing, and education programs.

The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual or the furnishing or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. Several courts have interpreted the statute's intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The Anti-Kickback Statute is broad and, despite a series of narrow safe harbors, prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. Penalties for violations of the federal Anti-Kickback Statute include criminal penalties and civil sanctions such as fines, imprisonment, and possible exclusion from Medicare, Medicaid, and other federal healthcare programs. Many states have also adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs.

1716

[Table of Contents](#)

The federal Ethics in Patient Referrals Act of 1989, commonly known as the "Stark **Law**," **Law**, prohibits, subject to certain exceptions, physician referrals of Medicare and, as applicable under state law, Medicaid patients to an entity providing certain "designated health services" if the physician or an immediate family member has any financial relationship with the entity. The Stark Law also prohibits the entity receiving the referral from billing any good or service furnished pursuant to an unlawful referral. Various states have corollary laws to the Stark Law, including laws that require physicians to disclose any financial interest they may have with a healthcare provider to their patients when referring patients to that provider. Both the scope and exceptions for such laws vary from state to state. The federal False Claims Act prohibits persons from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from the federal government. The False Claims Act defines "knowingly" to include actual knowledge, acting in deliberate ignorance of the truth or falsity of information, or acting in deliberate disregard of the truth or falsity of information. False Claims Act liability includes liability for reverse false claims for avoiding or decreasing an obligation to pay or transmit money to the government. This includes False Claims Act liability for failing to report and return overpayments within 60 days of the date on which the overpayment is **identified**. **identified**. Penalties under the False Claims Act can include exclusion from the Medicare program. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Suits filed under the False Claims Act, known as qui tam actions, can be brought by any individual on behalf of the government and such individuals, commonly known as **"whistleblowers,"** **"whistleblowers"**, may share in any amounts paid by the entity to the government in fines or settlement. The frequency of filing qui tam actions has increased significantly in recent years, causing greater numbers of **medicaldevice**, **pharmaceutical**, and healthcare companies to have to defend a False Claims Act action. When an entity is determined to have violated the federal False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. Various states have also enacted laws modeled after the federal False Claims Act.

HIPAA, and its implementing regulations, also created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the **payor** (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items, or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.

From time to time, the Company has been and is involved in various governmental audits, investigations, and reviews related to its operations. Reviews and investigations can lead to government actions, resulting in the assessment of damages, civil or criminal fines or penalties, or other sanctions, including restrictions or changes in the way we conduct business, loss of licensure, or exclusion from participation in Medicare, Medicaid, or other government programs. Additionally, as a result of these investigations, healthcare providers and entities may face litigation or have to agree to settlements that can include monetary penalties and onerous compliance and reporting requirements as part of a consent decree or corporate integrity agreement, or Corporate Integrity Agreement ("CIA"). If we fail to comply with applicable laws, regulations, and rules, **its** financial condition and results of operations could be adversely affected. Furthermore, becoming subject to these governmental investigations, audits, and reviews may result in substantial costs and divert management's attention from the business as we cooperate with the government authorities, regardless of whether the particular investigation, audit, or review leads to the identification of underlying issues.

We are unable to predict whether we could be subject to actions under any of these laws, or the impact of such actions. If we are found to be in violation of any of the laws described above or other applicable state and federal fraud and abuse laws, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from Medicare, Medicaid, and other government healthcare reimbursement programs, and the curtailment or restructuring of **its** operations.

Hospitals and clinicians may not buy, prescribe, or use our products in sufficient numbers, which could result in decreased revenues and profits.

Hospitals and clinicians may not accept any of our products as effective, reliable, or cost-effective. Factors that could prevent such institutional patient acceptance include:

- **If** patients conclude that the costs of these products exceed the cost savings associated with the use of these products;
- **If** patients are financially unable to purchase these products;

18 17

[Table of Contents](#)

- **If** adverse patient events occur with the use of these products, generating adverse publicity;
- **If** we lack adequate resources to provide sufficient education and training to our patients;
- **If** frequent product malfunctions occur, leading clinicians to believe that the products are unreliable;
- **Uncertainty** regarding or change in government or third-party payer reimbursement policies for our products; and
- **If** physicians or other health care providers believe that our products will not be reimbursed by insurers or decide to prescribe competing products.

Because our sales are dependent on prescriptions from physicians, if any of these or other factors result in fewer prescriptions for our products being written, we will have reduced revenues and may not be able to fully fund our operations. Although we experienced an increase in orders for our ZMI products during **2021** and 2022 compared to prior years, we can make no assurances that demand for our products will not decline in future periods.

Any new competitor could be larger than us and have greater financial and other resources than we do, and those advantages could make it difficult for us to compete with them.

Many competitors to our products may have substantially greater financial, technical, marketing, and other resources. Competition could result in fewer orders, reduced gross margins, and loss of market share. Our products are regulated by the FDA in the United States. Competitors may develop products that are substantially equivalent to our FDA-cleared products, thereby using our products as predicate devices to more quickly obtain FDA approval for their own products. If overall demand for our products should decrease, it could have a material adverse effect on our operating results. Substantial competition is expected in the future in the area of stroke rehabilitation that may directly compete with our NeuroMove product. These competitors may use standard or novel

signal processing techniques to detect muscular movement and generate stimulation to such muscles. Other companies may develop rehabilitation products that perform better and/or are less expensive than our products, which could have a material adverse effect on our operating results.

Failure to keep pace with the latest technological changes could result in decreased revenues.

The market for some of our products is characterized by rapid change and technological improvements. Failure to respond in a timely and cost-effective way to these technological developments could result in serious harm to our business and operating results. We have derived, and we expect to continue to derive, a substantial portion of our revenues from the development and sale of products in the medical device industry. As a result, our success will depend, in part, on our ability to develop and market product offerings that respond in a timely manner to the technological advances of our competitors, evolving industry standards, and changing patient preferences. There is no assurance that we will keep up with technological improvements.

Our business could be adversely affected by reliance on sole suppliers.

Notwithstanding our current multiple supplier approach, certain essential product components may be supplied in the future by sole, or a limited group of, suppliers. Most of our products and components are purchased through purchase orders rather than through long term long-term supply agreements, and large volumes of inventory may not be maintained. There may be shortages and delays in obtaining certain product components. Disruption of the supply or inventory of components could result in a significant increase in the costs of these components or could result in an inability to meet the demand for our products. In addition, if a change in the manufacturer of a key component is required, qualification of a new supplier may result in delays and additional expenses in meeting customer demand for products. These factors could adversely affect our revenues and ability to retain our experienced sales force.

1918

Table of Contents

A third-party manufacturer's inability to produce our products' components on time and to our specifications could result in lost revenue.

Third-party manufacturers assemble and manufacture components of the NexWave and NeuroMove and some of our other products to our specifications. The inability of a manufacturer to ship orders of our products in a timely manner or to meet our quality standards could cause us to miss the delivery date requirements of our patients for those items, which could result in cancellation of orders, refusal to accept deliveries, or a reduction in purchase prices, any of which could have a material adverse effect on our revenues. Because of the timing and seriousness of our business, and the medical device industry in particular, the dates on which patients need and require shipments of products from us are critical. Further, because quality is a leading factor when patients, doctors, health insurance providers, and distributors accept or reject goods, any decline in quality by our third-party manufacturers could be detrimental not only to a particular order, but also to our future relationship with that particular patient.

We could experience cost increases or disruptions in supply of raw materials or other components used in our products.

Our third-party manufacturers that assemble and manufacture components for our products expect to incur significant costs related to procuring raw materials required to manufacture and assemble our product. The prices for these raw materials fluctuate depending on factors beyond our control, including market conditions and global demand for these materials and could adversely affect our business, prospects, financial condition, results of operations, and cash flows. Further, any delays or disruptions in our supply chain could harm our business. For example, COVID-19, including associated variants, could cause disruptions to and delays in our operations, including shortages and delays in the supply of certain parts, including semiconductors, materials and equipment necessary for the production of our products, and the internal designs and processes we or third-parties may adopt in an effort to remedy or mitigate impacts of such disruptions and delays could result in higher costs. In addition, our business also depends on the continued supply of battery cells for our products. We are exposed to multiple risks relating to availability and pricing of quality battery cells. These risks include:

- the inability or unwillingness of battery cell manufacturers to build or operate battery cell manufacturing plants to supply the numbers of battery cells (including the applicable chemistries) required to support the growth of the electric or plug-in hybrid vehicle industry as demand for such cells increases;
- disruption in the supply of battery cells due to quality issues or recalls by the battery cell manufacturers; and
- an increase in the cost or decrease in the available supply of raw materials used in battery cells, such as lithium, nickel, and cobalt.

Furthermore, currency fluctuations, tariffs, or shortages in petroleum and other economic or political conditions may result in significant increases in freight charges and raw material costs. Substantial increases in the prices for raw materials or components would increase our operating costs and could reduce our margins.

We depend upon third parties to manufacture and to supply key semiconductor chip components necessary for our products. We do not have long-term agreements with our semiconductor chip manufacturers and suppliers, and if these manufacturers or suppliers become unwilling or unable to provide an adequate supply of semiconductor chips, with respect to which there is a global shortage, we would not be able to find alternative sources in a timely manner and our business would be adversely impacted.

Semiconductor chips are a vital input component to the electrical architecture of our products, controlling wide aspects of the products' operations. Many of the key semiconductor chips we use in our products come from limited or single sources of supply, and therefore a disruption with any one manufacturer or supplier in our supply chain would have an adverse effect on our ability to effectively manufacture and timely deliver our products. We do not have any long-term supply contracts with any suppliers and purchase chips on a purchase order basis. Due to our reliance on these semiconductor chips, we are subject to the risk of shortages and long lead times in their supply. We are in the process of identifying alternative manufacturers for semiconductor chips. We have in the past experienced, and may in the future experience, semiconductor chip shortages, and the availability and cost of these components would be difficult to predict. For example, our manufacturers may experience temporary or permanent disruptions in their manufacturing operations due to equipment breakdowns, labor strikes or shortages, natural disasters, component or material shortages, cost increases, acquisitions, insolvency, changes in legal or regulatory requirements, or other similar problems.

2019

[Table of Contents](#)

In particular, increased demand for semiconductor chips in 2020, due in part to the COVID-19 pandemic and increased demand for consumer electronics that use these chips, has resulted in a severe global shortage of chips in 2021 and 2022. As a result, our ability to source semiconductor chips to be used in our products has been adversely affected. This shortage may result in increased chip delivery lead times, delays in the production of our products, and increased costs to source available semiconductor chips. To the extent this semiconductor chip shortage continues, and we are unable to mitigate the effects of this shortage, our ability to deliver sufficient quantities of our products to fulfill our preorders and to support our growth through sales to new customers would be adversely affected. In addition, we may be required to incur additional costs and expenses in managing ongoing chip shortages, including additional research and development expenses, engineering design, and development costs in the event that new suppliers must be onboarded on an expedited basis. Further, ongoing delays in production and shipment of products due to a continuing shortage of semiconductor chips may harm our reputation and discourage additional preorders and sales, and otherwise materially and adversely affect our business and operations.

If we need to replace manufacturers, our expenses and cost of goods could increase, resulting in smaller low profit margins.

We compete with other companies for the production capacity of our manufacturers and import quota capacity. Some of these competitors have greater financial and other resources than we have and thus have an advantage in the competition for production and import quota capacity. If we experience a significant increase in demand, or if we need to replace an existing manufacturer, we may have to expand our third-party manufacturing capacity. We cannot assure that this additional capacity will be available when required on terms that are acceptable to us or similar to existing terms, which we have with our manufacturers, either from a production standpoint or a financial standpoint. We enter into a number of purchase order commitments specifying a time for delivery, method of payment, design and quality specifications, and other standard industry provisions, but we do not have long-term contracts with any manufacturer. None of the manufacturers we use produce our products exclusively. Should we be forced to replace one or more of our manufacturers, we may experience increased costs or an adverse operational impact due to delays in distribution and delivery of our products to our patients, which could cause us to lose patients or lose revenue because of late shipments.

We are a relatively small company with a limited number of products and staff. Sales fluctuations and employee turnover may adversely affect our business.

We are a relatively small company. Consequently, compared to larger companies, sales fluctuations could have a greater impact on our revenue and profitability on a quarter-to-quarter and year-to-year basis, and delays in patient orders could cause our operating results to vary significantly from quarter to quarter and year-to-year. In addition, as a small company we have limited staff and are heavily reliant on certain key personnel to operate our business. If a key employee were to leave the company, it could have a material impact on our business and results of operations, as we might not have sufficient depth in our staffing to fill the role that was previously being performed. A delay in filling the vacated position could put a strain on existing personnel, or result in a failure to satisfy our contractual obligations, or to effectively implement our internal controls, and which could materially harm our business.

If we are unable to retain the services of Mr. Sandgaard or if we are unable to successfully recruit qualified managerial and sales personnel, we may not be able to continue our operations.

Our success depends to a significant extent upon the continued service of Mr. Thomas Sandgaard, our Chief Executive Officer, Founder, and beneficial owner of approximately **41%** **50%** of our outstanding stock. stock as of February 28, 2024. Loss of the services of Mr. Sandgaard could have a material adverse effect on our growth, revenues, and prospective business. There is currently no employment agreement with Mr. Sandgaard. We do not maintain key-man insurance on the life of Mr. Sandgaard. In addition, in order to successfully implement and manage our business plan, we will be dependent upon, among other things, successfully retaining and recruiting qualified managerial and sales personnel. Competition for qualified individuals is intense. Various factors, such as marketability of our products, our reputation, our liquidity, and sales commission structure can affect our ability to find, attract, or retain sales personnel. There can be no assurance that we will be able to find and attract qualified new employees and sales representatives and retain existing employees and sales representatives.

2120

[Table of Contents](#)

We need to maintain insurance coverage, which could become very expensive or have limited availability.

Our marketing and sales of medical device products creates create an inherent risk of claims for product liability. As a result, we carry product liability insurance and will continue to maintain insurance in amounts we consider adequate to protect us from claims. We cannot, however, be assured that we have resources sufficient to satisfy liability claims in excess of policy limits if required to do so. Also, if we are subject to such liability claims, there is no assurance that our insurance provider will continue to insure us at current levels or that our insurance rates will not substantially rise in the future, resulting in increased costs to us or forcing us to either pay higher premiums or reduce our coverage amounts, which would result in increased liability to claims.

Although we do not manufacture the products we distribute, if one of the products distributed by us proves to be defective or is misused by a health care practitioner or patient, we may be subject to liability that could adversely affect our financial condition and results of operations.

Although we do not manufacture the products that we distribute, a defect in the design or manufacture of a product distributed or serviced by us, or a failure of a product distributed by us to perform for the use specified, could have a material and adverse effect on our reputation in the industry and subject us to claims of liability for injuries and otherwise. Misuse of the product distributed by us by a practitioner or patient that results in injury could similarly subject us to liability. Any substantial underinsured loss could have a material and adverse effect on our business, financial condition, results of operations, and cash flows. Furthermore, any impairment of our reputation could have a material and adverse effect on our revenues and prospects for future business.

We depend upon obtaining regulatory clearance of new products and/or manufacturing operations we develop and maintain clearances of current products; failure to obtain or maintain such regulatory clearances could result in increased costs, lost revenue, penalties, and fines.

Before marketing certain new products, we will need to complete one or more clinical investigations of each product. There can be no assurance that the results of such clinical investigations will be favorable to us. We may not know the results of any study, favorable or unfavorable to us, until after the study has been completed. Such data must be submitted to the FDA as part of any regulatory filing seeking clearance to market the product. Even if the results are favorable, the FDA may dispute the claims of safety, efficacy, or clinical utility and not allow the product to be marketed. The sales price of the product may not be enough to recoup the amount of our investment in conducting the investigative studies, and we may expend significant funds on research and development on products that are rejected by the FDA. Some of our products are marketed based upon our interpretation of FDA regulation allowing for changes to an existing device. If our interpretations are incorrect, we could suffer consequences that could have a material adverse effect on our results of operations and cash flows and could result in fines and penalties. There can be no assurance that we will have the financial resources to complete development of any new products, or to complete the regulatory clearance process, or to maintain regulatory compliance of existing products.

We may not be able to obtain clearance of a 510(k) pre-market notification or grant of a de novo classification request or approval of a pre-market approval application with respect to any products on a timely basis, if at all.

If timely FDA clearance or approval of new products is not obtained, our business could be materially adversely affected. Clearance of a 510(k) pre-market notification or de novo application may also be required before marketing certain previously marketed products, which have been modified after they have been cleared. Should the FDA so require, the filing of a new 510(k) pre-market notification for the modification of the product may be required prior to marketing any modified device. To determine whether adequate compliance has been achieved, the FDA may inspect our facilities at any time. Such compliance can be difficult and costly to achieve and maintain. Our compliance status may change due to future changes in, or interpretations of, FDA regulations or other regulatory agencies. Such changes may result in the FDA withdrawing marketing clearance or requiring or requesting product recall. In addition, any changes or modifications to a device or its intended use may require us to reassess compliance with good manufacturing practices guidelines, potentially interrupting the marketing and sale of products. We may also fail to comply with complex FDA regulations due to their complexity or otherwise. Failure to comply with

regulations could result in enforceable actions, including product seizures, product recalls, withdrawal of clearances or approvals, injunctions, and civil and criminal penalties, any of which could have a material adverse effect on our operating results and reputation.

2221

[Table of Contents](#)

Our products are subject to recall even after receiving FDA or foreign clearance or approval, which would harm our reputation and business.

We are subject to medical device reporting regulations that require us to report to the FDA or respective governmental authorities in other countries if our products cause or contribute to a death or serious injury or malfunction in a way that would be reasonably likely to cause or contribute to death or serious injury if the malfunction were to recur. The FDA and similar governmental authorities in other countries have the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacturing. A government mandated or voluntary recall by us could occur as a result of component failures, manufacturing errors or design defects, including defects in labeling.

Any recall would divert managerial and financial resources and could harm our reputation with customers. We cannot assure you that we will not have product recalls in the future or that such recalls would not have a material adverse effect on our business. We have not undertaken any voluntary or mandatory recalls to date.

We continue to incur expenses.

This area of medical device research is subject to rapid and significant technological changes. Developments and advances in the medical industry by either competitors or other parties can affect our business in either a positive or negative manner. Developments and changes in technology that are favorable to us may significantly advance the potential of our research, while developments and advances in research methods outside of the methods we are using may severely hinder or completely halt completely our development.

We are a small company in terms of employees and technical and research resources. We expect to incur research and development, sales and marketing, and general and administrative expenses. These amounts may increase, and recently have in connection with our efforts to expand our sales force, before any commensurate incremental revenue from these efforts may be obtained and may adversely affect our potential profits, and we may lack the liquidity to pay for such expenditures. These factors may also hinder our ability to meet changes in the medical industry as rapidly or effectively as competitors with more resources.

Substantial costs could be incurred defending against claims of intellectual property infringement.

Other companies, including competitors, may obtain patents or other proprietary intellectual property rights that would limit, interfere with, or otherwise circumscribe our ability to make, use, or sell products. Should there be a successful claim of infringement against us, and if we could not license the alleged infringed technology at a reasonable cost, our business and operating results could be adversely affected. There has been substantial litigation regarding patent and other intellectual property rights in the medical device industry. The validity and breadth of claims covered in medical technology patents involve complex legal and factual questions for which important legal principles remain unresolved. Any litigation claims against us, independent of their validity, may result in substantial costs and the diversion of resources with no assurance of success. Intellectual property claims could cause us to:

- Cease cease selling, incorporating, or using products that incorporate the challenged intellectual property;
- Obtain obtain a license from the holder of the infringed intellectual property right, which may not be available on reasonable terms, if at all; and
- Re-design re-design our products excluding the infringed intellectual property, which may not be possible.

We may be unable to protect our trademarks, trade secrets, and other intellectual property rights that are important to our business.

We consider our trademarks, trade secrets, and other intellectual property an integral component of our success. We rely on trademark law and trade secret protection and confidentiality agreements with employees, customers, partners, and others to protect our intellectual property. Effective trademark and trade secret protection may not be available in every country in which our products are available. We obtained utility patents on the fluid monitoring system in 2021 and 2018 in the U.S. and in 2020 in Europe. We cannot be certain that we have taken adequate steps to protect our intellectual property, especially in countries where the laws may not protect

22

[Table of Contents](#)

our rights as fully as in the United States. In addition, if our third-party confidentiality agreements are breached, there may not be an adequate remedy available to us. If our trade secrets become publicly known, we may lose competitive advantages.

23

[Table of Contents](#)

We may fail to protect the privacy, integrity and security of customer information.

We possess and process sensitive customer information and Protected Health Information protected by the Health Insurance Portability and Affordability Act ("HIPAA"). While we have taken reasonable and appropriate steps to protect that information, if our security procedures and controls were compromised, it could harm our business, reputation, results of operations, and financial condition and may increase the costs we incur to protect against such information security breaches, such as increased investment in technology, the costs of compliance with **health care** **healthcare** privacy and consumer protection laws. A compromise of our privacy or security procedures could also subject us to liability under certain **health care** **healthcare** privacy laws applicable to us.

Other federal and state laws restrict the use and protect the privacy and security of personally identifiable information are, in many cases, are not preempted by HIPAA and may be subject to varying interpretations by the courts and government agencies. These varying interpretations can create complex compliance issues for us and our partners and potentially expose us to additional expense, adverse publicity and liability, any of which could adversely affect our business. There is ongoing concern from privacy advocates, regulators and others regarding data privacy and security issues, and the number of jurisdictions with data privacy and security laws has been increasing. Also, there are ongoing public policy discussions regarding whether the standards for de-identification, anonymization or pseudonymization of health information are sufficient, and the risk of re-identification sufficiently small, to adequately protect patient privacy. We expect that there will continue to be new proposed and amended laws, regulations and industry standards concerning privacy, data protection and information security in the United States, such as the California Consumer Privacy Act ("CCPA"), as amended by the California Privacy Rights Act ("CPRA"), which amendments went into effect on January 1, 2023. The CCPA creates specific obligations with respect to processing and storing personal information, and the CPRA amendments created a new state agency that is vested with authority to implement and enforce the CCPA. Additionally, a similar law went into effect in Virginia on January 1, 2023, and further US-state comprehensive privacy laws are set to go into effect throughout 2023, including laws in Colorado, Connecticut, and Utah. These laws are substantially similar in scope and contain many of the same requirements and exceptions as the CCPA, including a general exemption for clinical trial data and limited obligations for entities regulated by HIPAA. However, we cannot yet determine the full impact these laws or other such future laws, regulations and standards may have on our current or future business. Any of these laws may broaden their scope in the future, and similar laws have been proposed on both a federal level and in more than half of the states in the U.S. A number of other states have proposed new privacy laws, some of which are similar to the above discussed recently passed laws. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.

Cyber-attacks and security vulnerabilities could lead to reduced revenue, increased costs, liability claims, or harm to our competitive position.

Increased sophistication and activities of perpetrators of cyber-attacks have resulted in an increase in information security risks in recent years. Hackers develop and deploy viruses, worms, and other malicious software programs that attack products and services and gain access to networks and data centers. In addition to extracting sensitive information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. The prevalent use of mobile devices also increases the risk of data security incidents. If we experience difficulties maintaining existing systems or implementing new systems, we could incur significant losses due to disruptions in our operations. Additionally, these systems contain valuable proprietary and confidential information and may contain personal data of our customers. While we believe we have taken reasonable steps to protect such data, techniques used to gain unauthorized access to data and systems, disable or degrade service, or sabotage systems, are constantly evolving, and we may be unable to anticipate such techniques or implement adequate preventative measures to avoid unauthorized access or other adverse impacts to such data or our systems. In addition, some of our third-party service providers and partners also collect and/or store our sensitive information and our customers' data on our behalf, and these service providers and

partners are subject to similar threats of cyber-attacks and other malicious internet-based activities, which could also expose us to risk of loss, litigation, and potential liability. A security breach could result in disruptions of our internal systems and business applications, harm

23

[Table of Contents](#)

to our competitive position from the compromise of confidential business information, or subject us to liability under laws that protect personal data. Additionally, actual, potential or anticipated attacks may cause us to incur increasing costs, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants. Specifically, as

24

[Table of Contents](#)

cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures and/or to investigate and remediate any information security vulnerabilities. Any of these consequences would adversely affect our revenue and margins. Additionally, although we maintain cybersecurity insurance coverage, we cannot be certain that such coverage will be adequate for data security liabilities actually incurred, will cover any indemnification claims against us relating to any incident, will continue to be available to us on economically reasonable terms, or at all, or that any insurer will not deny coverage as to any future claim. The successful assertion of one or more large claims against us that exceed available insurance coverage, or the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could have a material adverse effect on our reputation, business, prospects, results of operations and financial condition.

We have identified a material weakness in our internal controls over financial reporting and may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our consolidated financial statements or cause us to fail to meet our periodic reporting obligations.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company's annual or interim financial statements will not be prevented or detected on a timely basis. We identified a material weakness in our internal controls over financial reporting as of December 31, 2022, December 31, 2023 and 2022, related to information technology general controls or ITGCs, ("ITGCs") that were not designed and operating effectively to ensure (i) appropriate segregation of duties was in place to perform program changes and (ii) the activities of individuals with access to modify data and make program changes were appropriately monitored. Business process controls (automated and manual) that are dependent on the affected ITGCs were also deemed ineffective because they could have been adversely impacted. Also as of December 31, 2023, we identified a material weakness in our communications with our independent auditors as it relates to open or pending financial statement adjustments and the timing of decisions to take write-offs. Although the material weakness identified above did not result in any material misstatements in our consolidated financial statements for the periods presented and there were no changes to previously released financial results, our management concluded that these control weaknesses constitute a material weakness and that our internal control was not effective as of December 31, 2022 December 31, 2023.

Our management is committed to take comprehensive actions to remediate the material weakness in internal control over financial reporting. We are in the process of developing and implementing remediation plans to address the material weakness described above.

While we are committed to designing and implementing new controls and measures to remediate this material weakness, we cannot assure you that the measures will be sufficient to remediate the material weakness or avoid the identification of additional material weaknesses in the future. Our failure to implement and maintain effective internal control over financial reporting could result in errors in our consolidated financial statements that could result in a restatement of our financial statements and could cause us to fail to meet our periodic reporting obligations, any of which could diminish investor confidence in us and cause a decline in the price of our common stock.

Expansion of our operations and sales internationally may subject us to additional risks, including risks associated with unexpected events.

A component of our growth strategy is to expand our operations and sales internationally. There can be no assurance that we will be able to successfully market, sell, and deliver our products in foreign markets, or that we will be able to successfully expand our international operations. Global operations could cause us to be subject to unexpected, uncontrollable and rapidly changing risks, events, and circumstances.

The following factors, among others, could adversely affect our business, financial condition and results of operations:

- difficulties in managing foreign operations and attracting and retaining appropriate levels of senior management and staffing;
- longer cash collection cycles;
- proper compliance with local tax laws which can be complex and may result in unintended adverse tax consequences;

24

[Table of Contents](#)

- difficulties in enforcing agreements through foreign legal systems;

25

[Table of Contents](#)

- failure to properly comply with U.S. and foreign laws and regulations applicable to our foreign activities including, without limitation, product approval, healthcare and employment law requirements and the Foreign Corrupt Practices Act;
- fluctuations in exchange rates that may affect product demand and may adversely affect the profitability in U.S. dollars of the products we provide in foreign markets;
- the ability to efficiently repatriate cash to the United States and transfer cash between foreign jurisdictions; and
- changes in general economic conditions or political circumstances in countries where we operate.

Our acquisition of other companies could require significant management attention, disrupt our business, dilute stockholder value and adversely affect our operating results.

As part of our business strategy, we have made and may in the future acquire or make investments in other companies, solutions or technologies to, among other reasons, expand or enhance our product offerings. In the future, any significant acquisition would require the consent of our lenders. Any failure to receive such consent could delay or prohibit us from acquiring companies that we believe could enhance our business.

We may not ultimately strengthen our competitive position or achieve our goals from our recent or any future acquisition, and any acquisitions we complete could be viewed negatively by users, customers, partners or investors. In addition, if we fail to successfully integrate such acquisitions, or the technologies associated with such acquisitions, into our company, the revenues and operating results of the combined company could be adversely affected. For example, in December 2021 we acquired Kestrel Labs, Inc. and we must effectively integrate the personnel, products, technologies and customers and develop and motivate new employees. In addition, we may not be able to successfully retain the customers and key personnel of such acquisitions over the longer term, which could also adversely affect our business. The integration of our recently-acquired business or future-acquired business will require significant time and resources, and we may not be able to manage the process successfully. We may not successfully evaluate or utilize the acquired business and accurately forecast the financial impact of the acquisition, including accounting charges.

We may have to pay cash, incur debt or issue equity securities to pay for any acquisition, each of which could affect our financial condition or the value of our capital stock. For example, in connection with our acquisition of Kestrel Labs, Inc., we paid an approximate value of \$30.5 million, consisting of \$16.1 million in cash which was financed through Bank of America N.A. and approximately \$14.4 million in shares of our common stock, a portion of which was to be held in escrow until certain milestones are achieved. To fund any future acquisition, we may issue equity, which would result in dilution to our stockholders, or

incur more debt, which would result in increased fixed obligations and could subject us to additional covenants or other restrictions that would impede our ability to manage our operations.

If we are not able to integrate acquired businesses successfully, our business could be harmed.

Our inability to successfully integrate our recent and future acquisitions could impede us from realizing all of the benefits of those acquisitions and could severely weaken our business operations. The integration process may disrupt our business and, if implemented ineffectively, may preclude realization of the full benefits expected by us and could harm our results of operations. In addition, the overall integration of the combining companies may result in unanticipated problems, expenses, liabilities, and competitive responses, and may cause our stock price to decline. The difficulties of integrating an acquisition include, among others:

- unanticipated issues in integration of information, communications, and other systems;
- unanticipated incompatibility of logistics, marketing, and administration methods;
- maintaining employee morale and retaining key employees;
- integrating the business cultures of both companies;
- **preserving important strategic client relationships;**

26 25

[Table of Contents](#)

- **preserving important strategic client relationships;**
- consolidating corporate and administrative infrastructures and eliminating duplicative operations; and
- coordinating geographically separate organizations.

In addition, even if the operations of an acquisition are integrated successfully, we may not realize the full benefits of the acquisition, including the synergies, cost savings, or growth opportunities that we expect. These benefits may not be achieved within the anticipated time frame, or at all. For example, the failure to get regulatory approval to sell certain products of an acquired business may significantly reduce the anticipated benefits of the acquisition and could harm our results of operations, even if we have put in place contingencies for the delivery of closing consideration, such as the escrowed shares **initially** held back in our acquisition of Kestrel Labs, Inc. Further, acquisitions may also cause us to:

- issue securities that would dilute our current stockholders' ownership percentage;
- use a substantial portion of our cash resources;
- increase our interest expense, leverage, and debt service requirements if we incur additional debt to pay for an acquisition;
- assume liabilities, including environmental liabilities, for which we do not have indemnification from the former owners or have indemnification that may be subject to dispute or concerns regarding the creditworthiness of the former owners;
- record goodwill and non-amortizable intangible assets that are subject to impairment testing on a regular basis and potential impairment charges;
- experience volatility in earnings due to changes in contingent consideration related to acquisition liability estimates;
- incur amortization expenses related to certain intangible assets;
- lose existing or potential contracts as a result of conflict of interest issues;
- incur large and immediate write-offs; or
- become subject to litigation.

Our failure to comply with the covenants contained in our loan agreement could result in an event of default that could adversely affect our financial condition and ability to operate our business as planned.

We currently have an outstanding term loan and line of credit with Bank of America, N.A. under which we are obligated to pay monthly amortization payments. Our loan agreement contains, and any agreements to refinance our debt likely will contain, financial and restrictive covenants. Our failure to comply with these covenants in the future may result in an event of default, which if not cured or waived, could result in the bank preventing us from accessing availability under our line of credit and requiring us to repay any outstanding borrowings. There can be no assurance that we will be able to obtain waivers in the event of covenant violations or that such waivers will be available on commercially acceptable terms.

In addition, the indebtedness under our loan agreement is secured by a security interest in substantially all of our tangible and intangible assets, and therefore, if we are unable to repay such indebtedness the bank could foreclose on these assets and sell the pledged equity interests, which would adversely affect our ability to operate our business. If any of these were to occur, we may not be able to continue operations as planned, implement our planned growth strategy or react to opportunities for or downturns in our business.

27

[Table of Contents](#)

Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported results of operations.

We are required to prepare our financial statements in accordance with generally accepted accounting principles in the United States of America ("GAAP"), which is periodically revised and/or expanded. From time to time, we are required to adopt new or revised accounting standards issued by recognized authoritative bodies, including the Financial Accounting Standards Board ("FASB") and the SEC. It is possible that future accounting standards we are required to adopt may require additional changes to the current accounting treatment that we apply to our financial statements and may require us to make significant changes to our reporting systems. Such changes could result in a material adverse impact on our business, results of operations and financial condition.

The conversion feature of our convertible senior notes, if triggered, may adversely affect our financial condition and operating results.

We have outstanding a total of \$60 million of convertible senior notes. See Note 8: Convertible Senior Notes to the Consolidated Financial Statements included in "Part II, Item 8 - Financial Statements and Supplementary Data." If the conversion feature of any of

26

[Table of Contents](#)

those convertible senior notes is triggered, holders will be entitled to convert the notes at their option at any time during specified periods. If one or more holders elect to convert their notes, we may be required, or may choose, to settle the obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the convertible notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.

RISKS RELATED TO OUR COMMON STOCK

Sales of significant amounts of shares held by Mr. Sandgaard, or the prospect of these sales, could adversely affect the market price of our common stock

Sales of significant amounts of shares held by Mr. Sandgaard, or the prospect of these sales, could adversely affect the market price of our common stock. Mr. Sandgaard's stock ownership may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of the Company, which in turn could reduce our stock price or prevent our stockholders from realizing a premium over our stock price.

Our existing stockholders may experience dilution if we elect to raise equity capital

Due to our past liquidity issues, we have had to raise Previously, we've raised capital in the form of debt and/or equity to meet our working capital needs. We may also choose to issue equity or debt securities in the future to meet our liquidity or other needs which would result in additional dilution to our existing

stockholders. Although we will attempt to minimize the dilutive impact of any future capital-raising activities, we cannot offer any assurance that we will be able to do so. We may have to issue additional shares of our common stock at prices at a discount from the then-current market price of our common stock. If we raise additional working capital, existing stockholders may experience dilution.

We paid a dividend on our common stock, and cash used to pay dividends will not be available for other corporate purposes

In 2018, our Board of Directors declared a **special one-time** dividend of \$0.07 per share, which was paid in January 2019. In 2021, our Board of Directors declared a **special one-time** dividend of \$0.10 per share, which was paid in January 2022. The decision to pay dividends in the future will depend on general business conditions, the impact of such payment on our financial condition, and other factors our Board of Directors may consider. If we elect to pay future dividends, this could reduce our cash reserves to levels that may be inadequate to fund expansions to our business plan or unanticipated contingent liabilities.

Our stock price could become more volatile and your investment could lose value.

All of the factors discussed in this section could affect our stock price. A significant drop in our stock price could also expose us to the risk of securities class actions lawsuits, which could result in substantial costs and divert management's attention and resources, which could adversely affect our **business** **business**.

Conversion of our convertible senior notes into common stock may dilute the ownership interests of existing stockholders or may otherwise depress the price of our common stock.

If it were to occur, the conversion of convertible senior notes would dilute the ownership interests of existing stockholders to the extent we deliver shares of common stock upon conversion. Any sales in the public market of such shares could adversely affect prevailing market prices of our common stock. In addition, the existence of the convertible senior notes and the anticipated conversion of the notes into shares of our common stock could depress the price of our common stock.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

In October 2017, we signed a lease for our former corporate headquarters in Englewood, Colorado beginning in January 2018. In March 2019, we signed an amendment to this lease, which allowed the Company to expand its corporate offices. An additional amendment was entered into on January 3, 2020, which expanded our former corporate offices to approximately 85,681 square feet. During 2021, we moved our corporate headquarters to a new location, however, we continue to use the leased property for ZMS operations. The lease and subsequent amendments continue through June 30, 2023 with an option for a two-year extension through June 2025.

2827

[Table of Contents](#)

ITEM 1C. CYBERSECURITY

Risk Management and Strategy

We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data.

Managing Material Risks & Integrated Overall Risk Management

We have strategically integrated cybersecurity risk management into our broader risk management framework to promote a company-wide culture of cybersecurity risk management. This integration ensures that cybersecurity considerations are an integral part of our decision-making processes at every level.

Our management team works closely with our IT department to continuously evaluate and address cybersecurity risks in alignment with our business objectives and operational needs.

Oversee Third-party Risk

Because we are aware of the risks associated with third-party service providers, we have implemented stringent processes to oversee and manage these risks. We conduct thorough security assessments of all third-party providers before engagement and maintain ongoing monitoring to ensure compliance with our cybersecurity standards. The monitoring includes annual assessments of the SOC reports of our providers and implementing complementary controls. This approach is designed to mitigate risks related to data breaches or other security incidents originating from third-parties.

Risks from Cybersecurity Threats

We have not encountered cybersecurity challenges that have materially impaired our operations or financial standing.

ITEM 2. PROPERTIES

During February 2023, the Company entered into a lease agreement for approximately 41,427 square feet of office space for the operations of ZMS in Englewood, Colorado. The lease commenced on July 1, 2023 and runs through December 31, 2028. At the expiration of the lease term the Company has the option to renew the lease for one additional five-year period. The Company is entitled to rent abatements for the first six months of the lease and tenant improvement allowances.

In addition to April 2021, we signed a sublease for our corporate headquarters we in Englewood, Colorado beginning in May 2021 for up to approximately 110,754 square feet. This lease runs through April 2028.

We entered into a lease agreement for a warehouse and production facility with approximately 50,488 square feet in September 2020. The lease continues through June 2026 with an option for a five-year extension through June 2031.

In April 2021, we signed a sublease for a new corporate headquarters in Englewood, Colorado beginning in May 2021 for up to approximately 110,754 square feet. This lease runs through April 2028.

During March 2022, we entered into a lease agreement for approximately 4,162 square feet of office space for the operations of ZMS in Boulder, Colorado. The lease began on April 1, 2022 and will run through April 1, 2025.

We believe these leased properties are sufficient to support our current requirements and that we will be able to locate additional facilities as needed. See Note 11 12 to the Consolidated Financial Statements for additional information on these leases.

ITEM 3. LEGAL PROCEEDINGS

We are not a party to any material pending legal proceedings.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

Table of Contents

ITEM 4A. EXECUTIVE OFFICERS OF THE REGISTRANT

Set forth below is certain information concerning the Company's executive officers.

Name	Age	Title and Business Experience
------	-----	-------------------------------

Thomas Sandgaard

[65]

President and Chief Executive Officer. Mr. Sandgaard founded the Company in 1996 after a successful European-based career in the semiconductor, telecommunications and medical equipment industries with ITT, Siemens and Philips Telecom. Mr. Sandgaard has been our President, CEO and Chairman since 1996. Mr. Sandgaard held middle and senior management positions in the areas of international sales and distribution, technology transfers, mergers and acquisitions and marketing. Mr. Sandgaard holds a degree in electronics engineering from the University of Southern Denmark and an MBA from Copenhagen Business School. Mr. Sandgaard currently does not hold, and has not held in the past five years, directorships with any company with a class of securities registered pursuant to section 12 of the Exchange Act or subject to the requirements of section 15(d) of such Act or any company registered as an investment company under the Investment Company Act of 1940

Daniel Moorhead

[51]

Chief Financial Officer. Mr. Moorehead joined the Company in June 2017 as the Chief Financial Officer and is responsible for all finance and accounting functions. Prior to joining Zynex, Mr. Moorhead was Chief Financial Officer of Evolving Systems, Inc. (Nasdaq: EVOL) from January 2016 until May 2017, after having served as Vice President of Finance & Administration from December 2011 through December 2015 and in other financial management roles from 2002-2005 and 2008-2011. Mr. Moorhead is a CPA and holds a B.B.A. in Accounting from the University of Northern Colorado.

Anna Lucsok

[38]

Chief Operating Officer. Ms. Lucsok joined the company in 2018 and previously served as Vice President of Reimbursement and Sales Operations with Zynex Medical. In this position she was responsible for leading and expanding Zynex's order, reimbursement, patient experience, and inside sales support operations. Ms. Lucsok brings more than nine years of healthcare operations experience as well as critical knowledge of revenue cycle management and medical care collections. She's previously held key positions with companies such as University of Colorado Hospital, the US Air Force and Schryver Medical. Ms. Lucsok holds certification in medical billing as well as completed her degree in Healthcare Administration and Management from Colorado State University.

[Table of Contents](#)

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

On February 12, 2019, our common stock began trading on The Nasdaq Capital Market under the symbol "ZYXI". Prior to uplisting to the Nasdaq Capital Market, the Company's common stock was quoted on the OTCQB (managed by OTC Markets, Inc) under the symbol "ZYXI".

As of **March 13, 2023** **February 28, 2024**, there were **36,634,459** **32,170,182** shares of common stock outstanding and approximately **154** **188** record holders of our common stock.

Recent Sales of Unregistered Securities

None.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

Issuer Purchases On September 11, 2023, the Company announced that its board of **Equity** directors had approved a repurchase program of up to \$10.0 million of the Company's common stock (the "September 2023 Repurchase Program") beginning on September 13, 2023, and continuing through the earlier of September 12, 2024, or when all \$10.0 million worth of shares have been repurchased.

On November 1, 2023, the Company announced that its board of directors had approved a repurchase program of up to \$20.0 million of the Company's common stock (the "November 2023 Repurchase Program") beginning on November 1, 2023, and continuing through the earlier of October 31, 2024, or when all \$20.0 million worth of shares have been repurchased.

Under the Company's repurchase programs, the Company may repurchase its common stock from time to time in open market and negotiated transactions. Repurchases will be made subject to market conditions, available liquidity, cash flow, applicable legal requirements, and other factors. The specific prices, numbers of shares, and timing of purchase transactions will be determined by the Company from time to time. The repurchase programs do not obligate the Company to acquire any particular amount of common stock and may be suspended or discontinued at any time. The repurchase programs are intended to comply with Rule 10b-18 promulgated under the Securities Exchange Act of 1934.

The following table sets forth a summary of the Company's purchases of common stock during the fourth quarter of 2022/2023 pursuant to the Company's authorized share repurchase program: programs:

Period	Total Number of Shares				In Thousands
	Purchased as		of Shares That		
	Total	Average	Part of a	May Yet Be	
	Number of	Price	Publicly	Purchased	
	Shares	Paid Per	Announced	Under the	
	Purchased	Share	Plan	Plan	
October 1 - October 31, 2023					
Share repurchase program (1)	536,715	\$ 8.23	1,204,239	—	
November 1 - November 30, 2023					
Share repurchase program (2)	524,200	\$ 9.20	524,200	15,176	
December 1 - December 31, 2023					
Share repurchase program (2)	488,000	\$ 9.75	1,012,200	10,417	
Quarter Total					
Share repurchase program (1)	536,715	\$ 8.23	1,204,239	—	
Share repurchase program (2)	1,012,200	\$ 9.47	1,012,200	10,417	

[Table of Contents](#)

Period	Total Number of Shares				(In Thousands)
	Purchased as		of Shares That		
	Total	Average	Part of a	May Yet Be	
	Number of	Price	Publicly	Purchased	
	Shares	Paid Per	Announced	Under the	
	Purchased	Share	Plan	Plan	
October 1 - October 31, 2022					
Share repurchase program (1)	19,653	\$ 9.74	1,091,604	—	
November 1 - November, 2022					

Share repurchase program (2)	312,035	\$ 13.16	312,035	5,893
December 1 – December 31, 2022				
Share repurchase program (2)	183,103	\$ 13.87	495,138	3,352
Quarter Total				
Share repurchase program (1)	19,653	\$ 9.74	1,091,604	—
Share repurchase program (2)	495,138	\$ 13.43	495,138	3,352

(1) Shares were purchased through the Company's publicly announced share repurchase program dated June 9, 2022. September 2023 Repurchase program.

The program was fully utilized during the Company's fourth quarter.

(2) Shares were purchased through the Company's publicly announced share repurchase November 2023 Repurchase program approved by the Company's Board of Directors on October 31, 2022 dated November 1, 2023. The program expires at the earlier of October 31, 2023 on October 31, 2024, or reaching \$10.0 million \$20.0 million of repurchases.

Dividends

Our Board of Directors declared a special cash dividend of \$0.10 per share and a 10% stock dividend during the fourth quarter of 2021, which was paid out and issued in January 2022. There can be no guarantee that we will continue to pay dividends. Any future determination to pay cash dividends will be at the discretion of the Board of Directors and will be dependent upon our financial condition, results of operations, capital requirements and such other factors as the Board deems relevant.

30

[Table of Contents](#)

ITEM 6. [RESERVED]

Not required.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Annual Report on Form 10-K contains The information and financial data discussed below is derived from our consolidated financial statements that are forward-looking, such as for the years ended December 31, 2023, and 2022. The consolidated financial statements relating to plans for future organic growth of the Company were prepared and other business development activities, as well as the impact of reimbursement trends, other capital spending and financing sources. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results presented in accordance with generally accepted accounting principles in the United States. The information and financial data discussed below is only a summary and was prepared to provide a historical and narrative discussion of our financial condition and results of operations through the eyes of management and should be read in conjunction with the historical financial statements and related notes of the Company contained elsewhere in this Report. The consolidated financial statements contained elsewhere in this Report fully represent the Company's financial condition and operations; however, they are not indicative of the Company's future and, accordingly, such results may differ from those expressed in any performance. See "Cautionary Statement Regarding Forward Looking Statements" above for a discussion of forward-looking statements made by or on behalf and the significance of such statements in the Company. These risks include the ability to engage effective sales representatives, the need to obtain FDA clearance and CE marking context of new products, the acceptance of new products as well as existing products by doctors and hospitals, our dependence on the reimbursement from insurance companies for products sold or leased to our customers, acceptance of our products by health insurance providers for reimbursement, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on third-party manufacturers to produce key components of our products on time and to our specifications, implementation of our sales strategy including a strong direct sales force, and other risks described herein and included in "Item 1A-Risk Factors." this Annual Report.

OVERVIEW

We operate in one primary business segment, electrotherapy and pain management products. As of December 31, 2022 December 31, 2023, the Company's only active subsidiary is ZMI, a wholly-owned Colorado corporation, through which the Company conducts its U.S. electrotherapy and pain management operations, and ZMS. ZMS, a wholly-owned Colorado corporation, has developed a fluid monitoring system, which has received two

utility patents and FDA approval in the U.S. ZMS also acquired Kestrel during 2021, which had two pulse-oximeter products they are developing and numerous patents. However, ZMS has achieved no revenues to date.

The following information should be read in conjunction with our Consolidated Financial Statements and related notes contained in this Annual Report.

HIGHLIGHTS

During the year ended **December 31, 2022** **December 31, 2023**, the Company achieved the following:

ZMI

- Achieved a **23%** **43%** increase in order growth, **21%** **17%** growth in revenue, and a **98%** **29%** increase in operating cash flows compared to the prior year;
- Recorded net income of **\$17.0 million** **\$9.7 million** and our **7**⁸ consecutive profitable year;
- Achieved higher sales representative productivity with increase revenue per sales representative;

31

[Table of Contents](#)

- Due to strong results and related cash flow, we repurchased **over \$26 million** **approximately \$37.9 million** worth of **Company** **the Company's** common stock;
- Ranked 11th in Forbes list of "Americas Best Small Companies 2023";
- Ranked **33** **23**rd in the Top 100 Healthcare Technology Companies of **2022** **2023** according to The Healthcare Technology Report;
- Included in the Deloitte Technology Fast 500 Fastest Growing Companies for a **4**⁵ consecutive year.

31

[Table of Contents](#)

ZMS

- Fully integrated Kestrel Labs, Inc. in Q1 2022.
- Completed multiple IRB-approved clinical studies including the apheresis blood donation study with Vitalant Research Institute, **and studies detection of fluid changes in subjects during a dialysis procedure at DaVita**, **study at Yale University where subjects underwent simulated hemorrhage using a lower body negative pressure chamber**, **chamber and a non-cardiac surgery perioperative observational study to determine the impact of complex perioperative events on the parameters and Relative Index (RI) measured by the CM-1600 at Cleveland Clinic**; and
- **Applied to** **Completed a hypoxemia study at the U.S. Food** **University of California, San Francisco** **and Drug Administration ("FDA") in Q1 2023** **ongoing enrollments at Duke University for consideration through its Breakthrough Devices Program for NiCO**, **NiCO as well as Q-Submissions and meetings with the FDA.**

Inflation Reduction Act

On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, (i) directs the U.S. Department of Health and Human Services, or HHS, to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subjects drug manufacturers to civil monetary penalties and a potential excise tax for offering a price that is not equal to or less than the negotiated "maximum fair price" under the law; (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize drug price increases that outpace inflation; and (iii) redesigns the Medicare Part D program, increasing manufacturer rebates within the catastrophic coverage phase. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions **will begin to** **take effect progressively beginning in fiscal**

year 2023, although they may have been subject to legal challenges. It is currently unclear how the IRA will be effectuated but is likely to have a significant impact on the pharmaceutical industry.

The IRA also includes various tax provisions, including an excise tax on stock repurchases, expanded tax credits for clean energy incentives, and a corporate alternative minimum tax that generally applies to U.S. corporations with average adjusted financial statement income over a three year three-year period in excess of \$1 billion. The Company does not expect these tax provision provisions to materially impact its financial statements.

SUMMARY

Net revenue increased 21% 17% in 2022 2023 to \$184.3 million from \$158.2 million from \$130.3 million in 2021, 2022. Net income was \$17.0 million \$9.7 million and \$17.1 million \$17.0 million for the years ended December 31, 2022, December 31, 2023 and 2021, 2022, respectively.

Cash flows from operating activities increased 98% 29%, or \$6.8 million \$4.0 million, to \$13.7 million \$17.8 million for the year ended December 31, 2022 December 31, 2023. Increased orders for our devices and supplies and the related receivables and cash flows which from operations along with our current cash position allowed us to repurchase \$26.4 million \$37.9 million of common stock and maintain working capital of \$48.5 million at December 31, 2022 \$69.3 million for the year ended December 31, 2023.

[Table of Contents](#)

RESULTS OF OPERATIONS

The following table presents our consolidated statements of operations income in comparative format (in thousands).

	For the Years Ended			For the Years Ended		
	December 31,		\$	December 31,		\$
	2022	2021	change	2023	2022	change
NET REVENUE						
Devices	\$ 43,497	\$ 36,613	\$ 6,884	\$ 58,822	\$ 43,497	\$ 15,325
Supplies	114,670	93,688	20,982	125,500	114,670	10,830
Total net revenue	<u>158,167</u>	<u>130,301</u>	<u>27,866</u>	<u>184,322</u>	<u>158,167</u>	<u>26,155</u>
COSTS OF REVENUE AND OPERATING EXPENSES						
Costs of revenue – devices and supplies	32,005	27,321	4,684	38,366	32,005	6,361
Sales and marketing	67,116	54,290	12,826	86,659	67,116	19,543
General and administrative	36,108	26,324	9,784	48,517	36,108	12,409
Total costs of revenue and operating expenses	<u>135,229</u>	<u>107,935</u>	<u>27,294</u>	<u>173,542</u>	<u>135,229</u>	<u>38,313</u>
Income from operations	22,938	22,366	572	10,780	22,938	(12,158)
Other expense						
Other Income (expense)						
Gain on sale of fixed assets			39	—		39
Loss on change in fair value of contingent consideration	(300)	—	(300)	2,854	(300)	3,154
Interest expense	(440)	(95)	(345)	(1,094)	(440)	(654)
Other expense, net	<u>(740)</u>	<u>(95)</u>	<u>(645)</u>			
Other income/(expense), net				1,799	(740)	2,539
Income from operations before income taxes	22,198	22,271	(73)	12,579	22,198	(9,619)
Income tax expense	5,150	5,168	(18)	2,847	5,150	(2,303)
Net income	<u>\$ 17,048</u>	<u>\$ 17,103</u>	<u>\$ (55)</u>	<u>\$ 9,732</u>	<u>\$ 17,048</u>	<u>\$ (7,316)</u>

Net income per share:						
Basic	\$ 0.44	\$ 0.45	\$ (0.00)	\$ 0.27	\$ 0.44	\$ (0.17)
Diluted	\$ 0.44	\$ 0.44	\$ (0.00)	\$ 0.27	\$ 0.44	\$ (0.17)
Weighted average basic shares outstanding	38,467	38,317	150	35,555	38,467	(2,912)
Weighted average diluted shares outstanding	39,127	39,197	(70)	36,142	39,127	(2,985)

33

[Table of Contents](#)

The following table presents our consolidated statements of **operations income** reflected as a percentage of total revenue:

	For the Years Ended December 31,		For the Years Ended December 31,	
	2022		2023	
	2021	2022	2023	2022
NET REVENUE				
Devices	28 %	28 %	32 %	28 %
Supplies	72 %	72 %	68 %	72 %
Total net revenue	100 %	100 %	100 %	100 %
COSTS OF REVENUE AND OPERATING EXPENSES				
Costs of revenue – devices and supplies	20 %	21 %	21 %	20 %
Sales and marketing	42 %	42 %	47 %	42 %
General and administrative	23 %	20 %	26 %	23 %
Total costs of revenue and operating expenses	85 %	83 %	94 %	85 %
Income from operations	15 %	17 %	6 %	15 %
Other income/(expense)				
Gain on sale of fixed assets			— %	— %
Loss on change in fair value of contingent consideration	0 %	0 %	2 %	— %
Interest expense	0 %	0 %	(1)%	— %
Other income/(expense), net	0 %	0 %	1 %	— %
Income from operations before income taxes	14 %	17 %	7 %	14 %
Income tax expense	3 %	4 %	2 %	3 %
Net income	12 %	13 %	5 %	11 %
Net income per share:				
Basic	0.44	0.45	0.27	0.44
Diluted	0.44	0.44	0.27	0.44
Weighted average basic shares outstanding	38,467	38,317	35,555	38,467
Weighted average diluted shares outstanding	39,127	39,197	36,142	39,127

Net Revenue

Net revenues are comprised of device and supply sales, constrained by estimated third-party payer reimbursement deductions. The reserve for billing allowance adjustments and allowance for uncollectible accounts are adjusted on an ongoing basis in conjunction with the processing of third-party payer insurance claims and other customer collection history. **Inherent in these estimates is the risk that they will have to be revised as additional information**

becomes available and constraints are released. If initial estimates are updated these changes are accounted for as increases or decreases in the transaction price. Assuming the underlying performance obligation to which the change in price relates has already been satisfied, those changes in transaction price are immediately recognized as increases or decreases in revenue (not credit losses (bad debt expense)) in the period in which the estimate changes.

Product device revenue is primarily comprised of sales and rentals of our electrotherapy products and also includes complementary **rehabilitation** products such as our cervical traction, lumbar support, **bracing**, and hot/cold therapy products.

Supplies revenue is primarily comprised of sales of our consumable supplies to patients using our electrotherapy products, consisting primarily of surface electrodes and batteries. Revenue related to both devices and supplies is reported net, after adjustments for estimated third-party payer reimbursement deductions and estimated allowance for uncollectible accounts. The deductions are known throughout the **health care healthcare** industry as billing adjustments whereby the healthcare insurers unilaterally reduce the amount they reimburse for our products as compared to the sales prices charged by us. The deductions from gross revenue also take into account the estimated denials, net of resubmitted billings of claims for products placed with patients which may affect collectability. See our

34

[Table of Contents](#)

Significant Accounting Policies in Note 2 to the Consolidated Financial Statements for a more complete explanation of our revenue recognition policies.

34

[Table of Contents](#)

We occasionally receive, and expect to continue to receive, refund requests from insurance providers relating to specific patients and dates of service. Billing and reimbursement disputes are very common in our industry. These requests are sometimes related to a few patients and other times include a significant number of refund claims in a single request. We review and evaluate these requests and determine if any refund is appropriate. We also review claims that have been resubmitted or where we are pursuing additional reimbursement from that insurance provider. We frequently have significant offsets against such refund requests which may result in amounts that are due to us in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of such refund requests we are generally unable to determine if a refund request is valid.

Net revenue increased **\$27.9 million** **\$26.2 million** or **21% 17%** to **\$184.3 million** for the year ended December 31, 2023, from **\$158.2 million** for the year ended December 31, 2022, from **\$130.3 million** for the year ended December 31, 2021. The growth in net revenue is primarily related to the **23% 43%** growth in device orders which led to an increased customer base and drove higher sales of consumable supplies. During the fourth quarter of 2023, the Company placed an allowance of **\$6.2 million** on receivables which were determined to be uncollectible. The allowance was recorded to net revenue during the period.

Device Revenue

Device revenue is related to the purchase or lease of our electrotherapy products as well as complementary products including cervical traction, lumbar support, knee braces and hot/cold therapy products. Device revenue increased **\$6.9 million** **\$15.3 million** or **19% 35%** to **\$58.8 million** for the year ended December 31, 2023, from **\$43.5 million** for the year ended December 31, 2022, from **\$36.6 million** for the year ended December 31, 2021. The increase in device revenue is related to the growth in our device and complementary product orders of **23% 43%** from **2021 2022** to **2022 2023** as a result of **greater increased sales representative productivity**.

Supplies Revenue

Supplies revenue is related to the sale of supplies, typically electrodes and batteries, for our products. Supplies revenue increased **\$21.0 million** **\$10.8 million** or **22% 9%** to **\$125.5 million** for the year ended December 31, 2023, from **\$114.7 million** for the year ended December 31, 2022, from **\$93.7 million** for the year ended December 31, 2021. The increase in supplies revenue is primarily related to growth in our customer base from higher device sales in **2022 2023** and prior years.

Operating Expenses

Costs of Revenue –Devices and Supplies

Costs of revenue – devices and supplies consist primarily of device and supplies costs, operations labor and overhead, shipping and depreciation. Costs of revenue increased **\$4.7 million** **\$6.4 million** or **17%** **20%** to **\$38.4 million** for the year ended December 31, 2023, from **\$32.0 million** for the year ended December 31, 2022, from **\$27.3 million** for the year ended December 31, 2021. The increase in costs of revenue is directly related to the increase in device and supplies orders. As a percentage of revenue, cost of revenue –devices and supplies decreased to 20% for the year ended December 31, 2022 compared to 21% for the year ended December 31, 2021. The decrease in cost of revenue – devices and supplies as a percentage of revenue was due to expanding our supplier portfolio mix remained flat at 21% for the years ended December 31, 2023 and reducing supply costs. 2022, respectively.

Sales and Marketing Expense

Sales and marketing expense primarily consists of employee-related costs, including sales commissions and other direct costs associated with these personnel including travel and marketing expenses. Sales and marketing expense for the year ended December 31, 2022 December 31, 2023 increased **24%** **29%** to **\$67.1 million** **\$86.7 million** from **\$54.3 million** **\$67.1 million** for the year ended December 31, 2021 December 31, 2022. The increase in sales and marketing expense is primarily due to an increased salaries of head count in our direct sales personnel force and sales operations group, which includes our patient experience team, as well as increased compensation related to an expanded sales force, tightened job market and inflation, higher-than-normal inflation in the U.S. Increased orders also resulted in higher sales commissions as well as travel expenses. As a percentage of revenue, sales and marketing expense remained flat at increased to 47% from 42% for both years during the year ended December 31, 2022 and 2021. December 31, 2023 compared the same period in 2022. The increase as a percentage of revenue is primarily due to the aforementioned increase in expenses, partially offset by increased revenue during the year ended December 31, 2023.

[Table of Contents](#)

General and Administrative Expense

General and administrative expense primarily consists of employee related costs, facilities expense, professional fees and depreciation and amortization. General and administrative expense for the year ended December 31, 2022 December 31, 2023 increased **37%** **34%** to **\$36.1 million** **\$48.5 million** from **\$26.3 million** **\$36.1 million** for the year ended December 31, 2021 December 31, 2022. The increase in general and administrative expense is primarily due to the following:

- an increase of **\$2.6 million** and **\$2.5 million** **\$5.7 million** in compensation and benefits expense including non-cash stock driven by headcount growth in our ZMI reimbursement team, which is directly related to our 43% order growth during the period;
- an increase of **\$1.5 million** in compensation and benefits expense related to driven by headcount growth and inflationary salary increases for ZMI ZMS; and ZMS, respectively;
- an increase of **\$3.3 million** **\$5.2 million** in other expenses, including professional fees ZMS product development, of **\$2.3 million**, and other general and administrative costs of **\$2.9 million** associated primarily with the increase in order volumes;
- an increase of **\$0.7 million** in rent and facilities expenses due to a full year of expense, as we entered into a new corporate headquarters lease during May 2021. Much growth of the increase in facilities was non-cash as we received 21 months of free rent on the new corporate headquarters but for GAAP purposes the rent over the lease term is expensed on a straight-line basis; Company and
- an increase of **\$0.9 million** in amortization expense related due to a full year of expense of the intangible assets acquired in December 2021. order volume.

As a percentage of revenue, general and administrative expense increased to 26% for the year ended December 31, 2023 from 23% for the year ended December 31, 2022 from 20% for the year ended December 31, 2021. The increase as a percentage of revenue is primarily due to the aforementioned increase in expenses, partially offset by increased revenue during the year ended December 31, 2022 December 31, 2023.

The Company expects that general and administrative expenses will continue to increase through 2023 2024 as the Company continues to expand its corporate headcount to accommodate continued order growth and continued research and development activities at ZMS.

Other Income (Expense)

Other income was \$1.8 million for the year ended December 31, 2023, of which \$2.9 million related to a gain on the change in fair value of contingent consideration. Other income was offset by \$1.1 million in interest expense related to our Senior Convertible Notes, net of interest earned. Other expense was \$0.7 million for the year ended December 31, 2022, of which \$0.4 million was related to interest on debt obtained in December 2021, notes payable, and a \$0.3 million loss on the change in fair value of contingent consideration acquired in December 2021. Other expense was \$0.1 million for the year ended December 31, 2021, consideration.

Income Tax Expense

We recorded income tax expense of \$5.2 million \$2.8 million and \$5.2 million for the years ended December 31, 2022 December 31, 2023 and 2021, 2022, respectively. The effective income tax rate for the years ended December 31, 2022 December 31, 2023 and 2021, 2022 was 23% and 24%, respectively. The decrease in the effective rate during 2022 is primarily due to research and development credits for both periods.

FINANCIAL CONDITION

As of December 31, 2022 December 31, 2023, we had working capital of \$48.5 million \$69.3 million, compared to \$59.8 million \$48.5 million as of December 31, 2021 December 31, 2022. The decrease principal source of working capital was \$44.6 million in cash and cash equivalents and \$26.8 million in accounts receivable. The increase in working capital is primarily due to decreases driven from the offering of Convertible Senior Notes and the profitability during the year ended December 31, 2023. This increase was offset by the purchase of \$37.9 million in cash due to the Company's repurchase of \$26.6 million of Company treasury stock a cash dividend of \$3.6 million which was paid in January 2022, and principal payments on our long-term loan of \$5.3 million during 2022, 2023. We generated \$13.7 million \$17.8 million and \$6.9 million \$13.7 million in operating cash flows during the years ended December 31, 2022 December 31, 2023 and 2021, 2022, respectively.

LIQUIDITY AND CAPITAL RESOURCES

We have historically financed operations through cash flows from operations, debt and equity transactions. As of December 31, 2022 December 31, 2023, our principal source of liquidity was \$20.1 million \$44.6 million in cash \$35.1 million and cash equivalents, \$26.8 million in accounts receivables, and our working capital balance was \$69.3 million.

In May 2023, the Company issued \$52.5 million aggregate principal amount of \$48.5 million 5.00% Convertible Senior Notes due May 15, 2026 (the "2023 Convertible Senior Notes"). In May 2023, the Company issued an additional \$7.5 million aggregate principal amount of the 2023 Convertible Senior Notes upon the exercise by the initial purchasers of their over-allotment option. Interest on the 2023 Convertible Senior Notes is payable semiannually in arrears, beginning November 15, 2023. The 2023 Convertible Senior Notes will

[Table of Contents](#)

Upon closing mature on May 15, 2026, unless earlier converted or repurchased, and are redeemable at the Kestrel acquisition in December 2021, we entered into a loan and credit facility agreement with Bank option of America, N.A. The credit facility includes a line of credit in the amount of \$4.0 million available until December 1, 2024, which the Company has not drawn from since inception of the agreement. The loan is a fixed rate term loan in the amount of \$16.0 million and has an interest rate equal to 2.8% per year. The term loan is payable in equal principal installments of \$0.4 million per month through December 1, 2024 plus interest on the first day of each month beginning January 1, 2022, or after May 20, 2025 (See Note 7, 8).

Our anticipated uses of cash in the future will be to fund the expansion of our business.

Net cash provided by operating activities for the years ended December 31, 2022 December 31, 2023 and 2021, 2022 was \$13.7 million \$17.8 million and \$6.9 million \$13.7 million, respectively. The increase in cash provided by operating activities for the year ended December 31, 2022 December 31, 2023 was primarily due to increased improved collections and continued profitability in 2022, and an increase in non-cash amortization and stock compensation expenses. Cash provided by operating activities for the year ended December 31, 2021 December 31, 2022 was primarily due to profitability, which was cash collections related to net income of \$17.0 million, offset by increased accounts receivable due to revenue growth, inventory balances.

Net cash used in investing activities for the years ended December 31, 2022 December 31, 2023 and 2021, 2022 was \$0.4 million \$1.0 million and \$16.6 million \$0.4 million, respectively. Cash used in investing activities for the year ended December 31, 2023 was primarily related to the purchase of computer, office and warehouse equipment, and ongoing capital projects for ZMS operations. Cash used in investing activities for the year ended December 31, 2022

was primarily related to the purchase of computer, office and warehouse equipment. Cash used in investing activities for the year ended December 31, 2021 was primarily related to the acquisition of Kestrel and the purchase of computer, office and warehouse equipment.

Net cash used in financing activities for the year ended December 31, 2022 December 31, 2023 was \$7.6 million compared with net cash used in financing activities was \$35.8 million compared with net for the year ended December 31, 2022. The cash provided by financing activities of \$13.1 million \$7.6 million for the year ended December 31, 2021 December 31, 2023 was primarily due to net proceeds from the issuance of Senior Convertible Notes of \$57.0 million, offset by purchases of \$37.9 million in treasury stock and principal payments made on long term debt totaling \$10.7 million. The

Net cash used in financing activities of \$35.8 million for the year ended December 31, 2022 was primarily due to the repurchase of Company stock totaling \$26.4 million, principal payments made on our term loan totaling \$5.3 million and the payment of cash dividends in January 2022 totaling \$3.6 million.

The cash provided by financing activities of \$13.1 million for the year ended December 31, 2021 was primarily due to net proceeds from debt assumed in the Kestrel acquisition of \$16.0 million, which is slightly offset by the purchase of treasury stock totaling \$2.7 million.

We believe our cash, together with anticipated cash flow from operations will be sufficient to meet our working capital, and capital expenditure requirements for at least the next twelve months. In making this assessment, we considered the following:

- Our cash balance at December 31, 2022 December 31, 2023 of \$20.1 million \$44.6 million;
- Our working capital balance of \$48.5 million \$69.3 million;
- Our accounts receivable balance of \$35.1 million \$26.8 million;
- Our increasing profitability over the last 7 years; and
- Our planned capital expenditures of approximately \$2.0 million \$2.5 million during 2023, 2024.

Contractual Obligations

The following table summarizes the future cash disbursements to which we are contractually committed as of December 31, 2022 December 31, 2023 (in thousands).

	Total	2023	2024	2025	2026	2027	Thereafter	Total	2024	2025	2026	2027	2028	Thereafter
Operating leases	17,788	3,055	3,571	3,586	3,362	3,150	1,064	19,980	4,511	4,632	4,428	4,237	2,172	—
Finance leases	359	152	116	76	15	—	—	672	209	169	108	93	93	—
	\$ 18,147	\$ 3,207	\$ 3,687	\$ 3,662	\$ 3,377	\$ 3,150	\$ 1,064	\$ 20,652	\$ 4,720	\$ 4,801	\$ 4,536	\$ 4,330	\$ 2,265	\$ —

We lease office and warehouse facilities under non-cancelable operating leases. The current office facility leases include our current and former corporate headquarters and a production warehouse, all located in Englewood, Colorado and a lease in Boulder, Colorado

Table of Contents

for the operations of ZMS Boulder. We also rent a small office in Denmark. Rent expense was \$4.5 million \$4.0 million and \$3.5 million \$4.5 million for the years ended December 31, 2022 December 31, 2023 and 2021, 2022, respectively. A portion of the increase rent expense was non-cash in facilities was non-cash nature as we received 21 months of free rent on the new corporate headquarters but for abatements during both years ending December 31, 2023 and 2022. For GAAP purposes, the rent is expensed over the lease term on a straight-line basis.

[Table of Contents](#)

The Company also leases office equipment for its corporate and warehouse facilities under non-cancelable finance lease agreements.

CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT ESTIMATES

In preparing our consolidated financial statements in accordance with GAAP, we are required to make estimates and assumptions that affect the amounts of assets, liabilities, revenue, costs and expenses, and disclosure of contingent liabilities that are reported in the consolidated financial statements and accompanying disclosures. We believe that the estimates, assumptions and judgments involved in the accounting policies described below have the greatest potential impact on our financial statements because they involve the most difficult, subjective or complex judgments about the effect of matters that are inherently uncertain. Therefore, we consider these to be our critical accounting policies. Accordingly, we evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates and assumptions. See Note 2 to the Consolidated Financial Statements of this Annual Report on Form 10-K for information about these critical accounting policies, as well as a description of our other accounting policies.

Revenue Recognition and Accounts Receivable

Revenue is generated primarily from sales and leases of our electrotherapy devices and related supplies and complementary products. Sales are primarily made with, and shipped, direct to the patient with a small amount of revenue generated from sales to distributors.

In the healthcare industry there is often a third party involved that will pay on the patients' behalf for purchased or leased devices and supplies. The terms of the separate arrangement impact certain aspects of the contract with patients covered by third party payers, such as contract type, performance obligations and transaction price, but for purposes of revenue recognition the contract with the customer refers to the arrangement between the Company and the patient.

The Company does not have any material deferred revenue in the normal course of business as each performance obligation is met upon delivery of goods to the patient.

Device Sales

Device sales can be in the form of a purchase or a lease.

Revenue for purchased devices is recognized in accordance with Accounting Standards Codification ("ASC") 606 – "Revenue from Contracts with Customers" (ASC 606) when the device is delivered to the patient and all performance obligations are fulfilled.

Revenue related to devices out on lease is recognized in accordance with ASC 842, Leases. Using the guidance in ASC 842, we concluded our transactions should be accounted for as operating leases based on the following criteria below:

- The lease does not transfer ownership of the underlying asset to the lessee by the end of the lease term.
- The lease does not grant the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.
- The lease term is month to month, which does not meet the major part of the remaining economic life of the underlying asset. However, if the commencement date falls at or near the end of the economic life of the underlying asset, this criterion shall not be used for purposes of classifying the lease.
- There is no residual value guaranteed and the present value of the sum of the lease payments does not equal or exceed substantially all of the fair value of the underlying asset.
- The underlying asset is expected to have alternative uses to the lessor at the end of the lease term.

[Table of Contents](#)

Lease commencement occurs upon delivery of the device to the patient. The Company retains title to the leased device and those devices are classified as property and equipment on the balance sheet. Since our leases are month-to-month and can be returned by the patient at any time, revenue is recognized monthly for the duration of the period in which the patient retains the device.

[Table of Contents](#)

Supplies

Supplies revenue is recognized once supplies are delivered to the patient. Supplies needed for the device can be set up as a recurring shipment or ordered through the customer support team or online store as needed.

Variable Consideration

A significant portion of the Company's revenues are derived, and the related receivables are due, from patients with commercial or government health insurance plans. Revenues are estimated using the portfolio approach by third party payer type based upon historical rates of collection, the aging of receivables, trends in the historical reimbursement rates by third-party payer types and current relationships and experience with the third-party payers, which includes estimated constraints for third-party payer refund requests, deductions, allowance for uncollectible accounts, and billing allowance adjustments. Inherent in these estimates is the risk that they will have to be revised as additional information becomes available and constraints are released. Specifically, if initial estimates are updated these changes are accounted for as increases or decreases in the transaction price. Assuming the underlying performance obligation to which the change in price relates has already been satisfied, those changes in transaction price are immediately recognized as increases or decreases in revenue (not credit losses (bad debt expense)) in the period in which the estimate changes. Additionally, the complexity of third-party billing arrangements and the uncertainty of reimbursement amounts for certain products from third-party payers or unanticipated requirements to refund payments previously received may result in adjustments to amounts originally recorded. Due to continuing changes in the health care healthcare industry and third-party payer reimbursement, it is possible our forecasting model to estimate collections could change, which could have an impact on our results of operations and cash flows. Any differences between estimated settlements and final determinations are reflected as an increase or a reduction to in revenue in the period when such final determinations are known. Historically these differences have been immaterial, and the Company has not had to go back and reassess the adjustments of future periods for past billing adjustments.

The Company monitors the variability and uncertain timing over third-party payer types in our portfolios. If there is a change in our third-party payer mix over time, it could affect our net revenue and related receivables. We believe we have a sufficient history of collection experience to estimate the net collectible amounts by third-party payer type. However, changes to constraints related to billing adjustments and refund requests have historically fluctuated and may continue to fluctuate significantly from quarter to quarter and year to year.

During the quarter ended December 31, 2023, the Company had a change in the estimate of uncollectable receivables. The result of this change in allowance was a reduction of \$6.2 million to net revenue (\$4.6 million net of tax) or \$0.14 per basic and diluted share for the three months ended December 31, 2023, and \$0.13 per basic and diluted share for the year ended December 31, 2023.

Stock-based Compensation

The Company accounts for stock-based compensation through recognition of the cost of employee services received in exchange for an award of equity instruments, which is measured based on the grant date fair value of the award that is ultimately expected to vest during the period. The stock-based compensation expenses are recognized over the period during which an employee is required to provide service in exchange for the award (the requisite service period, which in the Company's case is the same as the vesting period). For awards subject to the achievement of performance metrics, stock-based compensation expense is recognized when it becomes probable that the performance conditions will be achieved.

Income Taxes

Significant judgment is required in determining our provision for income taxes. We assess the likelihood that our deferred tax asset will be recovered from future taxable income, and to the extent we believe that recovery is not likely, we establish a valuation allowance. We consider future taxable income projections, historical results and ongoing tax planning strategies in assessing the recoverability of deferred tax assets. However, adjustments could be required in the future if we determine that the amount to be realized is less or greater than the amount that we recorded. Such adjustments, if any, could have a material impact on our results of our operations.

[Table of Contents](#)

We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.

39 The Inflation Reduction Act ("IRA") was enacted into law on August 16, 2022. Included in the IRA was a provision to implement a 15% corporate alternative minimum tax on corporations whose average annual adjusted financial statement income during the most recently completed three-year period exceeds \$1 billion. This provision is effective for tax years beginning after December 31, 2022. The IRA did not have a material impact on our reported results, cash flows or financial position during the year ended December 31, 2023.

[Table of Contents](#)

Acquisition Method of Accounting for Business Combinations

We allocate the purchase price of acquired companies to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. The excess of the purchase price over these fair values is recorded as goodwill. We engage independent third-party valuation specialists to assist us in determining the fair values of certain assets acquired and liabilities assumed. Such valuation require management to make significant estimates and assumptions, especially with respect to intangible assets. Different valuations approaches are used to value different types of intangible assets. Under the income approach, the relief from royalty method is a valuation technique which is used to estimate the value of certain intangible assets. This method utilizes projected financial information and hypothetical royalty rates to estimate the cost savings associated with asset ownership. The estimated cost savings are discounted for risk and the time value of money to estimate an intangible asset's fair value. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable. If we do not achieve the results reflected in the assumptions and estimates, our goodwill impairment evaluations could be adversely affected, and we may impair a portion or all of our intangible assets, which would adversely affect our operating results in the period of impairment.

Impairment of Long-lived Assets, Including Goodwill

We assess impairment of goodwill annually and other long-lived assets when events or changes in circumstances indicates that their carrying value amount may not be recoverable. Long-lived assets consist of property and equipment, net and goodwill and intangible assets. Circumstances which could trigger a review include, but are not limited to: (i) significant decreases in the market price of the asset; (ii) significant adverse changes in the business climate or legal or regulatory factors; (iii) or expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than the carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value.

Contingent Considerations

We ~~classify~~ classified contingent consideration liabilities related to business acquisitions within Level 3 as factors used to develop the estimated fair value ~~are~~ were unobservable inputs that are not supported by market activity. We ~~estimate~~ estimated the fair value of contingent consideration liabilities using a Monte Carlo simulation which is based on equity volatility, the risk-free rate, the normal variate, projected milestone dates, discount rates, and probabilities of payment.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a "Smaller Reporting Company", this Item and the related disclosure is not required.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The consolidated financial statements, the notes thereto, and the report thereon of Marcum LLP, are filed as part of this report starting on page F-2.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

[Table of Contents](#)**ITEM 9A. CONTROLS AND PROCEDURES***Evaluation of disclosure controls and procedures*

Our management, including our Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of **December 31, 2022** **December 31, 2023**). Based on management's review, with participation of our Chief Executive Officer and Chief Financial Officer, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the quarter ended **December 31, 2022** **December 31, 2023**, our disclosure controls and procedures were not effective due to the material weakness in internal control over financial reporting as described below. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, or person performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Management's report on internal control over financial reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(e) of the Exchange Act). Management, with the participation of our Chief Executive Officer and Chief Financial Officer, has assessed the effectiveness of internal control over financial reporting as of **December 31, 2022** **December 31, 2023**, based upon the framework in *Internal Control- Integrated Framework* (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis. Based upon this evaluation and the material weakness identified below, our management concluded that our internal control over financial reporting was not effective as of **December 31, 2022** **December 31, 2023**.

Material Weakness in Internal Control

We identified a material weakness related to Information Technology General Controls (ITGCs) ("ITGCs") that were not designed and operating effectively to ensure (i) appropriate segregation of duties was in place to perform program changes and (ii) the activities of individuals with access to modify data and make program changes were appropriately monitored. Business process controls (automated and manual) that are dependent on the affected ITGCs were also deemed ineffective because they could have been adversely impacted. We also identified a material weakness in the design and operating effectiveness around the valuation of certain accounts receivables.

The material **weakness** **weaknesses** identified above did not result in any material misstatements in our financial statements or disclosures, and there were no changes to previously released financial results. Our management concluded that the consolidated financial statements included in this Annual Report on Form 10-K, present fairly, in all material respects, our financial position, results of operations, and cash flows for the periods presented in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP.

The effectiveness of our internal control over financial reporting as of **December 31, 2022** **December 31, 2023**, has been audited by Marcum LLP as stated in their report, which is included in Item 8 of this Annual Report on Form 10-K.

[Table of Contents](#)*Remediation Plan*

Our management is committed to maintaining a strong internal control environment. In response to the identified material weakness above, management will take comprehensive actions to remediate the material weakness in internal control over financial reporting. We are in the process of developing and implementing remediation plans to address the material weakness described above.

Changes in Internal Control over Financial Reporting

Except for the items referred to above, there were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended **December 31, 2022****December 31, 2023** that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Inherent Limitation on the Effectiveness of Internal Control

Our management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by

41

[Table of Contents](#)

management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Due to inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

ITEM 9B. OTHER INFORMATION

None. Rule 10b5-1 Trading Arrangement

During the three months ended December 31, 2023, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

42

[Table of Contents](#)

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

The information required by this item will be included in the Proxy Statement, which will be filed with the Securities and Exchange Commission not later than 120 days after the end of our fiscal year ended **December 31, 2022****December 31, 2023** in connection with the solicitation of proxies for the Company's **2023****2024** annual meeting of stockholders and is incorporated herein by reference.

ITEM 11. EXECUTIVE COMPENSATION

The information required by this item will be included in the Proxy Statement, which will be filed with the Securities and Exchange Commission not later than 120 days after the end of our fiscal year ended **December 31, 2022** **December 31, 2023** and is incorporated herein by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

EQUITY COMPENSATION PLAN INFORMATION

The following table provides information as of **December 31, 2022** **December 31, 2023** regarding shares of common stock available for issuance under our equity incentive plans (in thousands except exercise price):

Plan Category	Number of Securities to be Issued Upon		Number of Securities Remaining Available for Future Issuance		Number of Securities to be Issued Upon		Number of Securities Remaining Available for Future Issuance		
	Exercise of Outstanding Options, Warrants and Rights	Weighted Average Exercise Price of Outstanding Options, Warrants and Rights	Under Equity	Exercise of Outstanding Options, Warrants and Rights	Weighted Average Exercise Price of Outstanding Options, Warrants and Rights	Under Equity	Exercise of Outstanding Options, Warrants and Rights	Weighted Average Exercise Price of Outstanding Options, Warrants and Rights	Under Equity
	Options, Warrants and Rights	Outstanding	Compensation Plans	Options, Warrants and Rights	Outstanding	Compensation Plans	Options, Warrants and Rights	Outstanding	Compensation Plans
	Options, Warrants and Rights	Options, Warrants and Rights	reflected in the first column)	Options, Warrants and Rights	Options, Warrants and Rights	reflected in the first column)	Options, Warrants and Rights	Options, Warrants and Rights	reflected in the first column)
2005 Stock Option Plan (1) (2)	211	\$ 0.20	—	2	\$ 0.39	—			
Warrants	99	2.40	—	80	2.43	—			
2017 Stock Option Plan (3)	1,005	2.07	3,836	347	1.83	3,389			
Total	1,315	\$ 1.79	3,836	429	\$ 1.94	3,389			

(1) All of these securities are available for issuance under the Zynex, Inc. 2005 Stock Option Plan, approved by the Board of Directors on January 3, 2005 and by our stockholders on December 30, 2005.

(2) As of December 31, 2014, the 2005 Stock Option Plan was terminated. Termination expired. Expiration of the plan did not affect the rights and obligations of the participants and the company arising under options previously granted.

(3) The 2017 Stock Option Plan was approved by stockholders on June 1, 2017.

The additional information required by this item will be included in the Proxy Statement, which will be filed with the Securities and Exchange Commission not later than 120 days after the end of our fiscal year ended **December 31, 2022** **December 31, 2023** and is incorporated herein by reference.

[Table of Contents](#)

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information required by this item will be included in the Proxy Statement, which will be filed with the Securities and Exchange Commission not later than 120 days after the end of our fiscal year ended **December 31, 2022** **December 31, 2023** and is incorporated herein by reference.

The Board of Directors has determined that Messrs. Cress, Disbrow, and Michaels who together comprise the Audit Committee, are all "independent directors" within the meaning of Rule 5605 of the NASDAQ Listing Rules.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The information required by this item will be included in the Proxy Statement, which will be filed with the Securities and Exchange Commission not later than 120 days after the end of our fiscal year ended **December 31, 2022** **December 31, 2023** and is incorporated herein by reference.

[Table of Contents](#)

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

Consolidated Financial Statements:

Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting	F-1
Report of Independent Registered Public Accounting Firm (Marcum LLP, New York, NY PCAOB firm ID 688)	F-3
Report of Independent Registered Public Accounting Firm (Plante & Moran, PLLC, Denver, CO PCAOB firm ID 166)	F-5
Consolidated Balance Sheets as of December 31, 2022 December 31, 2023 and 2021	F-6 F-5
Consolidated Statements of Income for the years ended December 31, 2022 December 31, 2023 and 2021	F-7 F-6
Consolidated Statements of Cash Flows for the years ended December 31, 2022 December 31, 2023 and 2021	F-8 F-7
Consolidated Statements of Stockholders' Equity for the years ended December 31, 2022 December 31, 2023 and 2021	F-9 F-8
Notes to Consolidated Financial Statements	F-10 F-9

Exhibits:

Exhibit Number	Description
2.1	Asset Purchase Agreement, dated March 9, 2012, among Zynex NeuroDiagnostics, Inc., NeuroDyne Medical Corp. and the shareholders listed on Schedule A thereto (incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K 8K filed on March 13, 2012)
3.1	Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K 8K filed on October 7, 2008)
3.2	Amended and Restated Bylaws (incorporated by reference to Exhibit 10.2 of the Company's Current Report on Form 8-K 8K filed on October 7, 2008)
4.1	Zynex, Inc 2017 Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to the Company's Report on form S-8 S8 filed on September 6, 2017)
4.2	Description of registrant's securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.2 to the Company's Annual Report on Form 10-K filed on March 22, 2022)
4.3	Indenture dated as of May 9, 2023, between Zynex, Inc. And U.S. Bank Trust Company, National Association, as trustee, (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on May 9, 2023)
4.4	Form of certificate representing the 5.00% Convertible Senior Notes due 2023 (included as Exhibit A to Exhibit 4.3)
10.1†	2005 Stock Option Plan (incorporated by reference to Exhibit 10.5 of the Company's Annual Report on Form 10-KSB 10KSB for the year ended December 31, 2004)
10.2†	Form of Indemnification Agreement for directors and executive officers (incorporated by reference to Exhibit 10.3 of the Company's Current Report on Form 8-K 8K filed on October 7, 2008)
10.3†	Employment agreement for Daniel J. Moorhead dated June 5, 2017 (incorporated by reference of Exhibit 10.1 to the Company's Report on Form 8K filed on June 8, 2017)
10.4	Office Lease, effective October 20, 2017, between CSG Systems, Inc. and Zynex Medical, Inc. (incorporated by reference to Exhibit 10.1 of the Company's Report on Form 8-K 8K filed on October 26, 2017)

10.5 [Zynex, Inc. Non-Employee Director Compensation Plan \(incorporated by reference to Exhibit 10.1 to the Company's Report on Form 8-K filed on January 11, 2018\)](#)

10.6 [Equity Distribution Agreement, dated October 29, 2019 between Zynex, Inc. and Piper Jaffray & Co. \(incorporated by reference to Exhibit 1.1 of the Company's Current Report on Form 8-K filed on October 29, 2019\)](#)

45

[Table of Contents](#)

Exhibit Number	Description
10.7	Amendment to Sublease Agreement, effective January 3, 2020, between CSG Systems, Inc. and Zynex, Inc. (incorporated by reference to Exhibit 10.1 of the Company's Report on Form 8-K filed on January 7, 2020)
10.8	Underwriting Agreement dated July 14, 2020, among certain selling stockholders, Piper Sandler & Co., and Zynex, Inc. (incorporated by reference to Exhibit 10.11.1 of the Company's Report on Form 8-K filed on July 17, 2020)
10.9	Lease Agreement, effective September 30, 2020, between GIG CW Compark, LLC and Zynex, Inc. (incorporated by reference to Exhibit 10.1 of the Company's Report on Form 8-K filed on October 6, 2020).
10.10	Sublease Agreement between Zynex, Inc. and Cognizant Trizetto Software Group, Inc. dated April 8, 2021 (incorporated by reference to Exhibit 10.1 of the Company's Report on Form 8-K filed on April 9, 2021)
10.11	Stock Purchase Agreement by and among Kestrel Labs, Inc., Zynex Monitoring Solutions Inc., Zynex, Inc. and Selling Shareholders named herein dated as of December 22, 2021 (incorporated by reference to Exhibit 10.1 of the Company's Report on Form 8-K filed on December 23, 2021)
10.12	The Loan Agreement and accompanying documents dated December 22, 2021 among Bank of America N.A., Zynex Medical, Inc., and Zynex Monitoring Solutions (incorporated by reference to Exhibit 10.1 of the Company's Report on Form 8-K filed on December 30, 2021)
10.13	Amendment to Stock Purchase Agreement by and among Kestrel Labs, Inc., Zynex Monitoring Solutions, Inc. And Selling Shareholders named therein dated as of July 27, 2023 (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on July 31, 2023)

46

[Table of Contents](#)

Exhibit Number	Description
21*	Subsidiaries of the Company

23.1*	Consent of Marcum LLP, Independent Registered Public Accounting Firm (Filed herewith)
23.2*	Consent of Plante & Moran, PLLC, Independent Registered Public Accounting Firm (Filed herewith)
31.1*	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)13a14(a)/15d-14(a)15d14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
31.2*	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)13a14(a)/15d-14(a)15d14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
32.1*	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
97*	Zynex, Inc. Clawback Policy
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Calculation Linkbase Document
101.LAB*	XBRL Taxonomy Label Linkbase Document
101.PRE*	XBRL Presentation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed herewith

† Denotes management contract or compensatory plan or arrangement

ITEM 16. FORM 10-K SUMMARY

None.

[Table of Contents](#)

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ZYNEX, INC.

Date: **March 13, 2023** **March 12, 2024**

By : **/s/ Thomas Sandgaard**

Thomas Sandgaard

Chairman, President, Chief Executive Officer and Principal Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Date	Name and Title	Signature
March 13, 2023 12, 2024	Thomas Sandgaard, Chairman, President, Chief Executive Officer and Principal Executive Officer	/s/ Thomas Sandgaard
March 13, 2023 12, 2024	Daniel Moorhead Chief Financial Officer and Principal Financial Officer	/s/ Daniel Moorhead
March 13, 2023 12, 2024	Barry D. Michaels Director	/s/ Barry D. Michaels
March 13, 2023 12, 2024	Michael Cress Director	/s/ Michael Cress
March 13, 2023 12, 2024	Joshua R. Disbrow Director	/s/ Joshua R. Disbrow

48

[Table of Contents](#)

[Report of Independent Registered Public Accounting Firm](#) on Internal Control Over Financial Reporting

To the Shareholders and Board of Directors of
Zynex, Inc.

Adverse Opinion on Internal Control over Financial Reporting

We have audited Zynex, Inc.'s (the "Company" "Company") internal control over financial reporting as of **December 31, 2022****December 31, 2023**, based on criteria established in *Internal Control-Integrated Framework* (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, because of the effect of the material weaknesses described in the following paragraph on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of **December 31 2022**, **December 31, 2023**, based on criteria established in *Internal Control-Integrated Framework* (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

A material weakness is a control deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the **Company's** **Company's** annual or interim financial statements will not be prevented or detected on a timely basis. The following material weaknesses have been identified and included in **"Management's"** **Management's** Annual Report on Internal Control Over Financial Reporting":

IT General Controls ("ITGC") *It was determined that as of December 31, 2023, deficiencies were identified*

Information technology general the Company's primary change management controls (ITGCs) were not designed and operating implemented effectively to ensure (i) IT program and data changes affecting the Company's financial IT applications and underlying accounting records, are identified, tested, authorized and implemented appropriately to validate that appropriate segregation data produced by its relevant IT system(s) were complete and accurate Other Information Technology General Controls, automated process-level controls, and manual controls that are dependent upon the information derived from such financially relevant systems were also determined to be ineffective as a result of duties was in place to perform program changes and (ii) that the activities of individuals with access to modify data and make program changes were appropriately monitored such deficiency. Business process controls (automated and manual) that are dependent on the affected ITGCs were also deemed ineffective because they could have been adversely impacted impacted;

Ineffective design and implementation of controls over the valuation of accounts receivable to properly address the risk of material misstatement.

This material weakness was considered in determining the nature, timing and extent of audit tests applied in our audit of the fiscal December 31, 2022 December 31, 2023 consolidated financial statements, and this report does not affect our report dated March 13, 2023 March 12, 2024 on those consolidated financial statements.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB"), the consolidated balance sheets as of December 31, 2022 December 31, 2023 and 2022, the related consolidated statements of income, operations, changes in shareholders' equity, and cash flows for each of the December 31, 2022 two years in the period ended December 31, 2023, and related notes of the Company, and our report dated March 13, 2023 March 12, 2024 expressed an unqualified opinion on those consolidated financial statements.

Basis for Opinion

The Company's management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing

F-1

[Table of Contents](#)

the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

F-1

[Table of Contents](#)

Definition and Limitations of Internal Control over Financial Reporting

A company's company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's company's assets that could have a material effect on the financial statements.

Because of the inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that degree of compliance with the policies or procedures may deteriorate.

Marcum

/s/ Marcum LLP

Marcum LLP

We have served as the Company's auditor since 2022.

New York, NY

March 13, 2023 12, 2024.

F-2

[Table of Contents](#)

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of
Zynex Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet sheets of Zynex Medical, Inc. (the "Company") as of December 31, 2022, December 31, 2023 and 2022, the related consolidated statements of income, stockholders' equity and cash flows for each of the one year two years in the period ended December 31, 2022 December 31, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the year two years in the period ended December 31, 2022 December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB" ("PCAOB")), the Company's company's internal control over financial reporting as of December 31, 2022 December 31, 2023, based on the criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013 and our report dated

March 13, 2023March 12, 2024, expressed an adverse opinion on the effectiveness of the Company's internal control over financial reporting because of the existence of material weaknesses.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our **audit audits** in accordance with the standards of the PCAOB. Those standards require that we plan and perform the **audit audits** to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our **audit audits** included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our **audit audits** also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our **audit audits** provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Estimation of Transaction Price and Variable Consideration for Revenue Recognition including related Valuation of Accounts Receivable

Critical Audit Matter Description

The Company's revenue is derived from sales and leases of electrotherapy devices and sales of related supplies and complementary products. The Company recognizes revenue when control of the product has been transferred to the patient, in the amount that reflects

F-3

[Table of Contents](#)

the consideration the Company expects to receive. The Company estimates revenues using the portfolio approach based upon historical rates of collection, aging of receivables, product mix, trends in historical reimbursement rates by third-party payer types, and current relationships and experience with the third-party payers, which includes estimated variable consideration and relevant constraints for third-party payer refund requests, deductions and adjustments.

F-3

[Table of Contents](#)

We identified the Company's estimation of transaction price related to variable consideration for revenue recognition, including the related valuation of accounts receivable, as a critical audit matter. Auditing the Company's determination of variable consideration and the related constraint for revenue recognition including the recorded value for accounts receivable was challenging and complex due to the high degree of subjectivity involved in evaluating management's estimates. This required a high degree of auditor judgment and increased extent of effort to audit and evaluate management's key judgments.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to revenue recognition and accounts receivable include the following, among others:

- We gained an understanding of the design of the controls over the Company's contracts with customers including those controls over the processes to develop key management estimates.
- We performed testing throughout the year on a sample of contracts to test the validity of sales transactions and cash receipts application.
- We evaluated the significant assumptions and the accuracy and completeness of the underlying data used in management's calculations, including evaluating management's estimate of historical reimbursement experience as well as expected future payment behavior through a combination of underlying data validation by inspection of source documents, independent recalculation of management's analysis, review of correspondence with third-party payers, inquiries with management and evaluation of trends in collection rates and refund requests.
- We performed independent sensitivity analyses over the Company's significant assumptions embodied within their key estimates including evaluation of subsequent payment activity compared with management's estimate of expected collection rates.

/s/ Marcum LLP

Marcum LLP

We have served as the Company's auditor since 2022.

New York, NY

March 13, 2023 12, 2024

F-4

[Table of Contents](#)

Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors of Zynex, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Zynex, Inc. (the "Company") as of December 31, 2021 and the related consolidated statements of income, stockholders' equity, and cash flow for the year ended December 31, 2021, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and the results of its operations and its cash flows for the year ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

The Company's management is responsible for these financial statements. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company was not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we were required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ Plante & Moran, PLLC

We served as the Company's auditor from 2016-2022.

Denver, Colorado

March 21, 2022

F-5

[Table of Contents](#)

ZYNEX, INC.
CONSOLIDATED BALANCE SHEETS
(AMOUNTS IN THOUSANDS, EXCEPT SHARE DATA)

	December 31,		December 31,	
	2022		2021	
ASSETS	\$	\$	\$	\$
Current assets:				
Cash		\$ 20,144		\$ 42,612
Accounts receivable, net		35,063		28,632
Inventory, net		13,484		10,756
Prepaid expenses and other		868		689
Total current assets		69,559		82,689

Property and equipment, net	2,175	2,186
Operating lease asset	12,841	16,338
Finance lease asset	270	389
Deposits	591	585
Intangible assets, net of accumulated amortization	9,067	9,975
Goodwill	20,401	20,401
Deferred income taxes	1,562	711
Total assets	<u>\$ 116,466</u>	<u>\$ 133,274</u>

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:		
Accounts payable and accrued expenses	5,601	4,739
Cash dividends payable	16	3,629
Operating lease liability	2,476	2,859
Finance lease liability	128	118
Income taxes payable	1,995	2,296
Current portion of debt	5,333	5,333
Accrued payroll and related taxes	5,537	3,897
Total current liabilities	<u>21,086</u>	<u>22,871</u>
Long-term liabilities:		
Long-term portion of debt, less issuance costs	5,293	10,605
Contingent consideration	10,000	9,700
Operating lease liability	13,541	15,856
Finance lease liability	188	317
Total liabilities	<u>50,108</u>	<u>59,349</u>
Commitments and contingencies (Note 13)		
Stockholders' equity:		
Preferred stock, \$0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2022 and December 31, 2021	—	—
Common stock, \$0.001 par value; 100,000,000 shares authorized; 41,658,132 issued and 36,825,081 outstanding as of December 31, 2022 41,400,834 issued and 39,737,890 outstanding as of December 31, 2021 (including 3,606,970 shares declared as a stock dividend on November 9, 2021 and issued on January 21, 2022)	39	41
Additional paid-in capital	82,431	80,397
Treasury stock of 4,253,015 and 1,246,399 shares, at December 31, 2022 and 2021, respectively, at cost	(33,160)	(6,513)
Retained earnings	17,048	—
Total stockholders' equity	<u>66,358</u>	<u>73,925</u>
Total liabilities and stockholders' equity	<u>\$ 116,466</u>	<u>\$ 133,274</u>

December 31,	December 31,
2023	2022

ASSETS

Current assets:		
Cash and cash equivalents	\$ 44,579	\$ 20,144
Accounts receivable, net	26,838	35,063
Inventory, net	13,106	13,484
Prepaid expenses and other	3,332	868
Total current assets	<u>87,855</u>	<u>69,559</u>
Property and equipment, net	3,114	2,175
Operating lease asset	12,515	12,841
Finance lease asset	587	270
Deposits	409	591
Intangible assets, net of accumulated amortization	8,158	9,067

Goodwill	20,401	20,401
Deferred income taxes	3,865	1,562
Total assets	\$ 136,904	\$ 116,466
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable and accrued expenses	8,433	5,617
Operating lease liability	3,729	2,476
Finance lease liability	196	128
Income taxes payable	633	1,995
Current portion of debt	—	5,333
Accrued payroll and related taxes	5,541	5,537
Total current liabilities	18,532	21,086
Long-term liabilities:		
Long-term portion of debt, less issuance costs	—	5,293
Convertible senior notes, less issuance costs	57,605	—
Contingent consideration	—	10,000
Operating lease liability	14,181	13,541
Finance lease liability	457	188
Total liabilities	90,775	50,108
Commitments and contingencies (Note 14)		
Stockholders' equity:		
Preferred stock, \$0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and December 31, 2022	—	—
Common stock, \$0.001 par value; 100,000,000 shares authorized; 41,980,166 issued and 32,933,776 outstanding as of December 31, 2023, 41,658,132 issued and 36,825,081 outstanding as of December 31, 2022	33	39
Additional paid-in capital	90,878	82,431
Treasury stock of 8,545,044 and 4,253,015 shares at December 31, 2023 and December 31, 2022, respectively, at cost	(71,562)	(33,160)
Retained earnings	26,780	17,048
Total stockholders' equity	46,129	66,358
Total liabilities and stockholders' equity	\$ 136,904	\$ 116,466

See accompanying notes to consolidated financial statements.

F-6 F-5

[Table of Contents](#)

ZYNEX, INC.
CONSOLIDATED STATEMENT OF INCOME
(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)
YEARS ENDED DECEMBER 31, 2022 AND 2021

For the Years Ended December 31,	
2022	2021

NET REVENUE		
Devices	\$ 43,497	\$ 36,613
Supplies	114,670	93,688
Total net revenue	158,167	130,301
COSTS OF REVENUE AND OPERATING EXPENSES		
Costs of revenue - devices and supplies	32,005	27,321
Sales and marketing	67,116	54,290
General and administrative	36,108	26,324
Total costs of revenue and operating expenses	135,229	107,935
Income from operations	22,938	22,366
Other expense		
Loss on change in fair value of contingent consideration	(300)	—
Interest expense	(440)	(95)
Other expense, net	(740)	(95)
Income from operations before income taxes	22,198	22,271
Income tax expense	5,150	5,168
Net income	\$ 17,048	\$ 17,103
Net income per share:		
Basic	\$ 0.44	\$ 0.45
Diluted	\$ 0.44	\$ 0.44
Weighted average basic shares outstanding	38,467	38,317
Weighted average diluted shares outstanding	39,127	39,197
For the Years Ended December 31,		
2023		
NET REVENUE		
Devices	\$ 58,822	\$ 43,497
Supplies	125,500	114,670
Total net revenue	184,322	158,167
COSTS OF REVENUE AND OPERATING EXPENSES		
Costs of revenue - devices and supplies	38,366	32,005
Sales and marketing	86,659	67,116
General and administrative	48,517	36,108
Total costs of revenue and operating expenses	173,542	135,229
Income from operations	10,780	22,938
Other income (expense)		
Gain on sale of fixed assets	39	—
Gain (loss) on change in fair value of contingent consideration	2,854	(300)
Interest expense, net	(1,094)	(440)
Other income (expense), net	1,799	(740)
Income from operations before income taxes	12,579	22,198
Income tax expense	2,847	5,150
Net income	\$ 9,732	\$ 17,048
Net income per share:		

Basic	\$ 0.27	\$ 0.44
Diluted	\$ 0.27	\$ 0.44
Weighted average basic shares outstanding	35,555	38,467
Weighted average diluted shares outstanding	36,142	39,127

See accompanying notes to consolidated financial statements.

F-7 F-6

[Table of Contents](#)

ZYNEX, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(AMOUNTS IN THOUSANDS)
YEARS ENDED DECEMBER 31, 2022 AND 2021

	For the Years Ended December 31,	
	2022	2021
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income	\$ 17,048	\$ 17,103
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation	2,197	2,261
Amortization	930	25
Non-cash reserve charges	82	(107)
Stock-based compensation	2,342	1,630
Non-cash lease expense	800	1,398
Loss on change in fair value of contingent consideration	300	—
Benefit for deferred income taxes	(851)	(146)
Change in operating assets and liabilities, net of the effects of acquisitions:		
Accounts receivable	(6,430)	(14,781)
Prepaid and other assets	(180)	690
Accounts payable and other accrued expenses	1,834	2,889
Inventory	(4,320)	(3,776)
Deposits	(6)	(237)
Net cash provided by operating activities	13,746	6,949
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of property and equipment	(418)	(609)
Business acquisition, net of cash acquired	—	(15,997)
Net cash used in investing activities	(418)	(16,606)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Payments on finance lease obligations	(118)	(98)
Cash dividends paid	(3,613)	(1)
Purchase of treasury stock	(26,426)	(2,667)

Debt issuance costs	—	(16)
Proceeds from the issuance of common stock on stock-based awards	46	161
Proceeds from debt	—	15,953
Principal payments on long-term debt	(5,333)	—
Taxes withheld and paid on employees' equity awards	(352)	(236)
Net cash (used in) provided by financing activities	<u>(35,796)</u>	<u>13,096</u>
Net increase (decrease) in cash	(22,468)	3,439
Cash at beginning of period	42,612	39,173
Cash at end of period	<u>\$ 20,144</u>	<u>\$ 42,612</u>
Supplemental disclosure of cash flow information:		
Cash paid for interest	\$ (391)	\$ (82)
Cash paid for rent	\$ (3,622)	\$ (2,109)
Cash paid for income taxes	\$ (6,294)	\$ (3,305)
Supplemental disclosure of non-cash investing and financing activities:		
Right-of-use assets obtained in exchange for new operating lease liabilities	\$ 211	\$ 13,240
Right-of-use assets obtained in exchange for new finance lease liabilities	\$ —	\$ 175
Inventory transferred to property and equipment under lease	\$ 1,592	\$ 1,587
Capital expenditures not yet paid	\$ 138	\$ 47
Treasury stock not yet paid	\$ 224	\$ —
Accrual for cash dividend payable	\$ —	\$ 3,622
Contingent consideration related to acquisition	\$ —	\$ 9,700
Stock issued for acquisition	\$ —	\$ (4,701)
Stock dividend	\$ —	\$ (36,911)
	For the Years Ended December 31,	
	2023	2022
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income	\$ 9,732	\$ 17,048
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation	2,684	2,197
Amortization	1,536	930
Non-cash reserve charges	(91)	82
Stock-based compensation	2,296	2,342
Non-cash lease expense	904	800
Benefit for deferred income taxes	(2,303)	(851)
Change in fair value of contingent consideration	(2,854)	300
Gain on sale of fixed assets	(39)	—
Change in operating assets and liabilities:		
Short-term investments	(190)	—
Accounts receivable	8,225	(6,430)
Prepaid and other assets	(1,150)	(180)
Accounts payable and other accrued expenses	269	1,834
Inventory	(1,445)	(4,320)
Deposits	182	(6)
Net cash provided by operating activities	<u>17,756</u>	<u>13,746</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of property and equipment	(1,206)	(418)
Purchase of short-term investments	(9,810)	—
Maturity of short-term investments	10,000	—
Proceeds on sale of fixed assets	50	—
Net cash used in investing activities	<u>(966)</u>	<u>(418)</u>

CASH FLOWS FROM FINANCING ACTIVITIES:

Payments on finance lease obligations	(128)	(118)
Cash dividends paid	(3)	(3,613)
Purchase of treasury stock	(37,924)	(26,426)
Proceeds from issuance of convertible senior notes, net of issuance costs	57,018	—
Proceeds from the issuance of common stock on stock-based awards	86	46
Principal payments on long-term debt	(10,667)	(5,333)
Taxes withheld and paid on employees' equity awards	(737)	(352)
Net cash provided by (used in) financing activities	<u>7,645</u>	<u>(35,796)</u>

Net increase (decrease) in cash and cash equivalents	24,435	(22,468)
Cash and cash equivalents at beginning of year	20,144	42,612
Cash and cash equivalents at end of year	<u>\$ 44,579</u>	<u>\$ 20,144</u>

Supplemental disclosure of cash flow information:

Cash paid on interest, net	\$ (739)	\$ (391)
Cash paid for rent	\$ (3,055)	\$ (3,622)
Cash paid for income taxes	\$ (6,456)	\$ (6,294)

Supplemental disclosure of non-cash investing and financing activities:

Right-of-use assets obtained in exchange for new operating lease liabilities	\$ 4,214	\$ 211
Right-of-use assets obtained in exchange for new finance lease liabilities	\$ 464	\$ —
Lease incentive	\$ 1,400	\$ —
Vesting of restricted stock awards	\$ (3)	\$ —
Inventory transferred to property and equipment under lease	\$ 1,823	\$ 1,592
Capital expenditures not yet paid	\$ 366	\$ 138
Treasury Stock not yet paid	\$ 481	\$ 224
Non-cash dividend adjustment	\$ (1)	\$ —
Escrow share lock-up adjustment	\$ (7,146)	\$ —
Excise tax accrual	\$ 347	\$ —

See accompanying notes to consolidated financial statements.

F-7

F-8

[Table of Contents](#)

ZYNEX, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
YEARS ENDED DECEMBER 31, 2022 2023 AND 2021 2022
(AMOUNTS IN THOUSANDS, EXCEPT SHARE DATA)

	Additional						Stockholders'	Common Stock	
	Common Stock		Paid-in	Treasury	Retained	Total		Shares	Amount
	Shares	Amount	Capital	Stock	Earnings	Equity		Shares	Amount
Balance at December 31, 2020	38,244,310	\$ 36	\$37,235	\$ (3,846)	\$ 23,430	\$ 56,855			

Exercised and vested stock-based awards	234,388	1	160	—	—	161
Warrants exercised	11,000	—	—	—	—	—
Stock-based compensation expense	—	—	1,630	—	—	1,630
Shares of common stock withheld to pay taxes on employees' equity awards	(44,414)	—	(236)	—	—	(236)
Purchase of treasury stock	(175,179)	—	—	(2,667)	—	(2,667)
Stock issued for acquisition	489,262	—	4,701	—	—	4,701
Escrow shares issued for acquisition	978,523	—	—	—	—	—
Cash dividends declared (\$0.10 per share)	—	—	—	—	(3,622)	(3,622)
Stock dividends declared	—	4	36,907	—	(36,911)	—
Net income	—	—	—	—	17,103	17,103
Balance at December 31, 2021	39,737,890	\$ 41	\$80,397	\$ (6,513)	\$ —	\$ 73,925
Exercised and vested stock-based awards	322,237	1	45	—	—	46
Stock-based compensation expense	—	—	2,342	—	—	2,342
Shares of common stock withheld to pay taxes on employees' equity awards	(83,201)	—	(353)	—	—	(353)
Purchase of treasury stock	(3,006,616)	(3)	—	(26,647)	—	(26,650)
Escrow shares adjustment	(156,673)	—	—	—	—	(156,673)
Stock dividend adjustments	11,444	—	—	—	—	11,444
Net income	—	—	—	—	17,048	17,048
Balance at December 31, 2022	36,825,081	\$ 39	\$82,431	\$ (33,160)	\$ 17,048	\$ 66,358
Exercised and vested stock-based awards	—	—	—	—	459,246	(3)
Stock-based compensation expense	—	—	—	—	—	—
Shares of common stock withheld to pay taxes on employees' equity awards	—	—	—	—	(58,522)	—
Purchase of treasury stock	—	—	—	—	(4,292,029)	(3)
Excise tax on net treasury stock purchases	—	—	—	—	—	—
Escrow share adjustment	—	—	—	—	—	—
Net income	—	—	—	—	—	—
Balance at December 31, 2023	32,933,776	\$ 33	\$ —	\$ —	\$ —	\$ —

See accompanying notes to consolidated financial statements.

F-9 F-8

[Table of Contents](#)

ZYNEX, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 2022 2023 AND 2021 2022

(1) ORGANIZATION, NATURE OF BUSINESS

Organization

Zynex, Inc. (a Nevada corporation) has its headquarters in Englewood, Colorado. The term "the Company" refers to Zynex, Inc. and its active and inactive subsidiaries. The Company operates in one primary business segment, medical devices which include electrotherapy and pain management products. As of December 31, 2022 December 31, 2023, the Company's only active subsidiaries are Zynex Medical, Inc. ("ZMI," a wholly-owned Colorado corporation) through which the Company conducts most of its operations, and Zynex Monitoring Solutions, Inc. ("ZMS," a wholly-owned Colorado corporation). ZMS has developed a fluid monitoring system which received initial approval by the U.S. Food and Drug Administration ("FDA") during 2020 and is still awaiting pursuing CE Marking in Europe. ZMS has achieved no revenues to date. The Company's inactive subsidiaries include Kestrel Labs, Inc. ("Kestrel," a wholly-owned

Colorado corporation), Zynex Europe, Zynex NeuroDiagnostics, Inc. ("ZND," a wholly-owned Colorado corporation) and Pharmazy, Inc. ("Pharmazy", a wholly-owned Colorado Corporation), which was incorporated in June 2015. The Company's compounding pharmacy operated as a division of ZMI dba as Pharmazy through January 2016.

In December 2021, the Company acquired 100% of Kestrel Labs, Inc. ("Kestrel"), a laser-based, noninvasive patient monitoring technology company. Kestrel's laser-based products include the NiCO™ CO-Oximeter, a multi-parameter pulse oximeter, and HemeOx™, a total hemoglobin oximeter that enables continuous arterial blood monitoring. Both NiCO and HemeOx are yet to be presented to the U.S. Food and Drug Administration ("FDA") for market clearance. All activities related to Kestrel flow through our ZMS subsidiary.

Nature of Business

The Company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The Company's devices are intended for pain management to reduce reliance on **drugs and medications** and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current ("IFC"), neuromuscular electrical stimulation ("NMES") and transcutaneous electrical nerve stimulation ("TENS"). All of our medical devices are designed to be patient friendly and designed for home use. Our devices are small, portable, battery operated, and include an electrical pulse generator which is connected to the body via electrodes. All of our medical devices are marketed in the U.S. and are subject to FDA regulation and approval. Our products require a physician's prescription before they can be dispensed in the U.S. Our primary product is the NexWave device. The NexWave is marketed to physicians and therapists by our field sales representatives. The NexWave requires consumable supplies, such as electrodes and batteries, which are shipped to patients on a recurring monthly basis, as needed.

During the years ended **December 31, 2022** **December 31, 2023**, and **2021** **2022**, the Company generated all **of its** revenue in North America from sales and supplies of its devices to patients and **health care** **healthcare** providers.

The Company declared a 10% stock dividend on November 9, 2021, which was effective on January 21, 2022. Except as otherwise indicated, all related amounts reported in the consolidated financial statements, including common share quantities, earnings per share amounts and exercise prices of options, have been retroactively adjusted for the effect of this stock dividend.

(2) SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

F-10 F-9

Table of Contents

Use of Estimates

Preparation of financial statements in conformity with generally accepted accounting principles in the United States of America ("GAAP"), requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant management estimates used in the preparation of the accompanying consolidated financial statements are associated with the expected net collectable value of its accounts receivable and related revenue, inventory reserves, the life of its leased unit devices, stock-based compensation, valuation of long-lived assets acquired in business combinations, valuation of contingent consideration, and realizability of deferred tax assets.

Fair Value of Financial Instruments

The Company's financial instruments include cash, accounts receivable, accounts payable, and accrued liabilities. The carrying amounts of financial instruments, including cash, accounts receivable, accounts payable, and accrued liabilities approximate their fair value due to their short maturities. The

Company measures its long-term debt at fair value which approximates book value as the long-term debt bears market rates of interest.

The Company ~~classifies~~ classified contingent consideration liabilities related to business acquisitions within Level 3 as factors used to develop the estimated fair value ~~are~~ were unobservable inputs that are not supported by market activity. The Company ~~estimates~~ estimated the fair value of contingent consideration liabilities using a Monte Carlo simulation. Changes in the fair value of contingent liabilities in subsequent periods ~~are~~ were recorded as a loss (gain) gain or (loss) in the statements of ~~operations~~ income.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Short-term investments include investments with maturities greater than three months, but not exceeding 12 months, or highly liquid investments with maturities greater than 12 months that the Company intends to liquidate during the next 12 months for working capital needs.

Accounts Receivable, Net

The Company's accounts receivables represent unconditional rights to consideration and are generated when a patient receives one of the Company's devices, related supplies, or complementary products. In conjunction with fulfilling the Company's obligation to deliver a product, the Company bills the patient's third-party payer or the patient. Billing adjustments represent the difference between the list prices and the reimbursement rates set by third-party payers, including Medicare, commercial payers, and amounts billed directly to the patient. Specific amounts, if uncollected over a period of time, may be written off after several appeals, which in some cases may take longer than twelve months. Primarily, all ~~of~~ the Company's receivables are due from patients with commercial or government health plans and ~~workers~~ workers compensation claims with a small portion related to private pay individuals, attorney, and auto claims.

F-10

Table of Contents

Inventory, Net

Inventories are stated at the lower of cost or net realizable value. Cost is computed using standard costs, which approximates actual costs on an average cost basis. Following are the components of inventory as of ~~December 31, 2022~~ December 31, 2023 and ~~2021~~ 2022:

	December 31, 2022	December 31, 2021	2023	2022
Raw materials	\$ 3,506	\$ 4,471	\$ 4,601	\$ 3,506
Work-in-process	1,205	345	530	1,205
Finished goods	7,750	4,468	6,929	7,750
Inventory in transit	1,291	1,624	1,346	1,291
	\$ 13,752	\$ 10,908	\$13,406	\$13,752
Less: reserve	(268)	(152)	(300)	(268)
	\$ 13,484	\$ 10,756	\$13,106	\$13,484

F-11

Table of Contents

The Company monitors inventory for turnover and obsolescence and records losses for excess and obsolete inventory, as appropriate. The Company provides reserves for estimated excess and obsolete inventories equal to the difference between the costs of inventories on hand and the estimated market value based upon assumptions about future demand. If future demand is less favorable than currently projected by management, additional inventory write-downs may be required.

Long-lived Assets

The Company records intangible assets based on estimated fair value on the date of acquisition. Long-lived assets consist of net property and equipment and intangible assets. The finite-lived intangible assets are patents and are amortized on a straight-line basis over the estimated lives of the assets.

The Company assesses impairment of long-lived assets when events or changes in circumstances ~~indicates~~ indicate that their carrying value amount may not be recoverable. Circumstances which could trigger a review include but are not limited to: (i) significant decreases in the market price of the asset; (ii) significant adverse changes in the business climate or legal or regulatory factors; ~~or~~ (iii) ~~or~~ expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.

If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than the carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value.

Useful lives of finite-lived intangible assets by each asset category are summarized below:

	Estimated Useful Lives in years
Patents	11

Property and equipment is recorded at cost. Repairs and maintenance expenditures are charged to expense as incurred. We compute depreciation expense on a straight-line basis over the estimated useful lives of the assets as follows:

Classification	Estimated Useful Life
Office furniture and equipment	5 to 7 years
Assembly equipment	7 years
Vehicles	5 years
Leasehold improvements	Shorter of useful life or term of lease
Leased devices	9 months

F-11

Table of Contents

Leases

The Company determines if an arrangement is a lease at inception or modification of a contract.

The Company recognizes finance and operating lease right-of-use assets and liabilities at the lease commencement date based on the estimated present value of the remaining lease payments over the lease term. For our finance leases, the Company uses the implicit rate to determine the present value of future lease payments. For our operating leases that do not provide an implicit rate, the Company uses incremental borrowing rates to determine the present value of future lease payments. The Company includes options to extend or terminate a lease in the lease term when it is reasonably certain to exercise such options. The Company recognizes leases with an initial term of 12 months or less as lease expense over the lease term, and those leases are not recorded on our Consolidated Balance Sheets. For additional information on our leases where the Company is the lessee, see Note [11-12 - Leases](#).

[Table of Contents](#)

A significant portion of our device revenue is derived from patients who obtain our devices under month-to-month lease arrangements where the Company is the lessor. Revenue related to devices on lease is recognized in accordance with Accounting Standards Codification ("ASC") 842, **Leases**, "Leases" ("ASC 842"). Using the guidance in ASC 842, we concluded our transactions should be accounted for as operating leases based on the following criteria:

- The lease does not transfer ownership of the underlying asset to the lessee by the end of the lease term.
- The lease does not grant the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.
- The lease term is month to month, which does not meet the major part of the remaining economic life of the underlying asset. However, if the commencement date falls at or near the end of the economic life of the underlying asset, this criterion shall not be used for purposes of classifying the lease.
- There is no residual value guaranteed and the present value of the sum of the lease payments does not equal or exceed substantially all of the fair value of the underlying **asset**.
- The underlying asset is expected to have alternative uses to the lessor at the end of the lease term.

Lease commencement occurs upon delivery of the device to the patient. The Company retains title to the leased device and those devices are classified as property and equipment on the balance sheet. Since our leases are month-to-month and can be returned by the patient at any time, revenue is recognized monthly for the duration of the period in which the patient retains the device.

Revenue Recognition

Revenue is derived from sales and leases of the Company's electrotherapy devices and sales of related supplies and complementary products. Device sales can be in the form of a purchase or a lease. Supplies needed for the device can be set up as a recurring shipment or ordered through the customer support team or online store as needed. The Company recognizes revenue when control of the product has been transferred to the patient, in the amount that reflects the consideration the Company expects to receive. In general, revenue from sales of devices and supplies is recognized once the product is delivered to the patient, which is when control is deemed to have transferred to the patient.

Sales of devices and supplies are primarily shipped directly to the patient, with a small amount of revenue generated from sales to distributors. In the healthcare industry, there is often a third party involved that will pay on the patients' behalf for purchased or leased devices and supplies. The terms of the separate arrangement impact certain aspects of the contracts, with patients covered by third party payers, such as contract type, performance obligations, and transaction **price**, but **for** **price**. For purposes of revenue recognition, the contract with the customer refers to the arrangement between the Company and the patient. The Company does not have any material deferred revenue in the normal course of business as each performance obligation is met upon delivery of goods to the patient. There are no substantial costs incurred through support or warranty obligations.

[Table of Contents](#)

The following table provides a breakdown of net revenue related to devices accounted for as purchases subject to Accounting Standards Codification ("ASC") 606 – "Revenue from Contracts with Customers" ("ASC 606") and leases subject to ASC 842 (in thousands):

Device revenue	For the Years Ended December 31,		For the Years Ended December 31,	
	2022	2021	2023	2022

Purchased	\$ 14,393	\$ 9,240	\$ 23,971	\$ 14,393
Leased	29,104	27,373	34,851	29,104
Total device revenue	43,497	36,613	\$ 58,822	\$ 43,497
Supplies revenue	114,670	93,688	125,500	114,670
Total revenue	\$ 158,167	\$ 130,301	\$ 184,322	\$ 158,167

F-13

[Table of Contents](#)

Revenues are estimated using the portfolio approach by third-party payer type based upon historical rates of collection, aging of receivables, trends in historical reimbursement rates by third-party payer types, and current relationships and experience with the third-party payers, which includes estimated constraints for third-party payer refund requests, deductions, allowance for uncollectible accounts and billing allowance adjustments. Inherent in these estimates is the risk that they will have to be revised as additional information becomes available and constraints are released. Specifically, If initial estimates are updated these changes are accounted for as increases or decreases in the transaction price. Assuming the underlying performance obligation to which the change in price relates has already been satisfied, those changes in transaction price are immediately recognized as increases or decreases in revenue (not credit losses (bad debt expense)) in the period in which the estimate changes. Additionally, the complexity of third-party payer billing arrangements, and the uncertainty of reimbursement amounts for certain products from third-party payers, or unanticipated requirements to refund payments previously received may result in adjustments to amounts originally recorded. Settlements with third-party payers for retroactive revenue adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price using the expected amount method. These adjustments to transaction price are estimated based on the terms of the payment agreement with the payer, correspondence from the payer, and historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Due to continuing changes in the healthcare industry and third-party payer reimbursement, it is possible the Company's forecasting model to estimate collections could change, which could have an impact on the Company's results of operations and cash flows. Any differences between estimated and actual collectability are reflected in the period in which payment is received. Historically these differences have been immaterial, and the Company has not had a significant reversal of revenue from prior periods.

The Company monitors the variability and uncertain timing over third-party payer types in the portfolios. If there is a change in the Company's third-party payer mix over time, it could affect net revenue and related receivables. The Company believes it has a sufficient history of collection experience to estimate the net collectible amounts by third-party payer type. However, changes to constraints related to billing adjustments and refund requests have historically fluctuated and may continue to fluctuate significantly from quarter to quarter quarter-to-quarter and year to year year-to-year.

Goodwill

Goodwill is recorded as the difference between the fair value of the purchase consideration and the estimated fair value of the net identifiable tangible and intangible assets acquired.

Goodwill is not subject to amortization but is subject to impairment testing in the future. testing. The Company tests goodwill at least annually for impairment. The Company tests more frequently if indicators are present or changes in circumstances suggest that impairment may exist. These indicators include, among others, declines in sales, earnings, or cash flows, or the development of a material adverse change in the business climate. The Company assesses goodwill for impairment at the reporting unit level. The estimates of fair value and the determination of reporting units requires management judgment.

F-13

[Table of Contents](#)

Debt Issuance Costs

Debt issuance costs are costs incurred to obtain new debt financing. Debt issuance costs are presented in the accompanying consolidated balance sheets as a reduction in the carrying value of the debt and are accreted to interest expense using the effective interest method.

Advertising and Marketing Costs

Advertising and marketing costs are expensed as incurred. Advertising and marketing costs are included in Sales and marketing expense in the Company's Consolidated Statements of Income.

Segment Information

The Company defines operating segments as components of the business enterprise for which separate financial information is reviewed regularly by the **chief operating decision-makers** **Chief Operating Decision-Makers** to evaluate performance and to make operating decisions. The Company has identified our Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer as our Chief Operating Decision-Makers ("**CODM**" **CODMs**").

The Company currently operates business as one operating segment which includes two revenue types: Devices and Supplies.

F-14

[Table of Contents](#)

Stock-based Compensation

The Company accounts for stock-based compensation through recognition of the cost of employee services received in exchange for an award of equity instruments, which is measured based on the grant date fair value of the award that is ultimately expected to vest during the period. The stock-based compensation expenses are recognized over the period during which an employee is required to provide service in exchange for the award (the requisite service period, which in the Company's case is the same as the vesting period). For awards subject to the achievement of performance metrics, stock-based compensation expense is recognized when it becomes probable that the performance conditions will be achieved.

Earnings Per Share

The Company calculates basic earnings per share on the basis of the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is calculated using the weighted-average number of shares of common stock outstanding for the period plus the effect of potential dilutive common shares during the period using the treasury stock **method and if-converted** method. Potential shares of common stock outstanding include unvested restricted stock awards, **shares held in escrow**, vested and unvested unexercised stock options, **and** common stock purchase **warrants**, **warrants**, and **convertible notes**.

Research and Development

Research and **development** **Development** costs are expensed when incurred. During **2022** **2023** and **2021**, **2022**, we incurred **research** **approximately \$9.2 million** and **development** **\$7.1 million** in **operating** **expenses**, **of approximately \$7.1 million and \$2.6 million**, respectively, related to our ZMS operations. During **2023** and **2022**, approximately **\$1.0 million** **\$7.7 million and \$6.0 million** of the expenses, **qualified for** **respectively**, **required capitalization under** **Section 174 - "Amortization of Research and Experimental Expenditures"** **tax treatment**. **Research and development**, **which includes salaries related to** **We expect our research and development and raw materials, are included** **expenses to increase** **in general and administrative expenses on the consolidated statements of comprehensive income**. **2024** as our ZMS business expands.

Income Taxes

The Company records deferred tax assets and liabilities for the estimated future tax effects of temporary differences between the tax bases of assets and liabilities and amounts reported in the accompanying condensed consolidated balance **sheets**, as well as **operating loss and tax credit carry-forwards**. **sheets**. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary

F-14

[Table of Contents](#)

differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if, based on available evidence, it is more likely than not that these benefits will not be realized.

Tax benefits are recognized from uncertain tax positions if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position.

Recently Issued Accounting Pronouncements

In August 2020, October 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-06, "Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative" ("ASU 2023-06"). This ASU incorporates certain SEC disclosure requirements into the FASB Accounting Standards Update Codification ("ASU" ASC) 2020-06, Debt — Debt. The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of ASC Topics, allow users to more easily compare entities subject to the SEC's existing disclosures with Conversion those entities that were not previously subject to the requirements, and Other Options (Subtopic 470-20) align the requirements in the ASC with the SEC's regulations. The ASU has an unusual effective date and Derivatives and Hedging — Contracts in Entity's Own Equity (Subtopic 815-40) transition requirements since it is contingent on future SEC rule setting. If the SEC fails to enact required changes by June 30, 2027, this ASU is not effective for any entities. Early adoption is not permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): "Improvements to Reportable Segment Disclosures" ("ASU 2020-06" 2023-07") to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining information used to equity classification of contracts in an entity's own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity's own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 assess segment performance. This update is effective for beginning with the Company's 2024 fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, year annual reporting period, with early adoption permitted. The Company adopted ASU 2020-06 effective as of January 1, 2022. The is currently evaluating the impact that the adoption of ASU 2020-06 did not this standard will have an impact on the Company's its consolidated financial statements.

F-15

[Table of Contents](#)

In June 2016, December 2023, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) 2023-09, "Improvements to Income Tax Disclosures" ("ASU 2016-13" 2023-09"), Measurement to enhance the transparency and decision-usefulness of Credit Losses on Financial Instruments. The standard significantly changes how income tax disclosures, particularly in the rate reconciliation table and disclosures about income taxes paid. This ASU applies to all entities will measure credit losses for most financial assets and certain other instruments that aren't measured at fair value through net income. The standard will replace today's "incurred loss" approach with an "expected loss" model for instruments measured at amortized cost. For available-for-sale debt securities, entities subject to income taxes. This ASU will be required to record allowances rather than reduce the carrying amount, as they do today under the other-than-temporary impairment model. It also simplifies the accounting model effective for purchased credit-impaired debt securities and loans. This ASU is effective public companies for annual periods beginning after December 15, 2022, and interim periods therein for smaller reporting companies. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein December 15, 2024. The Company adopted is currently evaluating the impact that the adoption of this standard during the quarter ended June 30, 2022. The primary instrument that needed to be evaluated was the Company's trade receivables and the impact was not material.

Management has evaluated other recently issued accounting pronouncements and does not believe that those pronouncements will have a material impact on the Company's its consolidated financial statements.

(3) BUSINESS COMBINATIONS

On December 22, 2021, the Company and its wholly-owned subsidiary Zynex Monitoring Solutions, Inc., entered into a Stock Purchase Agreement (the "Agreement") with Kestrel Labs, Inc. ("Kestrel") and each of the shareholders of Kestrel (collectively, the "Selling Shareholders"). Under the Agreement, the Selling Shareholders agreed to sell all of the outstanding common stock of Kestrel (the "Kestrel Shares") to ZMS, the Company. The consideration for the Kestrel Shares consisted of \$16.1 million cash and 1,467,785 (as adjusted pursuant to the stock dividend, see note 1) shares of the Company's common stock (the "Zynex Shares"). All of the Zynex Shares are subject to a lockup lock-up agreement for a period of one year from the closing date under the Agreement (the "Closing Date"). The Agreement provides the Selling Shareholders with piggyback registration rights. 978,524 of the Zynex Shares were deposited in escrow (the "Escrow Shares"). The number of Escrow Shares is subject to adjustment on the one-year anniversary of the Closing Date (or in connection with any Liquidation Event (as defined in the Agreement) that occurs prior to such anniversary date) based on the number of shares equal to \$10 million \$10.0 million divided by a 30-day volume weighted average closing price of the Zynex Company's common stock. The Escrow Shares were adjusted on the anniversary date, which resulted in the cancellation of 156,673 Escrow Shares. Half of the Escrow Shares will be released on submission of a dossier on a laser-based photoplethysmographic device (the "Device") to the Food and Drug Administration (the "FDA") FDA for permission to market and sell the Device in the United States. The other half of the Escrow Shares will be released upon notification from determination by the FDA finding that the Device can be marketed and sold in the United States.

F-15

[Table of Contents](#)

On July 27, 2023, the Company, ZMS, Kestrel, and the Selling Shareholders, entered into an amendment to the Stock Purchase Agreement (the "Amendment"). The amount parties entered into the Amendment to modify certain terms of escrow shares were recalculated at December 31, 2021, and are included in the calculation Agreement related to the conditions to be satisfied for the release of diluted earnings per share for December 31, 2021. No additional calculation was required for the Escrow Shares at December 31, 2022, as to the Selling Shareholders. The Escrow Share number was finalized Shares were released from escrow, and simultaneously, the selling stockholders entered into a lock-up agreement. The lock-up agreement includes two lock-up periods which release certain restrictions on the anniversary date, Selling Shareholders on December 31, 2023 and the shares June 30, 2024, respectively.

The Escrow Shares are included in the Company's calculation of basic earnings per share. The maximum amount of Zynex shares that may be released are limited to 19.9% of the total number of common shares share for both years ended December 31, 2023 and total voting power of common shares. 2022.

The acquisition of Kestrel has been accounted for as a business combination under ASC 805.805 – "Business Combinations" ("ASC 805"). Under ASC 805, assets acquired, and liabilities assumed in a business combination must be recorded at their fair values as of the acquisition date.

Summary of Purchase Consideration

Presented below is a summary of the total purchase consideration for the Kestrel business combinations (in thousands except share data):

	Shares(1)	Fair Value	Cash	Total
Closing date cash	—	\$ —	\$ 16,000	\$ 16,000
Working capital distribution	—	—	78	78
Total cash paid	—	\$ —	\$ 16,078	\$ 16,078
Closing date equity				
Issued shares	444,784	4,701	—	4,701
Escrow shares	889,566	9,700	—	9,700
Total equity	1,334,350	\$ 14,401	\$ —	\$ 14,401
Total consideration	1,334,350	\$ 14,401	\$ 16,078	\$ 30,479

[Table of Contents](#)

(1) The amount of shares issued and included in escrow were not retroactively adjusted in the table above for the 10% stock dividend declared on November 9, 2021 and issued on January 21, 2022. The issued and escrow shares after retroactive adjustment for the 10% stock dividend were 489,262 and 978,523 shares, respectively, as shown in the Consolidated Statements of Stockholders' Equity.

Purchase Price Allocations

Presented below is a summary of the purchase price allocations for the Kestrel business combinations on the acquisition date (in thousands):

	Purchase Price Allocation
Current assets:	
Cash	\$ 80
Accounts receivable	15
Prepaid expenses and other	1
Total current assets	<u>\$ 96</u>
Long-term assets:	
Identifiable intangible assets	<u>10,000</u>
Total assets acquired	<u>\$ 10,096</u>
Less liabilities assumed:	
Accounts payable	(18)
Net identifiable assets acquired	<u>10,078</u>
Goodwill	<u>20,401</u>
Net assets acquired	<u><u>\$ 30,479</u></u>

The fair value of the identifiable intangibles assets is primarily related to patents which will be amortized over a useful life of 11 years. The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill. The goodwill is attributable to the benefits the Company expects to realize by enhancing its product offering and addressable markets, thereby contributing to an expanded revenue base.

(4) PROPERTY AND EQUIPMENT

The components of property and equipment are as follows (in thousands):

	December 31, 2022	December 31, 2021	December 31, 2023	December 31, 2022
Property and equipment				
Office furniture and equipment	\$ 2,819	\$ 2,391	\$ 2,768	\$ 2,819
Assembly equipment	110	100	178	110
Vehicles	203	203	75	203
Leasehold improvements	1,173	1,054	1,174	1,173
Leased devices	<u>1,162</u>	<u>1,080</u>	796	1,162
Capital projects			869	—
Less accumulated depreciation	\$ 5,467	\$ 4,828	\$ 5,860	\$ 5,467
	<u>(3,292)</u>	<u>(2,642)</u>	<u>(2,746)</u>	<u>(3,292)</u>
	<u><u>\$ 2,175</u></u>	<u><u>\$ 2,186</u></u>	<u><u>\$ 3,114</u></u>	<u><u>\$ 2,175</u></u>

The Company monitors devices out on lease for potential loss and places an estimated reserve on the net book value based on an analysis of the number of units of which are still with patients for which the Company cannot determine the current status.

Total depreciation expense related to our purchased property and equipment was ~~\$0.7 million~~ ~~\$0.8 million~~ and ~~\$0.9 million~~ ~~\$0.7 million~~ for the years ended December 31, 2022 December 31, 2023 and 2021, 2022, respectively.

F-17

[Table of Contents](#)

Total depreciation expense related to devices out on lease was ~~\$1.5 million~~ ~~\$1.9 million~~ and ~~\$1.4 million~~ ~~\$1.5 million~~ for the years ended December 31, 2022 December 31, 2023 and 2021, 2022, respectively. Depreciation on leased units is reflected on the income statement as cost of revenue.

(5) GOODWILL AND OTHER INTANGIBLES

During the year ended December 31, 2021 On December 22, 2021, the Company completed the acquisition of Kestrel, which resulted in goodwill of \$20.4 million (see Note 3).

As of December 31, 2022 December 31, 2023, there was no impairment indicators of the Company's net asset value.

The following table provides the summary of the Company's intangible assets as of December 31, 2022 December 31, 2023.

	Weighted-Average				Weighted-Average			
	Gross		Remaining	Life (in years)	Gross		Remaining	Life (in years)
	Carrying Amount	Accumulated Amortization			Carrying Amount	Accumulated Amortization		
Acquired patents	\$ 10,000	\$ (933)	\$ 9,067	10.0	\$ 10,000	\$ (933)	\$ 9,067	10.00
Acquired patents at December 31, 2022								
Amortization expense								
Acquired patents at December 31, 2023					\$ 10,000	\$ (1,842)	\$ 8,158	9.00

F-16

[Table of Contents](#)

The following table summarizes the estimated future amortization expense to be recognized over the next years and periods thereafter: five years:

	December 31, (In thousands)
2023	\$ 908
2024	911
2025	908
2026	908

2027	908
Thereafter	4,524
Total future amortization expense	<u>\$ 9,067</u>

	December 31, (in thousands)
2024	911
2025	908
2026	908
2027	908
2028	911
Thereafter	3,612
Total future amortization expense	<u>\$ 8,158</u>

(6) EARNINGS PER SHARE

The calculation of basic and diluted earnings per share for the years ended December 31, 2022 December 31, 2023 and 2021 2022 are as follows (in thousands, except per share data):

	For the Years Ended December 31,		For the Years Ended December 31,	
	2022	2021	2023	2022
Basic earnings per share				
Net income available to common stockholders	\$ 17,048	\$ 17,103		
Basic weighted-average shares outstanding	38,467	38,317		
Net income			\$ 9,732	\$ 17,048
Basic weighted average shares outstanding			35,555	38,467
Basic earnings per share	<u>\$ 0.44</u>	<u>\$ 0.45</u>	<u>\$ 0.27</u>	<u>\$ 0.44</u>
Diluted earnings per share				
Net income available to common stockholders	\$ 17,048	\$ 17,103		
Weighted-average shares outstanding	38,467	38,317		
Net income			\$ 9,732	\$ 17,048
Weighted average shares outstanding			35,555	38,467
Effect of dilutive securities - options and restricted stock	660	880	587	660
Diluted weighted-average shares outstanding	39,127	39,197	36,142	39,127
Diluted earnings per share	<u>\$ 0.44</u>	<u>\$ 0.44</u>	<u>\$ 0.27</u>	<u>\$ 0.44</u>

Table of Contents

For the years ended December 31, 2022 December 31, 2023 and 2021, 2022, 36,000 and 0.1 million and 0.4 million shares of common stock, respectively, were excluded from the dilutive stock calculation because their effect would have been anti-dilutive. The basic and diluted weighted-average

For the year ended December 31, 2023, convertible notes to purchase 3.6 million shares outstanding for December 31, 2021 has resulting from the 2023 Convertible Senior Notes, were excluded from the dilutive stock calculation because their effect would have been updated to include the retroactive impact of the 10% common stock dividend declared on November 11, 2021 anti-dilutive (see Note 8 – Convertible Senior Notes).

(7) NOTES PAYABLE

The Company entered into a loan agreement (the "Loan Agreement") with Bank of America, N.A. (the "Bank") in December 2021. Under this Loan Agreement, the Bank is extending extended two facilities to the Borrowers Company. Specified assets have been were pledged as collateral. One facility is was a line of credit in the amount of \$4.0 million \$4.0 million available until December 1, 2024 ("Facility" (the "Facility 1"). The Borrower pays interest Interest on Facility 1 was due on the first day of each month beginning January 1, 2022. The interest rate is was an annual rate equal to the sum of (i) the greater of the Bloomberg Short-term Bank Yield Index ("BSBY")

F-17

Table of Contents

BSBY Daily Floating Rate or (ii) the Index Floor (as defined in the Loan Agreement), plus 2.00%. As of The Company did not utilize the facility during the years ended December 31, 2023 and December 31, 2022. During May 2023, the Company has not utilized this facility and has no balance outstanding. was terminated.

The other facility being extended by the Bank to the Borrower is Company was a fixed rate term loan in the amount of \$16.0 million ("up to \$16.0 million (the "Facility 2"). Facility 2) bearing 2 was entered into and funded in conjunction with the purchase of Kestrel Labs at an interest at rate equal to 2.8% per year. The Borrower pays Company had to pay interest on the first day of each month beginning which began January 1, 2022, and the Borrower repays Company also repaid the principal amount in equal installments of \$0.4 million \$444,444 per month through December 1, 2024. month. All unpaid interest and principal on Facility 2 was entered into in conjunction with fully paid off and the purchase of Kestrel Labs.

The following table summarizes future principal payments on long-term debt as of December 31, 2022: Facility was terminated during May 2023.

	December 31, (in thousands)
2023	5,333
2024	5,334
Future principal payments	10,667
Less current portion	(5,333)
Less debt issuance costs	(41)
Long-term debt, net of debt issuance costs	<u>\$ 5,293</u>

(8) CONVERTIBLE SENIOR NOTES

In May 2023, the Company issued \$52.5 million aggregate principal amount of 5.00% Convertible Senior Notes due May 15, 2026 (the "2023 Convertible Senior Notes"). In May 2023, the Company issued an additional \$7.5 million aggregate principal amount of the 2023 Convertible Senior Notes upon the exercise by the initial purchasers of their over-allotment option.

Interest on the 2023 Convertible Senior Notes is payable semiannually in arrears, beginning November 15, 2023. The 2023 Convertible Senior Notes will mature on May 15, 2026, unless earlier converted or repurchased, and are redeemable at the option of the Company on or after May 20, 2025. The 2023 Convertible Senior Notes are direct, unsecured, and unsubordinated obligations of the Company, ranking equally with all of the Company's other unsecured and unsubordinated indebtedness from time to time outstanding, and are effectively subordinated to all secured indebtedness of the Company.

Holders may convert their 2023 Convertible Senior Notes at their option prior to the close of business on the business day preceding September 30, 2023, but only under the following circumstances: during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the Company's

common stock for at least twenty trading days (whether or not consecutive) during the period of thirty consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day as determined by the Company; during the five business day period after any ten consecutive trading day period (the "Measurement Period") in which the trading price per \$1,000 principal amount of 2023 Convertible Senior Notes for each trading day of the Measurement Period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on each such trading day; or upon the occurrence of certain corporate events specified in the indenture governing the 2023 Convertible Senior Notes.

On or after February 15, 2026, a holder may convert all or any portion of its 2023 Convertible Senior Notes at any time prior to the close of business on the second scheduled trading day immediately preceding the maturity date regardless of the foregoing conditions.

The Company will settle conversions of the 2023 Convertible Senior Notes by paying cash up to the aggregate principal amount of the 2023 Convertible Senior Notes to be converted and paying or delivering, as the case may be, cash, shares of common stock, or a combination of cash and shares of common stock, at the Company's election, in respect of the remainder, if any, of the Company's conversion obligation in excess of the aggregate principal amount of the 2023 Convertible Senior Notes being converted. The 2023 Convertible Senior Notes are initially convertible at a rate of 92.8031 shares of common stock per \$1,000 principal amount converted, which is approximately equal to \$10.78 per share of common stock. The conversion rate will be subject to adjustment upon the occurrence of certain specified events but will not be adjusted for accrued and unpaid interest. In addition, upon the occurrence of a make-whole fundamental change, which includes certain change in control transactions, the approval by Zynex's stockholders of any plan or proposal for the liquidation or dissolution of Zynex and certain de-listing events with respect to Zynex's common stock, the Company will, in certain circumstances, increase the conversion rate by a number of additional shares of common stock for conversions in connection with the make-whole fundamental change. On December 31, 2023, the closing price of the Company's common stock was \$10.89 and the conversion feature of our outstanding convertible senior notes allows their holders to convert principal at a conversion price of \$10.78. Under such circumstances, if all outstanding principal of \$60.0 million would have been converted into conversion shares, the market value of such shares would have been \$60.6 million.

F-18

(8)

[Table of Contents](#)

Upon the occurrence of a fundamental change, holders of the 2023 Convertible Senior Notes may require the Company to purchase all or a portion of their 2023 Convertible Senior Notes, in principal amounts equal to \$1,000 or an integral multiple thereof, for cash at a price equal to 100% of the principal amount of the 2023 Convertible Senior Notes to be purchased plus any accrued and unpaid interest. \$1.9 million of coupon interest expense and \$0.6 million of bond amortization costs were included in interest expense, net in the consolidated statement of income for the year ended December 31, 2023.

The following table summarizes the minimum interest payments over the next three years until maturity in May 2026.

	(In thousands)
2024	\$ 3,000
2025	3,000
2026	1,500

(9) STOCK-BASED COMPENSATION PLANS

Zynex, Inc. 2017 Stock Incentive Plan

The Company currently has one active long-term incentive plan. The Company's In June 2017, our stockholders approved the 2017 Stock Incentive Plan (the "2017 Stock Plan") is with a maximum of 5,500,000 shares reserved for issuance. Awards permitted under the Company's equity compensation plan 2017 Stock Plan include stock options and provides for grants of stock-based awards to employees, directors and other individuals providing services to the Company. restricted stock. Awards issued under the 2017 Stock Plan are at the discretion of the Board of Directors. The 2017 Stock Plan mandates a

maximum award term of 10 years and stipulates that stock options be granted with prices not less than fair market value on the date of grant. Stock option awards generally vest over four years. Restricted stock awards typically vest quarterly over three years for grants issued to members of our Board of Directors and quarterly or annually over two to four years for grants issued to employees. For stock option awards, all awards granted under the 2017 Stock Plan are stock-settled with common stock issued upon exercise. For restricted stock awards, shares are issued to the recipient upon grant with a restrictive legend and are not included in the calculation of outstanding shares until vesting occurs. At December 31, 2022 December 31, 2023, there were 3.8 million 3.4 million shares available for future grants under the 2017 Stock Plan.

Zynex, Inc. 2005 Stock Option Plan

The 2005 Stock Option Plan (the "2005 Stock Plan") expired as of December 31, 2014. Vesting provisions of the expired plan were to be determined by the Board of Directors. All stock options under the 2005 Stock Plan expire no later than ten years from the date of grant. Options granted in 2015, 2016, and through May 2017 prior to the approval of the 2017 Stock Incentive Plan were approved and certified by the ~~board~~ ~~Board of directors~~ ~~Directors~~ on September 6, 2017 under the existing 2005 Stock Plan.

As of December 31, 2023, the Company had the following stock options outstanding and exercisable:

Plan Category	Outstanding Number of Options	Exercisable Number of Options
	(in thousands)	(in thousands)
2005 Stock Option Plan	2	2
2017 Stock Option Plan	347	347
Total	349	349

The Company received \$0.1 million cash proceeds related to option exercises during the year ended December 31, 2023. The Company received cash proceeds of \$0.1 million related to option exercises during the year ended December 31, 2022.

During the year ended December 31, 2023, no stock option awards were granted under the 2017 Stock Plan. During the year ended December 31, 2022, 0.2 million stock option awards were granted under the 2017 Stock Plan. The Company used the Black Scholes

F-19

Table of Contents

As of December 31, 2022, the Company had the following stock options outstanding and exercisable:

Plan Category	Outstanding Number of Options	Exercisable Number of Options
	(in thousands)	(in thousands)
2005 Stock Option Plan	211	211
2017 Stock Option Plan	582	346
Total	793	557

The Company received \$0.1 million cash proceeds related to option exercises during the year ended December 31, 2022. The Company received cash proceeds of \$0.2 million related to option exercises during the year ended December 31, 2021.

During the year ended December 31, 2022, 0.2 million performance based stock option awards were granted under the 2017 Stock Plan. During the year ended December 31, 2021, no stock option awards were granted under the 2017 Stock Plan. The Company used the Black Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions during the year ended December 31, 2022.

Weighted average expected term	3 years
Weighted average volatility	73 %
Weighted average risk-free interest rate	2.81 %
Dividend yield	0 %

The weighted average expected term of stock options represents the period of time that the stock options granted are expected to be outstanding based on historical exercise trends. The weighted average expected volatility is based on the historical price volatility of the Company's common stock. The weighted average risk-free interest rate represents the U.S. Treasury bill rate for the expected term of the related stock options. The dividend yield represents the Company's anticipated cash dividend over the expected term of the stock options. Forfeitures are accounted for as they occur.

The following table summarizes stock-based compensation expenses recorded in the condensed consolidated statements of operations income (in thousands):

	For the Years Ended December 31,		For the Years Ended December 31,	
	2022		2023	
	\$ 47	\$ 56	\$ 34	\$ 47
Cost of Revenue				
Sales and marketing expense	2,104	155	253	191
General, and administrative	191	1,419	2,009	2,104
Total stock based compensation expense	\$ 2,342	\$ 1,630		
Total stock-based compensation expense			\$ 2,296	\$ 2,342

The excess tax benefit associated with our stock-based compensation plans for the years ended December 31, 2022 December 31, 2023 and 2021, 2022 was approximately \$0.0 million minimal in both periods.

A combined summary of stock option activity for all plans for the years ended December 31, 2023 and \$0.2 million, respectively, 2022 is presented below:

	Weighted-				
	Number of Shares (in thousands)	Weighted- Average		Aggregate	
		Exercise	Remaining	Intrinsic Value	
		Price	Term (Years)	(in thousands)	
Outstanding at December 31, 2021	765	\$ 1.36	4.68		5,896
Granted	200	\$ 6.23			
Exercised	(157)	\$ 0.66			
Forfeited	(15)	\$ 4.18			
Outstanding at December 31, 2022	793	\$ 2.67	5.03	\$	8,908
Granted	—	\$ —			
Forfeited	(206)	\$ 6.30			
Exercised	(238)	\$ 0.79			
Outstanding at December 31, 2023	349	\$ 1.82	4.12	\$	3,163
Exercisable at December 31, 2023	349	\$ 1.82	4.12	\$	3,163

[Table of Contents](#)

A combined summary of stock option activity for all plans for the years ended December 31, 2022 and 2021 is presented below:

		Weighted			
		Number of		Average	Aggregate
		Shares	Strike	Remaining	Intrinsic
		(in thousands)	Price	Life (Years)	(in thousands)
Outstanding at December 31, 2020		1,107	\$ 2.76		
Granted		—	\$ —		
Exercised		(116)	\$ 4.87		
Forfeited		(226)	\$ 6.45		
Outstanding at December 31, 2021		765	\$ 1.36	4.68	\$
Granted		200	\$ 6.23		
Exercised		(157)	\$ 0.66		
Forfeited		(15)	\$ 4.18		
Outstanding at December 31, 2022		793	\$ 2.67	5.03	\$
Exercisable at December 31, 2022		557	\$ 1.31	3.40	\$

Range	Outstanding Number of Options (in thousands)	Weighted average				Outstanding Number of Options (in thousands)	Weighted average				
		Remaining		Weighted Average Exercisable	Number of Exercisable Options (in thousands)		Weighted Average	Remaining		Weighted Average Options (in thousands)	
		Contractual	Life (years)					Contractual	Life (years)		
\$0 to \$2.00	354	2.31	\$ 0.30	354	2.31	\$ 0.30	145	3.43	0.43	Options	
\$2.01 to \$4.00	217	5.56	\$ 2.69	187	5.48	\$ 2.65	198	4.59	2.66	Options	
\$4.01 to \$10.00	222	8.86	\$ 6.45	15	3.23	\$ 8.33	6	5.72	8.13	Options	
	793	5.03	\$ 2.67	557	3.40	\$ 1.31	349	4.12	1.82	Options	

A summary of our unvested stock options as of December 31, 2022 December 31, 2023 and 2021 2022 and related activity is presented below:

		Non-vested	
		Shares	Weighted
		Under	Average
		Option	Grant Date
		(in thousands)	Fair Value
Non-vested at December 31, 2020		474	\$ 4.35
Granted		—	—
Vested		(167)	1.93
Forfeited		(212)	6.48
Non-vested at December 31, 2021		95	\$ 3.85
Granted		200	6.23
Vested		(49)	4.12

Forfeited	(9)	5.49
Non-vested at December 31, 2022	<u>237</u>	<u>\$ 5.90</u>

	Non-vested	
	Shares	Weighted
	Under	Average
	Option	Grant Date
	(in thousands)	Fair Value
Non-vested at December 31, 2021	95	\$ 3.85
Granted	200	6.23
Vested	(49)	4.12
Forfeited	(9)	5.49
Non-vested at December 31, 2022	<u>237</u>	<u>\$ 5.90</u>
Granted	—	—
Vested	(31)	3.18
Forfeited	(206)	6.30
Non-vested at December 31, 2023	<u>—</u>	<u>\$ —</u>

F-21

[Table of Contents](#)

A summary of restricted stock award activity under the 2017 Stock Plan for the years ended December **2022** **2023** and **2021** **2022** are presented below:

	Number of Shares (in thousands)	Weighted Average		Number of Shares	Weighted Average
		Grant Date	Fair Value		
Outstanding at December 31, 2020	295	\$	11.53		
Granted	381	\$	14.15		
Vested	(119)	\$	10.92		
Forfeited	(103)	\$	12.40		
Outstanding at December 31, 2021	<u>454</u>	<u>\$</u>	<u>13.69</u>	<u>454</u>	<u>\$ 13.69</u>
Granted	186	\$	8.52	194	8.52
Forfeited				(165)	12.90
Vested	(165)	\$	12.90	(52)	10.60
Outstanding at December 31, 2022				<u>431</u>	<u>\$ 11.92</u>
Granted				286	9.54
Forfeited	(52)	\$	10.60	(13)	11.13
Outstanding at December 31, 2022	<u>423</u>	<u>\$</u>	<u>11.94</u>		
Vested				(202)	11.56
Outstanding at December 31, 2023				<u>502</u>	<u>\$ 10.73</u>

The fair market value of restricted shares for share-based compensation expensing is equal to the closing price of our common stock on the date of grant. The vesting on the Restricted Stock Awards typically occurs quarterly over three years for the Board of Directors and quarterly or annually over two to four years for employees. As of **December 31, 2022** **December 31, 2023**, there was approximately **\$4.3 million** **\$4.4 million** of total unrecognized compensation costs related to unvested stock options and restricted stock. These costs are expected to be recognized over a weighted average period of 2.3 years.

F-21

[Table of Contents](#)

The total intrinsic value of stock option exercises for the years ended December 31, 2022 December 31, 2023 and 2021 2022 was \$1.1 million \$1.9 million and \$1.0 million \$1.1 million, respectively. The total fair value of restricted stock awards vested during the years ended December 31, 2022 December 31, 2023 and 2021 2022 was \$1.4 million \$2.1 million and \$1.3 million \$1.4 million, respectively.

(9)(10) STOCKHOLDERS' EQUITY EQUITYs

Common Stock Dividend

The Company's Board of Directors declared a cash dividend of \$0.10 per share and a stock dividend of 10% per share on November 9, 2021. The cash dividend of \$3.6 million was paid out on January 21, 2022 to stockholders of record as of January 6, 2022. The 10% stock dividend declaration resulted in the issuance of an additional 3.6 million shares on January 21, 2022 to stockholders of record as of January 6, 2022.

Treasury Stock

On March 8, 2021, our Board of Directors approved a program to repurchase up to \$10.0 million of our common stock at prevailing market prices either in the open market or through privately negotiated transactions through September 8, 2021. From the inception of the plan through September 8, 2021, the Company purchased 175,179 shares of our common stock for \$2.7 million or an average price of \$15.22 per share.

On April 11, 2022, the Company's Board of Directors approved a program to repurchase up to \$10.0 million of its common stock at prevailing market prices either in the open market or through privately negotiated transactions through April 11, 2023. From the inception of the plan through May 31, 2022 the Company purchased 1,419,874 shares of its common stock for \$10.0 million or an average price of \$7.04 per share, which completed this program.

On June 9, 2022, the Company's Board of Directors approved a program to repurchase up to \$10.0 million of the Company's common stock at prevailing market prices either in the open market or through privately negotiated transactions through June 9, 2023. From the inception of the plan through October 4, 2022, the Company purchased 1,091,604 shares of its common stock for \$10.0 million for an average price of \$9.06 \$9.16 per share, which completed this program.

F-22

[Table of Contents](#)

On October 31, 2022, the Company's Board of Directors approved a program to repurchase up to \$10.0 million of the Company's common stock at prevailing market prices either in the open market or through privately negotiated transactions through October 31, 2023. From the inception of the plan through December 31, 2022, the Company purchased 495,138 shares of its common stock for \$6.6 million or an average price of \$13.43 per share. Subsequent to December 31, 2022, During 2023, the Company purchased 232,698 shares of its common stock for \$3.3 million or an average price of \$14.41 per share, which completed this program.

On May 10, 2023, the disinterested members of the Board of Directors and Audit Committee approved the purchase of 300,000 shares of the Company's common stock from Thomas Sandgaard, Chairman, President, Chief Executive Officer and Principal Executive Officer, at the closing market price on May 10, 2023 of \$9.61 per share for \$2.9 million. See Note 17 - Related Parties for additional information.

On June 13, 2023, the disinterested members of the Board of Directors and Audit Committee approved the purchase of 300,000 shares of the Company's common stock from Thomas Sandgaard, Chairman, President, Chief Executive Officer and Principal Executive Officer, at the closing market price on June 13, 2023, of \$8.62 per share for \$2.6 million. See Note 17 - Related Parties for additional information.

On June 13, 2023 the Company announced that its Board of Directors approved a program to repurchase up to \$10.0 million of the Company's common stock at prevailing market prices either in the open market or through privately negotiated transactions through June 13, 2024. From the inception of the plan through

September 13, 2023, the Company purchased 1,242,892 shares of its common stock for \$10.0 million or an average price of \$8.05 per share, which completed this program.

On September 11, 2023, the Company announced that its Board of Directors approved a program to repurchase up to \$10.0 million of the Company's common stock at prevailing market prices either in the open market or through privately negotiated transactions through September 13, 2024. From the inception of the plan through October 19, 2023, the Company purchased 1,204,239 shares of its common stock for \$10.0 million or an average price of \$8.30 per share, which completed this program.

[Table of Contents](#)

On November 1, 2023, the Company announced that its Board of Directors approved a program to repurchase up to \$20.0 million of the Company's common stock at prevailing market prices either in the open market or through privately negotiated transactions through October 31, 2024. From the inception of the plan through December 31, 2023, the Company purchased 1,012,200 shares of its common stock for \$9.6 million or an average price of \$9.47 per share.

Warrants

A summary of stock warrant activity for the years ended **December 31, 2022** **December 31, 2023** and **2021** **2022** are presented below:

		Weighted				Weighted				
		Number of Warrants (in thousands)	Weighted Average Exercise Price	Average		Aggregate Intrinsic Value (in thousands)	Number of Warrants (in thousands)	Weighted Average Exercise Price	Average	
				Remaining	Intrinsic				Remaining	Intrinsic
				Contractual	Value				Contractual Life (Years)	Value (in thousands)
Outstanding at December 31, 2020		110	\$ 2.39	3.76	\$ 1,084					
Granted		—	\$ —							
Exercised		(10)	\$ 2.27	2.76	192					
Forfeited ⁽¹⁾		(1)	\$ 2.27	2.76	25					
Outstanding and exercisable at December 31, 2021		99	\$ 2.39	2.76	\$ 660					
Outstanding at December 31, 2021						99	\$ 2.39	2.76	\$ 660	
Granted		—	\$ —			—	\$ —	—	\$ —	
Exercised		—	\$ —	—	—	—	\$ —	—	\$ —	
Forfeited		—	\$ —	—	—	—	\$ —	—	\$ —	
Outstanding and exercisable at December 31, 2022		99	\$ 2.39	1.76	\$ 1,140	99	\$ 2.39	1.76	\$ 1,140	
Granted						—	\$ —	—	\$ —	
Exercised						(15)	\$ 2.27			
Forfeited ⁽¹⁾						(4)	\$ 2.27			
Outstanding and exercisable at December 31, 2023						80	\$ 2.43	0.76	\$ 677	

(1) Warrants were exercised under a net exercise provision in the warrant agreement. As a result, approximately **1,000** **4,000** warrants were forfeited in lieu of cash payment for shares during **2021** **2023**.

(10) (11) INCOME TAXES

The pre-tax income from continuing operations on which the provision for income taxes was computed is as follows for the years ended December 31, 2023 and 2022 (in thousands):

	2022	2021	2023	2022
United States	\$ 22,220	\$ 22,295	\$12,579	\$22,220
Foreign	(22)	(24)	—	(22)
Total	22,198	22,271	12,579	22,198

Income tax expense consists of the following for the years ended December 31, 2022 December 31, 2023 and 2021 2022 (in thousands):

	2022	2021	2023	2022
Current tax expense:				
Federal	\$ 4,891	\$ 4,289	\$ 3,433	\$ 4,891
State	1,110	1,025	1,717	1,110
Total tax expense:	6,001	5,314	5,150	6,001
Deferred tax expense/(benefit)				
Deferred tax benefit				
Federal	(730)	(135)	(1,873)	(730)
State	(121)	(11)	(430)	(121)
Total deferred tax expense/(benefit)	\$ (851)	\$ (146)		
Total deferred tax benefit				\$ (2,303) \$ (851)
Total	\$ 5,150	\$ 5,168	\$ 2,847	\$ 5,150

F-23

[Table of Contents](#)

A reconciliation of income tax computed at the U.S. statutory rate of 21% to the effective income tax rate is as follows:

	2022	2021	2023	2022
Statutory rate	21 %	21 %	21 %	21 % 21 %
State taxes	3 %	4 %	7 %	3 %
Meals and entertainment			3 %	— %
Excess officer's compensation			3 %	— %
Stock based compensation	0 %	(1)%	(7)%	— %
Research and development credit	(1)%	0 %	(4)%	(1)%
Effective rate	23 %	24 %	23 %	23 %

The tax effects of temporary differences that give rise to deferred tax assets (liabilities) at December 31, 2022 December 31, 2023 and 2021 2022 are as follows (in thousands):

	2022	2021	2023	2022
Deferred tax assets:				
Accrued expenses	\$ 31	\$ 26	\$ 34	\$ 31
Lease liability	3,955	4,620	4,540	3,955

Accounts receivable	18	18	—	18
Inventory	198	484	261	198
Stock based compensation	253	271	371	253
Right of use asset	—	8	—	—
Amortization	—	90	—	—
Section 174 costs	991	—	2,829	991
	5,446	5,517	8,035	5,446
Deferred tax assets	\$ 5,446	\$ 5,517	\$ 8,035	\$ 5,446
Deferred tax liabilities:				
Property and equipment	(519)	(599)	(469)	(519)
Finance lease	(67)	(96)	(149)	(67)
Prepaid expenses	(116)	(77)	(198)	(116)
Right-of-use asset	(3,170)	(4,034)	(3,172)	(3,170)
Amortization	(12)	—	(182)	(12)
Deferred tax liabilities	\$ (3,884)	\$ (4,806)	\$ (4,170)	\$ (3,884)
Net deferred tax assets	\$ 1,562	\$ 711	\$ 3,865	\$ 1,562

As of December 31, 2022, the Company has no net operating loss. The Company had no recorded valuation allowances at December 31, 2022 and 2021.

The accounting standard related to income taxes applies to all tax positions and defines the confidence level that a tax position must meet in order to be recognized in the financial statements. The accounting standard requires that the tax effects of a position be recognized only if it is "more-likely-than-not" to be sustained by the taxing authority as of the reporting date. If a tax position is not considered "more-likely-than-not" to be sustained, then no benefits of the position are to be recognized. Differences between financial and tax reporting which do not meet this threshold are required to be recorded as unrecognized tax benefits. This standard also provides guidance on the presentation of tax matters and the recognition of potential interest and penalties. As of **December 31, 2022** **December 31, 2023** and **2021, 2022**, the Company does not have an unrecognized tax liability.

The Company does not classify penalty and interest expense related to income tax liabilities as an income tax expense. Penalties and interest are included within general and administrative expenses on the consolidated statements of income.

The Company files income tax returns in the U.S. and various state jurisdictions, and there are open statutes of limitations for taxing authorities to audit our tax returns from **2017** **2020** through the current period.

[Table of Contents](#)

(11) (12) LEASES

The Company **category****ategorizes** leases at their inception as either operating or financing leases. Leases include various office and warehouse facilities which have been categorized as operating leases, while certain equipment is leased under financing leases.

During March 2022, the Company entered into a lease agreement for approximately 4,162 square feet of office space for the operations of ZMS in Boulder, Colorado. The lease began on April 1, 2022 and will run through April 1, 2025. The rent and common area maintenance charges are equal to \$17.00 per square foot with annual increases of 3%. Upon lease commencement, the Company recorded an operating lease liability and corresponding right-of-use asset for \$0.2 million each.

During February 2023, the Company entered into a lease agreement for approximately 41,427 square feet of office space for the operations of ZMS in Englewood, CO. The lease commences on July 1, 2023 and runs through December 31, 2028. At the expiration of the lease term the Company has the option to renew the lease for one additional five-year period. The Company is entitled to rent abatements for the first six months of the lease and tenant improvement allowances. Payments based on the initial rate of \$24.75 per square foot begin in January 2024. The price per square foot increases by an additional \$0.50 during each subsequent twelve-month period of the lease after the abatement period. Upon lease commencement, the Company recorded an operating lease liability of \$4.2 million and a corresponding right-of-use asset for \$2.8 million.

The Company's operating leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring the lease liability. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company's weighted average borrowing rate was determined to be 4.03% 4.78% for its operating lease liabilities. The Company's equipment lease agreements have a weighted average rate of 9.39% 2.72% which was used to measure its finance lease liability.

As of December 31, 2022 December 31, 2023, the Company's operating and financing leases have a weighted average remaining term of 4.76 4.32 years and 2.63 3.98 years, respectively.

The table below reconciles the undiscounted future minimum lease payments under the Company's operating and finance leases to the total operating and capital lease liabilities recognized on the consolidated balance sheets as of December 31, 2022 December 31, 2023 (in thousands):

	Operating Lease Liability	Finance Lease Liability	Operating Lease Liability	Finance Lease Liability
2023	3,055	152		
2024	3,571	116	4,511	209
2025	3,586	76	4,632	169
2026	3,362	15	4,428	108
2027	3,150	—	4,237	93
2028	1,064	—	2,172	93
Thereafter			—	—
Total undiscounted future minimum lease payments	\$ 17,788	\$ 359	\$ 19,980	\$ 672
Less: Difference between undiscounted lease payments and discounted lease liabilities	(1,771)	(43)		
Less: difference between undiscounted lease payments and discounted lease liabilities:			(2,070)	(19)
Total lease liabilities	\$ 16,017	\$ 316	\$ 17,910	\$ 653

Operating and finance lease costs were \$4.6 million \$4.2 million and \$3.7 million \$4.6 million for years ended December 31, 2022 December 31, 2023 and 2021, 2022, respectively, which were included in the consolidated statement of income under the following headings (in thousands):

	For the years ended December 31,	
	2022	2021
<i>Operating Lease expense</i>		
Costs of revenue - devices and supplies	\$ 359	\$ 399
Sales and marketing expense	1,456	1,186
General and administrative	2,643	1,964
Total operating lease expense	\$ 4,458	\$ 3,549
<i>Finance Lease expense</i>		
Amortization of right-of-use asset:		
Sales and marketing expense	\$ 117	\$ 104
General and administrative	2	1
Total amortization of right-of-use asset	\$ 119	\$ 104
Interest expense and other	36	41
Total finance lease expense	\$ 155	\$ 145

Prior year amounts for Financing Lease expense have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

F-25

[Table of Contents](#)

	For the years ended December 31,	
	2023	2022
<i>Operating Lease expense</i>		
Costs of revenue - devices and supplies	\$ 367	\$ 359
Sales and marketing expense	1,105	1,456
General and administrative	2,542	2,643
Total operating lease expense	<u>\$ 4,014</u>	<u>\$ 4,458</u>
<i>Finance Lease expense</i>		
Amortization of right-of-use asset:		
Selling, general and administrative	\$ 116	\$ 117
General and administrative	31	2
Total amortization of right-of-use asset	<u>147</u>	<u>119</u>
Interest expense and other	24	36
Total finance lease expense	<u>\$ 171</u>	<u>\$ 155</u>

(12) (13) FAIR VALUE CONSIDERATION

The Company's asset and liability classified financial instruments include cash, accounts receivable, accounts payable, accrued liabilities, and contingent consideration. The carrying amounts of financial instruments, including cash, accounts receivable, accounts payable, and accrued liabilities approximate their fair value due to their short maturities. The Company measures its long-term debt at fair value which approximates book value as the long-term debt bears market rates of interest. The fair value of acquisition-related contingent consideration is based on a Monte Carlo models. The valuation policies are determined by management, and the Company's Board of Directors is informed of any policy change.

Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows:

Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Zynex for identical assets or liabilities;

Level 2: Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and

Level 3: Unobservable inputs that are supported by little or no market activity.

The Company's assets and liabilities, which are measured at fair value, on a recurring basis, are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The Company's policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. The Company has consistently applied the valuation techniques discussed below in all periods presented.

The following table presents Company's financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022, by level within the fair value hierarchy:

	Fair Value Measurements at December 31, 2022			
	Quoted			
	Priced in			
	Active			
	Markets		Significant	
	for		Other	Significant
Fair Value at		Identical	Observable	Unobservable
December 31,		Assets	Inputs	Inputs
2022		(Level 1)	(Level 2)	(Level 3)
(In thousands)				
Contingent consideration	\$ 10,000	\$ —	\$ —	\$ 10,000
Total	\$ 10,000	\$ —	\$ —	\$ 10,000

Contingent Consideration.

The Company **classified** its contingent consideration liability in connection with the acquisition of Kestrel **Labs** within Level 3 as factors used to develop the estimated fair value are unobservable inputs that are not supported by market activity.

F-26

Table of Contents

The contingent consideration related to Kestrel was valued at \$9.7 million using a Monte Carlo simulation as of December 22, 2021. As of December 31, 2022, the contingent consideration was estimated at \$10.0 million, and the adjustment of \$0.3 million during 2022 was recorded as a loss on change in fair value of contingent consideration in the Company's Consolidated Statements of Income. The Company's policy is to fair value of acquisition-related contingent consideration **liabilities using** was based on a Monte Carlo model. model prior to December 31, 2023. See Note 3 - Business Combinations for additional details on the removal of contingent consideration during the year ended December 31, 2023. The following table presents the Company's financial liabilities that were accounted for at fair value on a recurring basis prior to December 31, 2023, which were included within Level III of the fair value hierarchy:

	Contingent Consideration
Balance as of December 31, 2022	\$ 10,000
Change in fair value of contingent consideration	(2,854)
Escrow share adjustment	(7,146)
Balance as of December 31, 2023	\$ —

(13) (14) COMMITMENTS AND CONTINGENCIES

See Note 11 12 for details regarding commitments under the Company's long-term leases.

From time to time, the Company may become party to litigation and other claims in the ordinary course of business. To the extent that such claims and litigation arise, management provides for them if losses are determined to be both probable and estimable. On occasion, the Company engages outside counsel related to a broad range of topics including employment law, third-party payer matters, intellectual property, and regulatory and compliance matters.

The Company is currently not a party to any material pending legal proceedings that would give rise to potential loss contingencies.

(14) (15) CONCENTRATIONS

The Company is exposed to concentration of credit risk related primarily to its cash balances. The Company maintains its cash balances in major financial institutions that exceed amounts insured by the FDIC (up to \$250,000, per financial institution as of December 31, 2022). The Company has not experienced any realized losses in such accounts and believes it is not exposed to any significant credit risk related to its cash.

The Company had two four major vendors from which it sourced approximately 28% 45% and two major vendors from which it sourced approximately 34% 28%, respectively, of supplies for its electrotherapy products for the years ended December 31, 2022 December 31, 2023 and 2021 2022. Management believes that its the Company's relationships with its suppliers are good. If the relationships were to be replaced, there may be a short-term disruption for a period of time in which products may not be available and additional expenses may be incurred as the Company locates additional or replacement suppliers.

The Company had gross receivables from no third-party payers which made up 10% of the accounts receivable balance at December 31, 2023. The Company had gross receivables from one third-party payer at December 31, 2022, which made up approximately 14% of the accounts receivable balance. The Company had receivables from one third-party payer at December 31, 2021, which made up approximately 22% of the accounts receivable balance.

(15) (16) RETIREMENT PLAN

In 2012, the Company established a defined contribution retirement plan for its employees under section 401(k) of the Internal Revenue Code (the "401(k) Plan") that is available to all employees 18 years of age or older with at least three months of service. All employee contributions are fully vested immediately and employer contributions vest over a period of four years. The Company has a discretionary employee match program and currently matches 35% of the first 6% of an employee's contributions.

During the years ended December 31, 2022 December 31, 2023 and 2021, 2022, the Company recorded an expense of \$0.7 million \$0.8 million and \$0.5 million \$0.7 million, respectively, under the aforementioned plan related to associated with the Company match.

F-27

F-27

Table of Contents

(16) QUARTERLY FINANCIAL INFORMATION (UNAUDITED)

Quarterly financial information is as follows (in thousands, except per share data):

	2022			
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
Total Revenue	\$ 31,083	\$ 36,759	\$ 41,520	\$ 48,805
Less: cost of revenue and operating expenses	29,177	32,395	34,962	38,695
Income from operations	1,906	4,364	6,558	10,110
Income before income taxes	1,982	4,149	6,352	9,715
Net income	\$ 1,377	\$ 3,346	\$ 4,873	\$ 7,452
Net income per common share:				
Basic income per share - net income	\$ 0.03	\$ 0.09	\$ 0.13	\$ 0.20
Diluted income per share - net income	\$ 0.03	\$ 0.08	\$ 0.13	\$ 0.20

	2021			
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
Total Revenue	\$ 24,127	\$ 31,022	\$ 34,785	\$ 40,367
Less: cost of revenue and operating expenses	<u>25,207</u>	<u>27,209</u>	<u>26,739</u>	<u>28,780</u>
Income from operations	(1,080)	3,813	8,046	11,587
Income before income taxes	<u>(1,087)</u>	<u>3,768</u>	<u>8,028</u>	<u>11,562</u>
Net income	<u>\$ (706)</u>	<u>\$ 2,808</u>	<u>\$ 6,107</u>	<u>\$ 8,894</u>
Net income per common share:				
Basic income per share - net income	\$ (0.02)	\$ 0.07	\$ 0.16	\$ 0.24
Diluted income per share - net income	\$ (0.02)	\$ 0.07	\$ 0.16	\$ 0.23

(17) RELATED PARTIES

On May 10, 2023, the disinterested Board and Audit Committee approved the purchase of 300,000 common shares of ZYXI from Mr. Sandgaard, Chairman, President, Chief Executive Officer and Principal Executive Officer, at the closing market price on May 10, 2023 of \$9.61 per share, resulting in a total transactional value of \$2,883,000.

On June 13, 2023, the disinterested Board and Audit Committee approved the purchase of 300,000 common shares of ZYXI from Mr. Sandgaard at the closing market price on June 13, 2023 of \$8.62 per share, resulting in a total transactional value of \$2,586,000.

At the time of each aforementioned transaction, the disinterested Board and Audit Committee Members deemed it to be in the best interest of the Company to purchase the shares as they believe the current market price for the Company's stock is undervalued and the Company's cash position is such that the purchase of shares from Mr. Sandgaard is a good use of the Company's funds at the time of each transaction. For each transaction, the following impacts were discussed before approval of the sale:

(i) the Company's cash position and capital needs for its continuing operations; (ii) the alternative uses for the cash used to purchase the Sandgaard Shares, including repayment of outstanding indebtedness; (iii) the possible effect on earnings per share and book value per share; and (iv) the potential effect of the trading of the Company's shares, if Mr. Sandgaard were to sell the shares in the open market.

(18) SUBSEQUENT EVENTS

During February 2023, On February 6, 2024, the Company entered into a lease agreement for approximately 41,427 square feet of office space announced that it has received clearance from the FDA for the operations next generation M-Wave Neuromuscular Electrical Stimulation ("NMES") device.

NMES treatments have several uses, including aiding recovery from surgery, managing chronic conditions, and even enhancing exercise performance in healthy individuals.

The M-Wave replaces its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998. The E-Wave was the most powerful and versatile muscle stimulation device on the market for over two decades and the M-Wave builds on that history of ZMS in Englewood, CO. The lease commences on July 1, 2023 performance with a more intuitive design and runs through December 31, 2028. At additional functionality. As of March 12, 2024, the expiration Company does not anticipate a material financial impact of the lease term the Company has the option to renew the lease for one additional five year period. The Company is entitled to rent abatements for the first six months of the lease. Payments based M-Wave on the initial rate of \$24.75 per square foot begin in January 2024. The price per square foot increases by an additional \$0.50 during each subsequent twelve-month period of the lease after the abatement period. Company's consolidated financial statements.

(18)(19) COVID-19

In December 2019, a novel Coronavirus disease ("COVID-19") was reported, and on March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. During 2020 and 2021, the Company's operations were impacted by closures of clinics and reductions in elective surgeries which decreased availability of physicians to prescribe our products. Additionally, the Company had to navigate the impacts it COVID-19 had on employee and supply chain issues. While the Company did not see a significant impact on its operating results or financial position during the years ended December 31, 2022 December 31, 2023 and 2022 from COVID-19, it is unable at this time to predict the impact that COVID-19 will have on its business, financial position and

operating results in future periods due to numerous uncertainties. The Company has been and continues to closely monitor the impact of the pandemic on all aspects of its business.

F-28

F-28

Exhibit 21

SUBSIDIARIES OF ZYNEX, INC.

Name	Jurisdiction
Zynex Medical, Inc.	Colorado
Zynex Monitoring Solutions, Inc.	Colorado
Zynex NeuroDiagnostics, Inc.	Colorado
Zynex Europe, ApS	Denmark
Kestrel Labs, Inc.	Colorado

Exhibit 23.1

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S CONSENT

We consent to the incorporation by reference in the Registration Statement of Zynex, Inc. on Form S-3 (file Nos. 333-230128 and 333-232367) and Form S-8 (File No. 333-220366) of our report dated **March 13, 2023** **March 12, 2024**, with respect to our audit of the consolidated financial statements of Zynex, Inc. as of **December 31, 2022** **December 31, 2023** and for the year ended **December 31, 2022** **December 31, 2023** and our report dated **March 13, 2023** **March 12, 2024**, which includes an adverse opinion because of the existence of a material weakness, with respect to our audit of internal control over financial reporting of Zynex, Inc. as of **December 31, 2022** **December 31, 2023**, which reports are included in this Annual Report on Form 10-K of Zynex, Inc. for the year ended **December 31, 2022** **December 31, 2023**.

/s/ Marcum LLP

Marcum LLP
New York, NY
March 13, 2023

Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Zynex, Inc.'s Registration Statements on Form S-3 (File Nos. 333-230128 and 333-232367) and on Form S-8 (File No. 333-220366) of our report dated March 21, 2022, relating to the December 31, 2021 consolidated financial statements which appears in Zynex, Inc.'s

/s/ Plante & Moran, PLLC

March 13, 2023

Denver, Colorado

Exhibit 31.1

CERTIFICATION

I, Thomas Sandgaard, certify that:

1. I have reviewed this annual report on Form 10-K of Zynex, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: **March 13, 2023** **March 12, 2024**

/s/ THOMAS SANDGAARD

Thomas Sandgaard

Chairman, President, Chief Executive Officer and Principal Executive Officer

CERTIFICATION

I, Daniel Moorhead, certify that:

1. I have reviewed this annual report on Form 10-K of Zynex, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: **March 13, 2023** **March 12, 2024**

/s/ DANIEL MOORHEAD

Daniel Moorhead

Chief Financial Officer and Principal Financial and Accounting Officer

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002**

Each of the undersigned hereby certifies, for the purposes of Section 1350 of Chapter 63 of Title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Zynex, Inc. ("Zynex"), that to his knowledge:

1. This Annual Report on Form 10-K for the year ended **December 31, 2022** **December 31, 2023** (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of Zynex for the period covered by this Report.

This Certification is executed as of **March 13, 2023** **March 12, 2024**

/s/ THOMAS SANDGAARD

Thomas Sandgaard

Chairman, President, Chief Executive Officer and Principal Executive Officer

Exhibit 32.2

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002**

Each of the undersigned hereby certifies, for the purposes of Section 1350 of Chapter 63 of Title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Zynex, Inc. ("Zynex"), that to his knowledge:

1. This Annual Report on Form 10-K for the year ended **December 31, 2022** **December 31, 2023** (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of Zynex for the period covered by this Report.

This Certification is executed as of **March 13, 2023** **March 12, 2024**

/s/ DANIEL MOORHEAD

Daniel Moorhead

Chief Financial Officer and Principal Financial and Accounting Officer

ZYNEX, INC.

CLAWBACK POLICY

EFFECTIVE November 28, 2023

1. **Purpose.** The purpose of this Zynex Inc. (the "Company") Clawback Policy (this "Policy") is to enable the Company to recover Erroneously Awarded Compensation from Covered Executive Officers in the event that the Company is required to prepare an Accounting Restatement. This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified in Section 10D of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), Rule 10D-1 promulgated under the Exchange Act ("Rule 10D-1") and Listing Rule 5608 of the corporate governance rules of The Nasdaq Stock Market ("Nasdaq") (the "Listing Standards"). Unless otherwise defined in this Policy, capitalized terms shall have the meaning ascribed to such terms in Section 2.
2. **Definitions.** As used in this Policy, the following capitalized terms shall have the meanings set forth below.

a. **"Accounting Restatement"** means an accounting restatement of the Company's financial statements due to the Company's material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (i.e., a "Big R" restatement), or to correct an error that is not material to the previously issued financial statements, but that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (i.e., a "little r" restatement).

b. **"Accounting Restatement Date"** means the earliest to occur of (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if the Board's action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement and (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.

c. **"Applicable Period"** means, with respect to any Accounting Restatement, the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (that results from a change in the Company's fiscal year) within or immediately following those three completed fiscal years (except that a transition period that comprises a period of at least nine months shall count as a completed fiscal year).

d. **"Board"** means the board of directors of the Company.

e. **"Code"** means the U.S. Internal Revenue Code of 1986, as amended. Any reference to a section of the Code or regulation thereunder includes such section or regulation, any valid regulation or other official guidance promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing, or superseding such section or regulation.

f. **"Covered Executive Officer"** means an individual who is currently or previously served as the Company's principal executive officer, principal financial officer, principal accounting

officer (or, if there is no such accounting officer, the controller), vice president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), an officer who performs (or performed) a policy-making function, or any other person who performs (or performed) similar policy-making functions for the Company or is otherwise determined to be an executive officer of the Company pursuant to Item 401(b) of Regulation S-K. An executive officer of the Company's parent or subsidiary is deemed a "Covered Executive Officer" if the executive officer performs (or performed) such policy-making functions for the Company.

g. **"Erroneously Awarded Compensation"** means, in the event of an Accounting Restatement, the amount of Incentive-Based Compensation previously received that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the restated amounts in such Accounting Restatement, and must be computed without regard to any taxes paid by the relevant Covered Executive Officer; provided, however, that for Incentive-Based Compensation based on stock price or total stockholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement: (i) the amount of Erroneously Awarded Compensation must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total stockholder return upon which the Incentive-Based Compensation was received and (ii) the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq.

h. **“Financial Reporting Measure”** means any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements and any measure that is derived wholly or in part from such measure. A Financial Reporting Measure is not required to be presented within the Company’s financial statements or included in a filing with the U.S. Securities and Exchange Commission to qualify as a “Financial Reporting Measure.”

i. **“Incentive-Based Compensation”** means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. Incentive-Based Compensation is deemed “received” for purposes of this Policy in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period.

3. **Administration.** This Policy shall be administered by the Board, the Compensation Committee of the Board (the “Compensation Committee”), the Audit Committee of the Board (the “Audit Committee”) or a special committee comprised of members of the Compensation Committee and Audit Committee. For purposes of this Policy, the body charged with administering this Policy shall be referred to hereinafter as the “Administrator.” The Administrator is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy, in each case, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from) the application of Section 409A of the Code. All determinations and decisions made by the Administrator pursuant to the provisions of this Policy shall be final, conclusive and binding on all persons, including the Company, its affiliates, its stockholders and Covered Executive Officers, and need not be uniform with respect to each person covered by this Policy.

In the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee’s responsibility and authority. Subject to any limitation at applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee). Any action or inaction by the Administrator with respect to a Covered Executive Officer under this Policy in now way limits the Administrator’s decision to act or not to act with respect to any other Covered Executive Officer under this Policy or under any similar policy, agreement or arrangement, nor shall any such action or inaction serve as a waiver of any rights the Company may have against any Covered Executive Officer other than as set forth in this Policy.

4. **Application of this Policy.** This Policy applies to all Incentive-Based Compensation received by a person: (a) after beginning service as a Covered Executive Officer; (b) who served as a Covered Executive Officer at any time during the performance period for such Incentive-Based Compensation; (c) while the Company had a listed class of securities on a national securities exchange; and (d) during the Applicable Period. For the avoidance of doubt, Incentive-Based Compensation that is subject to both a Financial Reporting Measure vesting condition and a service-based vesting condition shall be considered received when the relevant Financial Reporting Measure is achieved, even if the Incentive-Based Compensation continues to be subject to the service-based vesting condition.

5. **Recovery Erroneously Awarded Compensation.** In the event of an Accounting Restatement, the Company must recover Erroneously Awarded Compensation reasonably promptly, in amounts determined pursuant to this Policy. The Company’s obligation to recover Erroneously Awarded Compensation is not dependent on the filing of restated financial statements. Recovery under this Policy with respect to a Covered Executive Officer shall not require the finding of any misconduct by such Covered Executive Officer or such Covered Executive Officer being found responsible for the accounting error leading to an Accounting Restatement. In the event of an Accounting Restatement, the method for recouping Erroneously Awarded Compensation shall be determined by the Administrator in its sole and absolute discretion, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code.

Recovery may include, without limitation, (i) reimbursement of all or a portion of any incentive compensation award, (ii) cancellation of incentive compensation awards and (iii) any other method authorized by applicable law or contract.

The Company is authorized and directed pursuant to this Policy to recover Erroneously Awarded Compensation in compliance with this Policy unless the Compensation Committee has determined that recovery would be impracticable solely for the following limited reasons, and subject to the following procedural and disclosure requirements:

- a. The direct expenses paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered. Before reaching such conclusion, the Administrator must make a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to recover, and provide that documentation to Nasdaq;
- b. Recovery would violate home country law where that law was adopted prior to November 28, 2022. Before reaching such conclusion, the Administrator must obtain an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such a violation,

and must provide such opinion to Nasdaq; or

- c. Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Code.
6. Prohibition on Indemnification and Insurance Reimbursement. The Company is prohibited from indemnifying any Covered Executive Officer against the loss of any Erroneously Awarded Compensation. Further, the Company is prohibited from paying or reimbursing a Covered Executive Officer for the cost of purchasing insurance to cover any such loss. The Company is also prohibited from entering into any agreement or arrangement whereby this Policy would not apply or fail to be enforced against a Covered Executive Officer.
7. Required Policy-Related Disclosure and Filings. The Company shall file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including disclosures required by U.S. Securities and Exchange Commission filings. A copy of this Policy and any amendments thereto shall be posted on the Company's website and filed as an exhibit to the Company's annual report on Form 10-K.
8. Acknowledgement. Each Covered Executive Officer shall sign and return to the Company within thirty (30) calendar days following the later of (i) the effective date of this Policy set forth below or (ii) the date such individual becomes a Covered Executive Officer, the Acknowledgement Form attached hereto as Exhibit A, pursuant to which the Covered Executive Officer agrees to be bound by, and to comply with, the terms and conditions of this Policy.
9. Amendment; Termination. The Board may amend this Policy from time to time in its sole and absolute discretion and shall amend this Policy as it deems necessary to reflect the Listing Standards or to comply with (or maintain an exemption from the application of) Section 409A of the Code. The Board may terminate this Policy at any time; provided, that the termination of this Policy would not cause the Company to violate any federal securities laws, or rules promulgated by the U.S. Securities and Exchange Commission or the Listing Standards.
10. Other Recovery Obligations; General Rights. The Board intends that this Policy shall be applied to the fullest extent of the law. To the extent that the application of this Policy would provide for recovery of Incentive-Based Compensation that the Company already recovered pursuant to Section 304 of the Sarbanes-Oxley Act or other recovery obligations, any such amount recovered from a Covered Executive Officer will be credited to any recovery required under this Policy in respect of such Covered Executive Officer.

11. **Effective Date.** This Policy shall be effective as of November 28, 2023. The terms of this Policy shall apply to any Incentive-Based Compensation that is received by Covered Executive Officers on or after October 2, 2023, even if such Incentive-Based Compensation was approved, awarded or granted to Covered Executive Officers prior to such date.

This Policy shall not limit the rights of the Company to take any other actions or pursue other remedies that the Company may deem appropriate under the circumstances and under applicable law, in each case, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code.

This Policy is binding and enforceable against all Covered Executive Officers and their beneficiaries, heirs, executors, administrators or other legal representatives.

EXHIBIT A
ZYNEX, INC. CLAWBACK POLICY
ACKNOWLEDGEMENT FORM

By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Zynex, Inc. (the "Company") Clawback Policy (the "Policy").

By signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned's employment or service with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner consistent with, the Policy.

EXECUTIVE OFFICER



Signature



Print Name



Date

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.